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QUILL ON SCALPEL
T h e Perfect Graft: the Ongoing
K.A. Harris, MD, FRCSC
Department o f Surgery, St. Joseph's Health Centre, The University o f Western Ontario, London.
Ont.
S ince the introduction of bypass grafting, investigators have 
sought the optimal vascular con­
duit. It must have the properties of 
host acceptance, long-term patency 
and durability. The recognized gold 
standard for grafts in the infraingui- 
nal position is the long saphenous 
vein (reversed or in situ), but this 
vein is not always available. Other 
suitable autogenous tissues are 
more difficult to harvest and have 
variable failure rates.1 Various syn­
thetic and biologic grafts have been 
used in the infrainguinal region; 
however, many early reports of 
good graft behaviour are not easily 
reproduced. Batt and colleagues in 
this issue of the Journal (pages 61
to 65) give an honest and informa­
tive overview of their experience 
with the chemically processed 
human umbilical vein graft.
The concept of transplanting bio­
logic vascular tissue is not new, and 
much initial experience of bypass 
grafting was gained with bovine 
heterografts as well as human ho­
mografts. The resultant aneurysm 
formation and graft failures have 
provided gainful employment for 
many vascular surgeons. The con­
cept of tanning human umbilical 
veins was introduced by Dardick in 
the 1970s.2 To prevent aneurysm 
formation, this graft has been 
wrapped with Dacron mesh. Results 
have been variable, ranging from
Quest
excellent to the very poor results 
reported by Batt’s group.34 Al­
though the experimental design of 
their article is that of a case series, 
much useful information can be 
gained from this study.
All grafts were inserted into out­
flow sites distal to the popliteal 
artery and more than 50% were 
inserted into “poor” runoff beds, 
resulting in a 1-month primary pat­
ency rate of less than 50% and a 
1-year rate of only 18%. Although 
grafts to these outflow beds charac­
teristically have poor results, the 
incidence of above-knee amputation 
for graft thrombosis seems high. 
The graft material itself was respon­
sible for six serious complications
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(mural thrombosis, graft rupture 
and infection) and possibly three 
aneurysms, raising important con­
cerns about graft stability. Guidoin 
and colleagues have led the field in 
their investigations of graft failure 
and in outlining potential complica­
tions possibly related to structural 
defects in grafts.
The human umbilical vein graft 
described in Batt’s study provides 
neither stability nor satisfactory 
patency. In his ongoing work on 
graft stability, Guidoin and his 
group have shown5 that 26% of 
human umbilical vein grafts ex- 
planted after a mean duration of 9.7 
months were colonized by bacteria. 
He also demonstrated frequent in­
flammatory responses. He has im­
plicated folds on the graft surface 
as facilitating bacterial colonization 
and thrombosis. In the past, he has 
called for more rigorous quality 
control based on identification of 
structural deficiencies and variable 
mechanical properties identified in 
virgin human umbilical vein.6
Although, ideally, the long sa­
phenous vein would be used for all 
lower limb revascularizations, when 
it is not available alternative con­
duits include other autologous 
veins or prostheses. There are in­
creasing numbers of reports sug­
gesting that autologous vein is su­
perior. These veins may be har­
vested from a number of sites — 
the arm, the contralateral leg, the 
short saphenous system. They have 
the theoretical advantage of being 
autologous living tissue lined by 
endothelium. However, to date no 
randomized study has compared 
“alternative vein’’ long-term paten­
cy to that of prosthetic materials. It 
is refreshing to see an honest report 
of poor results of distal bypass 
grafting with nonautogenous tis­
sue.
Although from this study, we 
cannot conclude whether the poor 
results are related to the graft mate­
rial or the poor outflow tracts of 
the selected patients, Batt and col­
leagues do determine that chemical­
ly processed human umbilical vein 
is not a satisfactory conduit for the 
very distal bypass. In addition, it is 
apparent that new graft materials 
must be thoroughly tested in a 
variety of situations before their 
general use is recommended. This 
process may take many years. To 
help facilitate the understanding of 
many of these reports, standards 
suggested by the Society for Vascu­
lar Surgery have been used.7 Gui- 
doin’s group are to be commended 
for their ongoing studies into the 
durability and safety of a variety of 
graft materials.
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Desmopressin: Do We Now Know Its 
Role?
G.F.O. Tyers, MD, FRCSC, FACS, FACC
Member. Editorial Board. Canadian Journal o f Surgery. Professor and Head. Division o f 
Cardiovascular and Thoracic Surgery. Vancouver General Hospital. University o f  British 
Columbia. Vancouver. BC
The posterior pituitary peptide, antidiuretic hormone (ADH) 
has been useful in the treatment of 
diabetes insipidus through its multi­
ple effects on renal salt and water 
transport. However, its effective­
ness is limited by a short half-life 
and potent and potentially perilous 
vasoconstrictive properties, hence 
its alternative name vasopressin. In 
the early 1960s, workers in Czecho­
slovakia set out to develop vaso­
pressin analogue peptides with spe­
cifically tailored biological spectra. 
One result was desamino-D-arginine 
vasopressin (DDAVP) or desmo­
pressin. It has an antidiuretic poten­
cy 2000 to 3000 times, and a 
half-life more than 10 times, that of 
naturally secreted ADH, and has 
little or no vasoconstrictive (hyper­
tensive), arrhythmogenic or entero- 
uterotonic effects. It is now the 
treatment of choice for central dia­
betes insipidus.1
It is widely appreciated that the 
secretion of ADH in response to 
dehydration increases water absorp­
tion by the kidney. However, ADH 
is also secreted in response to hem­
orrhagic shock and other emergen­
cy conditions causing hypotension. 
One of the initial targets of ADH 
molecular engineering was selective 
restriction of gastrointestinal and 
uterine blood flow to allow ’’blood­
less field” surgery, for example in 
establishing a portacaval shunt.
Early studies also demonstrated sys­
temic hemostatic effects.1-2 Intrave­
nously administered DDAVP greatly 
increases the levels of Factor VIII, 
von Willebrand factor, and plas­
minogen activator for over 6 hours. 
These changes are associated with 
decreases in partial thromboplastin 
and bleeding times, and enhanced 
fibrinolysis. They occur not only in 
patients with bleeding tendencies, 
including the effects of Aspirin in­
gestion, but also in normal sub­
jects.2-3 In addition, increased plate­
let aggregation, especially at sites 
of vascular injury, leads to a vari­
able drop in platelet count. Al­
though controlled studies have 
never been done, DDAVP is now 
the treatment of choice to prevent 
bleeding complications after dental 
extraction and similar surgery in 
patients with mild to moderate he­
mophilia or von Willebrand’s dis­
ease.
The preceding developments led 
to successful trials of the prophy­
lactic use of DDAVP to minimize 
postoperative bleeding in patients 
with normal hemostatic function 
who undergo orthopedic proce­
dures,4 and in patients who have 
the complex and variable coagula­
tion defects that may follow open- 
heart surgery. In 1986, in a ran­
domized double-blind trial of 70 
patients who underwent complex 
cardiac operations, there was a sig­
nificant reduction in blood loss and 
homologous blood requirements 
when DDAVP was given.5 Subse­
quently, a nonrandomized prospec­
tive study6 of patients who had a 
blood loss of over 100 m l/h and 
prolonged bleeding times after 
open-heart surgery showed a sig­
nificant reduction in transfusion re­
quirements, platelet use and reoper­
ation for bleeding after treatment 
with DDAVP.
It was therefore hypothesized 
that use of DDAVP after all open- 
heart surgery might save immense 
quantities of blood on a national 
basis and markedly reduce the risks 
and costs associated with blood- 
borne diseases, including hepatitis 
and AIDS (risks of 1 /400  trans­
fused units and 1 /40  000 trans­
fused units respectively of carefully 
screened blood). Unfortunately, a 
subsequent trial7 involving 100 pa­
tients who underwent cardiopulmo­
nary bypass surgery showed no 
substantial difference in total blood 
loss after DDAVP administration, 
even though bleeding time de­
creased, Factor VIII and von Wille­
brand factor levels increased and 
intraoperative blood loss was less in 
the treated group.
The study by Hedderich and col­
leagues in this issue (pages 33 to 
36) appears to confirm that DDAVP 
does not reduce blood requirements 
after relatively low-risk open-heart
CJS, VOL. 33, NO. 1, FEBRUARY 1990 5
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surgery, for example in elective cor­
onary revascularization with cardi­
opulmonary bypass times of ap­
proximately 90 minutes as in the 
previous negative study.7 However, 
it does raise some questions. The 
DDAVP group had one more pa­
tient who required late reoperation, 
two more who had internal mamma­
ry artery harvesting, three versus 
one patient with postoperative 
bleeding more than 200 m l/h re­
quiring early reoperation, and a 
higher average intraoperative blood 
loss. However, total blood loss and 
blood loss during the first 6 hours 
after surgery (the period of the 
drug’s effect) were each 100 ml less 
in the treatment than in the control 
group. Furthermore, the preopera­
tive von Willebrand factor level was 
somewhat lower in the DDAVP 
group and increased significantly (p 
< 0.001) after administration of the 
drug to a little lower, but essentially 
the same, level as in the control 
group. The significant (p < 0.05) 
decrease in platelet count in the 
treatment group may also confirm a 
hemostatic action secondary to in­
creased platelet aggregation at sites 
of vascular injury.
Another controlled study of 150 
patients prospectively randomized 
to DDAVP or placebo groups has 
also been published recently.8 In 
relatively uncomplicated open-heart 
surgical cases, it showed similarly 
that DDAVP had no significant ef­
fect on blood loss even though 
average cardiopulmonary bypass 
times were more than 150 minutes. 
Again there were minor differences 
between the control and experimen­
tal groups; more patients in the 
control group had increased preop­
erative levels of von Willebrand fac­
tor multimers and valvular or atrial 
septal defect procedures, and more
patients in the DDAVP group had 
double internal mammary artery 
procedures and preoperative Aspirin 
ingestion. Patients in the treatment 
group also had significantly higher 
levels of antianginal medication.
Could the patients in the DDAVP 
groups of the two most recent 
studies have been at somewhat 
higher risk than those in the con­
trol groups?
Whatever the answer to this 
question it now seems probable that 
the small potential risks, such as 
hypercoagulability with stroke or 
myocardial infarction, of routine 
DDAVP administration after every 
open-heart procedure will outweigh 
any potential benefits. With careful 
technique, perioperative autotrans­
fusion and autologous predonation, 
the majority of patients can under­
go elective open-heart surgery with­
out transfusion. As with single-ves­
sel coronary artery disease, it is 
very difficult to demonstrate a sig­
nificant benefit of treatment when 
the risk in the control population is 
very low.
On the other hand, the use and 
study of DDAVP in selected pa­
tients with primary or acquired pre­
operative bleeding disorders, includ­
ing Aspirin ingestion, and in pa­
tients at increased risk of periopera­
tive hemorrhage are still indicated. 
High-risk patients would include 
those subjected to long cardiopul­
monary bypass times, reoperation 
and double internal mammary ar­
tery harvesting, and patients who 
have prolonged postoperative bleed­
ing times. The goal should be to 
identify pre- and postoperatively 
those patients at increased risk. In 
these patients, the potential benefits 
of prophylactic or therapeutic 
DDAVP therapy should be more 
easily confirmed or ruled out. The
majority of patients scheduled for 
open-heart surgery who are not at 
significant risk should probably be 
spared nonselective hemostatic 
therapy.
As the bloom fades from another 
magic potion that it was hoped 
might limit postoperative bleeding 
without inducing intravascular co­
agulation, it is predictable that faith 
will be transferred to the next gen­
eration. Can the nonselective use of 
aprotinin (Trasylol) succeed where 
aminocaproic acid (Amicar) and 
DDAVP have failed?
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Introducing...
CARE of the SURGICAL PATIENT
from  SCIENTIFIC AMERICAN Medicine
(> Because the quality of your care depends on the quality of your information.
Treating pre and post operative patients poses a unique set of 
challenges. Yet in one way it’s no different than any other 
practice issue.
Doing it well takes the right information.
That’s why scientific American Medicine is pleased to 
|v announce the publication of CARE o f  the SURGICAL PATIENT.
The definitive resource on pre and post­
operative care.
CARE o f  the SURGICAL PATIENT gives you ready access to the 
most authoritative and current information on pre and post- 
k operative standards available anywhere.
Written and designed by prominent surgeons under the 
supervision of the American College of Surgeons’ Committee on 
Pre and Postoperative Care, CARE o f  the SURGICAL PATIENT
provides two volumes —over 1,500 pages —of practical 
information on both critical and elective care.
And, CARE o f  the SURGICAL PATIENT is updated twice a year, 
with each surgeon-author reviewing his own specialty. Updates 
include new information on significant topics, such as current 
developments on AIDS.
In short, CARE o f  the SURGICAL PATIENT presents the 
standards for pre and postoperative treatment. You simply won’t 
find a more important resource. Or one that organizes its 
information in such an intelligent way.
A unique system for rapid information 
retrieval.
CARE o f  the SURGICAL PATIENT is designed to get you the 
information you need, the way you need it.
Quickly. And intelligently.
The key is the system’s three-part format. Chapters begin with 
a full page algorithm-the relevant facts at a moment’s glance. 
Next, there’s a detailed explanation of each element laid out in 
the treatment pathway. The third section covers etiology, 
pathobiology, and relevant clinical advances, as well as current 
references.
You choose the level of detail you need at the moment.
Without having to wade through everything else. And unlike 
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QUILL ON SCALPEL
D ukes’ Classification: American Chaos 
Versus British Order
Warren Schubert, MD
Department o f  Surgery. The Montreal General Hospital. McGill University. Montreal. PQ
A ssimilation of a large volume of information and devoting long 
hours to clinical work is onerous 
for student, resident and practising 
physician alike. The seemingly loga­
rithmic increase of information to 
learn is often of a complexity that is 
totally unwarranted. The Dukes’ 
classification for staging of cancer 
of the rectum is a good example of 
this unwarranted complexity.
Cuthbert E. Dukes, a pathologist 
from St. Mark’s Hospital in Lon­
don, described, in 1932, a simple 
and clear classification for stag­
ing cancer of the rectum.1 Some 
“purists”2 have criticized it as being 
improper for staging other intesti­
nal tumours, but, although his orig­
inal paper did not include tumours 
of the colon, Dukes did state that 
his classification could “be applied 
to all intestinal carcinomas”.1 Under 
this classification, A was defined as 
growth limited to the wall of the 
rectum; B as extension of growth to 
extrarectal tissues but no metasta- 
ses in regional lymph nodes; and C 
as metastases in regional lymph 
nodes. Although many authors 
have since misinterpreted or rede­
fined “wall of the rectum”, Dukes 
included a clear diagram (Fig. 1) in 
which “the wall” referred to the 
circular and longitudinal muscles of 
the bowel.
Few structures of such impor­
tance have been given such a pleth­
ora of names as Dukes’ “wall”. The 
circular and longitudinal muscles 
have been referred to as the muscu­
lar coat, tunica muscularis, mus- 
cularis propria and muscularis ex­
terna. These are often confused 
with the thin inner muscular layer,
commonly known as the muscularis 
mucosae or lamina muscularis mu­
cosae. Whether muscularis interna 
refers to the circular muscle of the 
muscularis propria or to the mus­
cularis mucosae remains unclear, 
and when authors or pathologists 
abbreviate the previous terms, de­
scribing the depth of invasion of a 
carcinoma relative to the "muscula- 
ris", the problem is compounded.
The first to suggest a relation­
ship between depth of invasion and 
prognosis was Lockhart-Mummery, 
working in the same institution as 
Dukes. In 1927, he coined his own 
classification3 in which stage A can­
cer had not invaded the “muscular 
coat” , B involved the “muscular 
coat” and C represented large, fixed 
growths or extensive involvement 
of nodes.
Dukes is partially to blame for 
the confusion surrounding his clas­
sification. Before the publication of 
his classic 1932 paper, he and Gor- 
don-Watson outlined the system 
suggested by Lockhart-Mummery.3 
In their paper they suggested that 
stage B cancers “may be further 
subdivided into B1 in which the 
circular muscle is the limit of 
growth, and B2 in which the longi­
tudinal muscle has been reached. C 
cases may also be subdivided into 
Cl without glandular involvement, 
and C2 with metastasis in the lym­
phatic glands.”4
At St. Mark’s Hospital there 
evolved an interest in the lymphatic 
spread of cancer of the rectum and 
its association with survival. Gabriel 
and colleagues5 detailed the find­
ings of 100 dissections of the anal 
canal, rectum and surrounding peri­
rectal tissues in which lymphatic 
m etastasis was meticulously 
mapped. They found that the 5-year 
survival for perineal resection was
A. _ . g r o w t m  l i m i t e d  t o  w a u  o r  r e c t u m .
EAT EN 6 ION OF G R O W TH  TO E X T R A
B. . R E C T A L .  T I B S U E B  B U T  NO M E T A S T A S E S
IN REG IONAL LY M P H  NODES .
C ....M E T A S T A S I S  IN REGIONAL LYM PH  NOOES.
Extent of spread of cancer of rectum.
FIG. 1. Photograph of Dukes’ classifi­
cation from his original 1932 article. 
Diagram was drawn by Dr. H.J.R. 
Bussey, consulting research fellow at 
St. Mark’s Hospital, London. At that 
time, Dr. Bussey was research assis­
tant under Cuthbert Dukes and was 
responsible for several drawings in 
Dukes’ subsequent publications. (Re­
produced by permission of the Patho­
logical Society of Great Britain and 
Northern Ireland from Dukes CE: The 
classification of cancer of the rectum. J 
Pathol Bacteriol 1932; 35: 323-332.)
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91% for stage A cancers, 64% for 
stage B and 16% for stage C. They 
also noted that the first “glands” to 
receive metastases were those at the 
same level or immediately above the 
primary growth, and they usually 
found lymphatic spread by “upward 
uninterrupted extension”. A sub­
categorization of C was devised 
from Dukes’ 1932 classification. 
Cancers in which the lymph-node 
metastasis did not reach the mesen­
teric vascular ligature around the 
inferior mesenteric pedicle were 
classified as Cl and had a better 
prognosis than those in which lym­
phatic spread reached the point of 
ligature, which were classified as 
C2. This C1/C2 subcategorization 
was occasionally used by Dukes in 
his later papers,67 and has been 
used by others.8-9 However, this 
subcategorization is quite different 
from the C1/C2 classifications of 
most other authors.
Dukes noted that the survival 
rate decreased as the number of 
involved nodes increased.10 He also 
noted that in only 2% of cases was 
there lymphatic spread before “di­
rect continuity spread has extended 
through the outer muscular 
coats”.11 None of Dukes’ papers 
made reference to a D category, 
although Dukes stated that “if a 
malignant growth has spread to 
distant organs such as the liver, 
this is described as the fourth 
stage”.6 In 1958, Dukes and Bus­
sey7 published an update report, 
based on 2447 patients studied over 
25 years. The crude 5-year survival 
for patients with stage A cancer was 
81.2% for stage B 64.0% and for 
stage C 27.4% and, after allowing 
for intercurrent deaths, the “cor­
rected” 5-year survival rates were 
97.7%, 77.6% and 32.2%, respec­
tively.
The importance of Dukes’ work 
is well recognized. A system was 
finally devised to assess a patient’s 
prognosis, with implications for fol­
low-up and possible adjuvant treat­
ment. Furthermore, a way was 
found to categorize patients with 
colorectal tumours to compare dif­
ferent modalities of treatment. 
Studies in later years (using a dif­
ferent staging system) confirmed 
that survival by staged groups was 
similar for both rectal and colonic 
cancer.12 Despite the various ramifi­
cations studied by Dukes, the basic 
A, B, C staging system is acknowl­
edged as Dukes’ classification in 
most of the British literature.
Since 1932, American authors 
have tried to modify Dukes’ classifi­
cation. In many cases the modifica­
tions were based on fewer cases 
than in Dukes’ original study. 
These authors failed to prove any 
advantage of their new system over 
the original except to increase its 
complexity and cause confusion. 
The first to initiate this labyrinth of 
nomenclature were Kirklin and col­
leagues.13 They used a “slight mod­
ification of the Dukes method”. In 
131 cases, they described “type A, 
lesion limited to the mucosa; type 
Bl, lesion extended into the mus- 
cularis propria but did not penetrate 
it; type B2, lesion penetrated 
through the muscularis propria; 
and type C, lesion of either type Bl, 
or B2, with involvement of lymph 
nodes”. This was not a refinement 
of Dukes’ system; instead these 
authors used terminology similar to 
Dukes’ to denote completely differ­
ent levels.
In 1954, Astler and Coller14 
worsened the situation by suggest­
ing a more complex modified 
Dukes’ classification, which more 
accurately should have been called 
a “modified Kirklin classification”. 
Using Kirklin’s system they further 
subdivided Kirklin’s type C into 
“Cl (limited to the wall with posi­
tive nodes) and C2 (through all 
layers with positive nodes)” .
In 1967, Turnbull and associ­
ates15 published their findings on
the no-touch technique for colorec­
tal cancer. They introduced a new 
A, B, C, D staging system, but did 
not refer to it as a “modified Dukes’ 
classification” . Another completely 
different “modified Dukes’ classifi­
cation” was proposed by Smith and 
associates,16 based on only 100 pa­
tients; one group had no patients 
and another had only 1. Newland 
and colleagues17 proposed a classifi­
cation with as many as four stages 
and nine substages. Although there 
were significant differences in sur­
vival between the four major stages 
over 5 years, these authors failed to 
show statistical differences between 
many of the more complicated sub­
stages. In yet another system used 
by the Gastrointestinal Tumor 
Study Group,18 stage C was subdi­
vided into Cl, those patients who 
had one to four involved nodes, and 
C2, those having five or more in­
volved nodes.
Finally, a truly radical departure 
from the A, B, C staging of cancer 
was the invention of the TNM clas­
sification of malignant tumours 
used by the International Union 
Against Cancer.19 Relatively few cli­
nicians can remember this system 
without looking it up.
Several large studies have been 
based on incorrect definitions of 
Dukes’ classification,20-23 but in re­
viewing the major texts written by 
British authors, they have clearly 
not been led astray by the American 
“ modified Dukes’ classifica­
tions”.9-24 On the other hand, Amer­
ican authors have supported trends 
toward pandemonium; some25 have 
even decided to change the spelling 
from Dukes’ classification to 
Duke’s classification.
Leading American texts are in 
disagreement as to which classifica­
tion should be used. For example, 
the surgical textbook Principles o f 
Surgery has gone through an inter­
esting evolution. The first through 
third editions advocated the use of
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Astler and Coder's system with the 
addition of type D, for distant le­
sions, and the fourth and fifth edi­
tions rediscovered Dukes’ 1932 
classification. However, the fourth 
edition went on to describe the 
“ latest and most detailed modified 
(Australian) Dukes’ classification” , 
that of Newland and colleagues,17 
which included the substages Al, 
A2, A3, Bl, B2, Cl, C2, D1 and 
D2. Although the substages failed 
to prove a difference in longevity, 
this classification is more worthy of 
the eponym “ modified Dukes’” 
than others, in that stages A1 to A3 
combined agree with Dukes’ origi­
nal classification of stage A, Bl and 
B2 combined agree with Dukes’ 
stage B and Cl and C2 agree with 
Dukes’ 1935 classification; only D1 
and D2 are new.
The 11th edition of Sabiston’s 
Textbook o f Surgery advocated the 
use of a “modified Dukes classifica­
tion” incorrectly described by De- 
Peyster and Gilchrist.26 In Sabis­
ton’s 12th and 13th editions 
Dukes’, Kirklin’s and Astler’s clas­
sifications are mentioned, but it is 
stated that the American Joint Com­
mittee Classification based on the 
TNM staging of cancer of the colon 
and rectum “should be utilized in 
any reference to colon or rectal 
cancer” .
In Way’s textbook, Dukes’ prop­
er classification is presented27 and 
an explanation given that stage D 
has become common usage to as­
sign patients with “distant metasta­
sis or locally unresectable tumor” . 
Spiro28 stated that the Dukes’ clas­
sification is the most widely accept­
ed, but made no attempt to describe 
it, giving instead a redefinition of 
the classification as described by 
the Gastrointestinal Tumor Study 
Group.
In the third edition of Sleisenger 
and Fordtran’s Gastrointestinal Dis­
ease, Dukes’ stage A is incorrectly 
described as being “ limited to the
mucosa and submucosa” .29 This in­
accuracy is resolved in the fourth 
edition.
Clearly, there must be some con­
formity in the staging of colorectal 
cancer. This is particularly impor­
tant in comparisons of therapeutic 
regimens. The use of the eponym 
“modified Dukes’” must be discon­
tinued, since it has been inappropri­
ately used to describe classifications 
that Dukes would not recognize. 
The obsession to subdivide and sub­
categorize a simple system must be 
resisted, especially since most of the 
complicated classifications offer 
nothing for patient management. I 
(an American) wish to join Goligh- 
er30 and Roseman and Straus31 in 
their plea to Americans for a return 
to the simplicity of the Dukes’ 1932 
classification in which A represents 
tumours limited to the wall, B ex­
tension through the wall and C 
lymph-node metastasis. An attempt 
to edify rather than mystify medical 
students is occasionally healthy. If 
in future new subdivisions are need­
ed to institute different therapeutic 
modalities, these subdivisions 
should not be referred to as a 
“modified Dukes’ classification”.
With the current political trends, 
Canadian-American free trade, in­
creased exchange of ideas and pos­
sible further conformity, it is to be 
hoped that the “high tech” quag­
mires of the American classifica­
tions will not also flow north.
References
1. Dukes CE: The classification of cancer 
of the rectum. J Pathol Bacteriol 1932; 
35: 323-332
2. Rubio CA, Emas S, Nylander G: A 
critical reappraisal of Dukes' classifica­
tion. Surg Gynecol Obstet 1977; 145: 
682-684
3. Lockhart-Mummery JP: Two hundred 
cases of cancer of the rectum treated by 
perineal excision. Br J Surg 1926- 
1927; 14: 110-124
4. Gordon-Watson C, Dukes CE: Treat­
ment of carcinoma of rectum with radi­
um, with introduction on spread of 
cancer of rectum. Br J Surg 1930; 17: 
643-669
5. Gabriel WB. Dukes C, Bussey HJR: 
Lymphatic spread in cancer of the rec­
tum. B rJS u rg  1935; 23: 395-413
6. Dukes CE: The surgical pathology of 
rectal cancer. J Clin Pathol 1949; 2: 
95-98
7. Dukes CE, B ussey HJR: The spread of 
rectal cancer and its effect on prognosis. 
Br J Cancer 1958; 12: 309-320
8. S hepherd JM, J ones JS: Adenocarcino­
ma of the large bowel. Br J Cancer 
1971; 25: 680-690
9. Ellis H: Tumours of the rectum and 
anal canal. In S chwartz SI, Ellis H 
(eds): Maingot's Abdominal Operations. 
8th ed, ACC. Norwalk, Conn., 1985: 
1459-1460
10. Dukes C: Surgical pathology of rectal 
cancer; president’s address. Proc R Soc 
Med 1944; 37: 131-144
11. Dukes CE: The significance of the un­
usual in the pathology of intestinal 
tumours. Ann R Coll Surg Engl 1949; 
4: 90-103
12. Wood DA. Robbins GF, Zippin C, et al: 
Staging of cancer of the colon and 
cancer of the rectum. Cancer 1979; 43: 
961-968
13. K irklin JW, Dockerty MB, Waugh JM: 
The role of the peritoneal reflection in 
the prognosis of carcinoma of the rec­
tum and sigmoid colon. Surg Gynecol 
Obstet 1949; 88: 326-331
14. Astler VB. Coller FA: The prognostic 
significance of direct extension of carci­
noma of the colon and rectum. Ann 
Surg 1954; 139: 846-852
15. Turnbull RBjr, Kyle K, Watson FR, 
et al: Cancer of the colon: the influence 
of the no-touch isolation technic on 
survival rates. Ann Surg 1967; 166: 
420-427
16. S mith LA, Masood S. J agadish B, et al: 
A modification of the Dukes’ classifica­
tion of carcinoma of the colon and 
rectum. Am Surg 1978; 44: 94-97
17. Newland RC. Chapuis PH, Pheils MT, 
et al: The relationship of survival to 
staging and grading of colorectal carci­
noma: a prospective study of 503 cases. 
Cancer 1981; 47: 1424-1429
18. Adjuvant therapy of colon cancer — 
results of a prospectively randomized 
trial. Gastrointestinal Tumor Study 
Group. N  Engl J Med 1984; 310: 737- 
743
19. Hermanek P, S obin LH (eds): TNM 
Classification o f Malignant Tumours. 
4th ed, Springer-Verlag, Berlin, 1987: 
47-49
20. Mackman S, Curreri AR, Ansfield FJ: 
Second-look operation for colon carci­
noma after fluorouracil therapy. Arch 
Surg 1970; 100: 527-531
21. Falterman KW, Hill CB, Markey JC, et 
al: Cancer of the colon, rectum, and
10 CJS. VOL. 33. NO. I, FEBRUARY 1990
DUKES’ CLASSIFICATION
anus: a review of 2313 cases. Cancer 
1974: 34 (suppl): 951-959
22. Recalde M, Holyoke ED, Elias EG: 
Carcinoma of the colon, rectum, and 
anal canal in young patients. Surg Gvne- 
col Obstet 1974: 139: 909-913
23. W ilson SM, Beahrs OH: The curative 
treatment of carcinoma of the sigmoid, 
rectosigmoid, and rectum. Ann Surg 
1976: 183: 556-565
24. Golicher JC: Surgery o f the Anus. 
Rectum and Colon, 5th ed, Bailliere-Tin- 
dall. London, 1984: 458-460
25. RomsiNS SL, Cotran RS. Kumar V:
BOOK REVIEWS
CANCER OF THE BREAST. 3rd edi­
tion. Edited by William L. Donegan 
and John S. Spratt. 796 pp. IUust. 
W.B. Saunders Company, Philadel­
phia; W.B. Saunders Company Canada 
Limited, Toronto, 1988. $142.75. 
ISBN 0-7216-1819-7.
Not so long ago, a surgeon familiar 
with the relevant anatomy and patholo­
gy and the surgical techniques required 
to diagnose and extirpate breast cancer 
could deal competently with the disease. 
Today, a competent surgeon requires 
knowledge in fields far removed. This 
textbook has addressed this problem 
and fulfils the need well. The fact that 
the two authors are recognized experts 
in rather diverse fields — one in general 
surgery, the other in community medi­
cine — provides a unique flavour to the 
comprehensive coverage of the subject.
The sections on anatomy, physiolo­
gy, diagnosis, pathology, staging and 
surgical management are excellent; 
however, the same information is avail­
able in a number of other first-class 
textbooks. Not available in other texts 
are the excellent chapters on epidemiol­
ogy and etiology, cell kinetics, growth 
rates, nursing care, psychosocial fac­
tors, physical fitness and weight con­
trol. The section on nutrition is out­
standing and even includes an appendix 
detailing sources of additional informa­
tion for patients who seek diet counsel­
ling. Many women presenting with 
breast disease (either benign or malig­
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nant) request authoritative information 
on diet and weight reduction. This 
appendix provides the perfect answer. 
The chapter on statistical methods in 
cancer research should alert any reader 
who is contemplating even a simple 
study to seek the assistance of a bio­
statistician.
The chapter on heat imaging in­
cludes an overenthusiastic promotion of 
mammography. This is well balanced, 
however, by the chapter on breast 
screening and follow-up. Unfortunately, 
the overenthusiastic recommendations 
for adjuvant radiotherapy in the chapter 
on radiation are not balanced. Most 
modern radiotherapy centres have con­
cluded that adjuvant radiotherapy after 
total mastectomy and axillary dissection 
does more harm than good. This chap­
ter suggests that it is nearly innocuous 
and may be curative. The author appar­
ently clings to the outmoded concept 
that breast cancer is a localized (rather 
than systemic) disease at the time of 
detection and is potentially curable 
postoperatively by extended radio- 
therapeutic efforts to sterilize regional 
nodes. The suggestion that preoperative 
adjuvant radiotherapy especially to the 
internal mammary nodes may be associ­
ated with improved survival impairs the 
credibility of this chapter even more. 
One can only hope that the radiothera­
pists to whom the readers of this sec­
tion may be referring their patients will 
be better informed.
This book will be of value to all
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surgeons whose practice embraces a 
considerable number of patients with 
breast disease. It is an excellent refer­
ence for other health professionals and 
should be in the library of every teach­
ing hospital.
Leo Mahoney. BA. MD. MS. FRCSC, 
FACS
Associate Professor o f Surgery.
Director.
St. Michael’s Hospital Breast Centre.
55 Queen St. E.
Ste. 405.
Toronto. Ont.
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DISORDERS OF THE SPLEEN. Pa­
thophysiology and Management. Edit­
ed by Carl Pochedly, Richard H. Sills 
and Allen D. Schwartz. 464 pp. Illust. 
Marcel Dekker, Inc., New York, 1989. 
$125.00 (US). ISBN 0-8247-7933-9.
In ancient medicine the spleen was a 
mystical organ, and in modern times the 
mystery persists. There are few text­
books devoted to the spleen. Diseases 
o f the Spleen, therefore, is a welcome 
addition to that section of the medical 
library. Because of the decreasing indi­
cations for splenectomy in recent years, 
surgeons and pathologists now have
continued on page 74
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F rinding an effective treatment for intra­
abdominal infections has become much 
easier since the advent of cephalosporins. 
Their broad spectrum of activity has greatly 
improved the prognosis for many patients 
with serious infections.
The trouble is, the cost of cephalosporins has 
been making many hospital pharmacists 
(and cost control staff) see red. It is also now 
increasingly more difficult for many hospital 
formulary committees to be able to strike an 
agreeable balance between effectiveness 
and cost control.
New Cefizox™ may be the answer everyone's 
been looking for. Not only does it give much 
wider pathogen coverage* (including B. 
fragilis) than cefoxitin,1,2 but its superior 
dosage schedule (example: q!2h vs q6h) 
may make Cefizox™ much less expensive?'4 
It even has packaging designed for easy 
identification.
So if the cost of effective cephalosporin 
therapy is just too much for your hospital to 
handle, consider new Cefizoxy™ Its 
combination of efficacy and low cost may 
just be what everybody ordered.
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HOW I DO IT
Modified Subtotal Cholecystectomy for 
High-Risk Patients
Amitai Bickel, MD; Ida Lunsky, MD; Solly Mizrahi, MD; Benjamin Stamler, MD
W hen high-risk patients in poor condition must undergo 
cholecystectomy, the procedure 
should be performed rapidly, main­
taining a stable hemodynamic state. 
Occasionally, the gallbladder is 
found to be necrotic, severely in­
flamed with a thickened wall or 
embedded into the liver tissue. The 
anatomy may be thoroughly obliter­
ated by a diffuse inflammatory proc­
ess. In such cases, division and 
removal of the gallbladder from its 
bed might prolong the operation 
and be accompanied by serious 
bleeding (particularly in conditions 
such as cirrhosis and portal hyper­
tension). A subtotal cholecystecto­
my, leaving part of the posterior 
wall of the gallbladder attached to 
the liver, should avoid these prob­
lems.
Patients
Between 1984 and 1987, eight 
high-risk patients, ranging in age 
from 49 to 79 years, underwent 
modified subtotal cholecystectomy. 
All suffered from severe cholecysti­
tis. Four patients had obstructive 
jaundice; two of them had ascend­
ing cholangitis and sepsis. Preoper­
ative work-up included tests of liver 
function, ultrasonography (all pa­
tients) and endoscopic retrograde 
cholangiopancreatography (three 
patients).
Operative Technique
After abdominal exploration, the 
fundus of the gallbladder is grasped 
between two forceps. A small trocar 
is inserted through the fundus and 
the content evacuated. A thin suc­
tion tube is inserted into the gall­
bladder to evacuate secretions dur­
ing the operation and to delineate 
the cystic duct. The gallbladder wall 
is cut using electrocautery, adjacent 
to the liver, on both sides of the 
gallbladder, which is opened up 
(Fig. 1). With a diathermy from 
within, the posterior wall is cut 
transversely at the proper level to 
complete the removal of the gall­
bladder from the liver, leaving a 
portion of its posterior wall behind. 
Electrocoagulation of the posterior 
wall mucosa is then carried out and 
the cholecystectomy completed.
Results
In all eight patients, severe chole­
cystitis accompanied by marked an­
atomical and inflammatory changes 
was found. Choledocholithiasis, ne­
cessitating exploration of the com­
mon bile duct, was discovered in 
four patients. One patient had 
macronodular cirrhosis. Another 
had carcinoma of the pancreas.
All patients made a smooth re­
covery. There were no cases of 
wound infection.
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Discussion
Although incomplete cholecystec­
tomy does not resemble cholecys- 
tostomy1 with respect to its rapidity 
and relative ease and cannot be 
done under local anesthesia, it does 
have certain advantages.
Unlike cholecystostomy, subtotal 
cholecystectomy is a definitive oper­
ation, rendering further gallstone 
formation impossible. Such a tech­
nique could be used in high-risk 
patients when the operator suspects 
that gallbladder dissection will be 
accompanied by severe bleeding and 
prolonged operating time.
This technique should not be 
used as a last resort when an at­
tempt at total resection has failed.
Cutting out the posterior wall by 
coagulation diathermy does not 
cause pronounced bleeding even 
when performed before ligation of 
the cystic artery. However, after 
opening the gallbladder and discon­
necting it from its posterior wall, 
exposure of the cystic vessels is 
greatly improved.
Electrocoagulation of the posteri­
or-wall mucosa may prevent the 
development of postoperative infec­
tion and the possible occurrence of 
gallbladder carcinoma.2-3
In the modified technique, we 
used coagulation diathermy instead 
of a scalpel and did not suture the 
remaining edges of the posterior 
wall, as in the original procedure.4
The technique we used differs 
from electrosurgical obliteration of 
the gallbladder described by Tho- 
rek.5 In that description, the tech­
nique of removing the redundant 
portion of the gallbladder is some-
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FIG. 1. Modified subtotal cholecystectomy. Gallbladder wall is cut adjacent to liver 
(top left). Posterior wall is cut transversely, using electrocoagulation (middle 
right). Procedure is completed, leaving posterior wall attached to gallbladder bed 
(bottom).
what different and seems to take 
more time. The electrocoagulated 
edges of the gallbladder are approx­
imated by interrupted sutures, and 
the falciform ligament is applied. 
We regard the latter step as unnec­
essary.
Although we use this technique 
infrequently, our impression is that 
it provides a safe and simple alter­
native to cholecystectomy in high- 
risk patients.
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SESAP VI Question
Item 206
Which of the following agents produces direct cellular damage to the liver?
(A) Ether
(B) Halothane
(C) Enflurane
(D) Isoflurane
(E) None of the above
For the question above, select the one answer that is best of the five given.
For the critique of Item 206 see page 75.
(Reproduced by permission from SESAP VI Syllabus; Surgical Education and Self-Assessment Program No. 6. 
For enrolment in the Surgical Education and Self-Assessment No. 6, please apply to the American College of 
Surgeons, 55 East Erie St., Chicago, IL 60611.)
14 C'JS, VOL. 33. NO. 1. FEBRUARY 1990
,<&#8Sp
CUSTOMER SERVICE 1-800-361-9611
n im  -m m  
■
i-
I®
» w f
%S5*L*.
...then
LYOSTYPTl__
Collagen Haemostatic Felt
is the medium of choice
mm
wms- Indicationscapillary bleedings 
H I  . parenchymatous haemorrhages 
, oozing wound haemorrhages and 
as supporting measure for other techniques
of haemostasis
Advantages
immediate and secure haemostasis
excellent tissue compatibility
short absorption time
good handling properties because of fluid
stability
:J  T
..
. Exclusive Canadian distributor:
Fax: (5 14) 748-6240, Telex: 05-8276 55
CUSTOMER SERVICE 1-800-361-9611
>70 Barre, St. Laurent, H4L 4M6 Tel:. (514) Z-48-6558
Manufactured by:
B. Braun• —" - ~ ir_.
Woundhealing Division
D-3508 Melsungen/W.-<
-IT -* * *  ■ > - '  -  i  (  ^  *  JM . a .-k . .^ ^ 9  - f . . ;
CANADIAN ASSOCIATION OF CLINICAL SURGEONS
R esults of Fine-Wire Localization Breast 
Biopsies at the Cancer Control Agency of 
British Columbia
M.G. Clay, MD, FRCSC
Over the past 7 years at the Cancer Control Agency of British Columbia, fine-wire 
localization breast biopsies were performed with increasing frequency for 
mammographic findings suggestive of malignant disease. Because the rate of biopsy 
specimens negative for malignant disease was high, a policy was instituted to review 
all mammograms before carrying out a biopsy. As a result, the rate of positive 
biopsy findings increased from a mean of 29% to 33% and a further 16% of biopsy 
specimens were positive for premalignant disease. Of patients in whom a diagnosis 
of malignant disease was made, 60% had in-situ disease compared with 8.5% in the 
province overall. As a result of the earlier diagnosis, less radical surgery was 
possible. These findings support the value of mammography with fine-wire 
localization biopsy as a valid method for making an earlier diagnosis of breast 
cancer.
Au cours des 7 dernieres annees, l’Agence de surveillance du cancer de Colombie- 
Britannique a eu de plus en plus recours a la biopsie de localisation a l’aiguille fine 
lorsque les resultats de l’examen mammographique suggeraient la possibility d’une 
lesion mammaire maligne. A cause du taux eleve de biopsies negatives pour la 
presence de tumeurs malignes, on a instaure une politique de revision de tous les 
mammogrammes avant de proceder aux biopsies. II en a resulte une baisse du taux 
moyen des biopsies positives de 29% a 33% et, de plus, un autre 16% des biopsies a 
revele la presence de lesions premalignes. Parmi les patientes chez qui on a 
diagnostique une lesion premaligne, 60% souffraient d’un cancer in situ comparati- 
vement a un taux de 8.5% pour l’ensemble de la province. Consequence d’un 
diagnostic plus precoce, des interventions moins radicales ont ete possibles. Ces 
resultats montrent l’importance de la mammographie combinee a la biopsie de 
localisation a l’aiguille fine comme methode pour obtenir un diagnostic plus precoce 
du cancer du sein.
The lack of significant improve­ment in the long-term survival 
of women who have breast carcino­
ma continues to stimulate efforts to 
diagnose the disease earlier. Mam­
mography is an important feature
of these efforts. As the availability 
of mammography has increased, so 
has the frequency of fine-wire local­
ization biopsies.
During the 7 years that fine-wire 
localization biopsy has been per­
formed at the Cancer Control Agen­
cy of British Columbia, findings of 
malignant disease from the biopsy 
specimens have ranged from 44% in 
the initial year when only 27 biop­
sies were performed to 21% 2 years 
later when 138 biopsies were done 
(mean of 29% from 1983 to 1986 
inclusive). We considered these re­
sults unsatisfactory. In an attempt 
to overcome the high frequency of 
benign biopsy specimens, we insti­
tuted a policy whereby all mammo­
grams thought to demonstrate pos­
sible areas of malignancy are re­
viewed by Agency radiologists be­
fore the biopsy is carried out. Insti­
tution of this policy resulted in a 
rate of biopsy specimens positive 
for malignant disease of 33% in 
1988 (Table I).
In each of the last 6 years, we 
have diagnosed between 30 and 40 
malignant tumours from fine-wire 
localization biopsies, with a consid­
erable variation in the number of 
biopsies performed annually. In 
1986, before we initiated the current 
review process, the rate of biopsy 
specimens found positive for malig­
nant disease was 33% which was 
equalled only by the 1988 figures 
after we had begun the review proc­
ess. Discounting our initial year of
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performing this procedure, the 
highest recovery ever achieved was 
26%.
Biopsy Findings
Review of the patients who had 
breast biopsy in 1988 demonstrat­
ed that 77 had “benign” lesions 
and 38 had carcinoma (Table II). Of 
the benign lesions, 58 (50% of the 
total number of patients in the 
series) were completely benign, the 
diagnoses being fibrocystic disease, 
fibroadenoma and intramammary 
lymph nodes. However, in 19 
women (16% overall) marked epi­
thelial atypia was noted, and in 6 of 
them histologic changes approach­
ing, but not reaching, in-situ carci­
noma were demonstrated.
Analysis of the 38 women who, 
in 1988, had a diagnosis of malig­
nant disease demonstrated that 23 
(61%) had in-situ disease and 15 
(39%) invasive disease. This distri­
bution is in direct contrast to the 
distribution overall through the 
province where, in 1987, the latest 
year with complete reports, only 144 
(8.5%) of the 1698 new patients who 
had a diagnosis of breast carcino­
ma, had in-situ disease and the 
other 1554 (91.5%) had invasive dis­
ease. Such contrasting figures 
strongly support the value of the 
mammography program with fine- 
wire localization biopsy as a valid 
approach to the early diagnosis of 
breast carcinoma.
In addition to the possibility of 
increased long-term survival as a
result of early diagnosis, the poten­
tial for conservative surgery in our 
patients was increased. Of the 23 
women with in-situ disease, 4 had 
lobular carcinoma (Table III); of the 
19 with intraductal disease, 5 had 
comedocarcinoma with the antici­
pated risk of widespread intraductal 
disease in the involved breast. 
Women with invasive disease dem­
onstrated the expected distribution; 
only 1 had a lobular tumour and the 
other 14 had invasive ductal carcino­
ma.
Treatment
The treatment of most patients 
was dictated by the histologic find­
ings. Of the four women who had 
in-situ lobular carcinoma (Table IV), 
two initially underwent wide exci­
sion; one who had apparently com­
plete resection of the residual dis­
ease was thought to require no 
further treatment; another had such 
widespread in-situ disease that a 
total mastectomy was considered 
necessary. Analysis of the mastecto­
my specimen failed to reveal any 
residual disease. A third woman had 
wide excision and the specimen 
demonstrated generalized noninva- 
sive disease. She underwent a modi­
fied radical mastectomy in the prov­
ince where she lived. We would not 
have been as radical and would 
have advised a total mastectomy 
without axillary dissection; in fact, 
this woman had no involved nodes. 
The final woman had a total mas­
tectomy as her initial treatment, but
T a b le D a ta  o n  F in e -W ire  L o c a l iz a t io n  B io p s ie s  P e r fo rm e d  B e tw e e n  1 9 8 2  a n d  1 9 8 8
Y e a r
T o ta l
b io p s ie s
No.
p o s itiv e
%
p o s it iv e
1 9 8 2 2 7 12 4 4
1 9 8 3 1 1 6 3 0 2 6
1 9 8 4 1 3 8 29 21
1 9 8 5 1 3 3 3 0 2 3
1 9 8 6 1 2 0 4 0 3 3
1 9 8 7 1 4 6 35 2 4
1 9 8 8 1 1 5 38 3 3
she had previously had lobular car­
cinoma involving her other breast; 
we consider her treatment appropri­
ate.
Of the five patients with intraduc­
tal disease who had comedocar­
cinoma, only one had wide excision 
(Table V); fortunately there was no 
residual disease in the surgical 
specimen. We believe that patients 
with comedocarcinoma require a 
total mastectomy because of the 
high risk of multifocal disease. This 
opinion is justified by our findings 
in the four other patients treated by 
total mastectomy who were found 
to have widespread residual disease, 
one with extensive involvement 
throughout the breast.
The remaining patients with in- 
situ disease had ductal carcinoma 
without a comedo component (Ta­
ble VI). One had no further treat­
ment because the tumour was
T a b le  II.  B re a k d o w n  o f  " B e n ig n "  L e s io n s  
F o u n d  o n  F in e -W ire  L o c a l iz a t io n  B io p s y  in  
1 9 8 8
T y p e  ot les io n N o. ( % )
" C o m p le te ly ”  b e n ig n 5 8  (5 0 )
P re m a lig n a n t 1 9 ( 1 6 )
A ty p ia 1 3
A p p ro a c h in g  in  s itu 6
T o ta l 7 7  (6 6 )
T a b le  I I I .  B io p s y  R e s u lts  o f  P a t ie n ts  W ith  
C a rc in o m a
T y p e  ot c a n c e r N o . ( %  of to ta l)  
o f p a tie n ts
M a lig n a n t 2 3  (2 0 )
In -s itu  lo b u la r 4
In t ra d u c ta l ( c o m e d o  5 ) 1 9
In v a s iv e 1 5 ( 1 3 )
L o b u la r 1
D u c ta l 14
T o ta l 3 8  (3 3 % )
T a b le  IV . T re a tm e n t  o f  F o u r P a t ie n ts  W ith  
L o b u la r  C a rc in o m a  in  S itu
P ro c e d u re N o.
W id e  e x c is io n 1
W id e  e x c is io n  +  to ta l
m a s te c to m y 1
W id e  e x c is io n  +  m o d if ie d
ra d ic a l m a s te c to m y 1
T o ta l m a s te c to m y 1
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found to be contained within a 
fibroadenoma. A second patient had 
another disseminated nonmammary 
malignant tumour and received che­
motherapy for the other tumour 
without further treatment of the 
breast lesion. Seven patients had 
wide excision; of these, only two 
had no residual disease demonstrat­
ed in their second specimen. Of the 
five with residual disease, three had 
no invasion and, since their disease 
was considered to have been re­
moved completely, they had no fur­
ther treatment. The other two had 
infiltrating disease in the second 
specimen; one underwent a modi­
fied radical mastectomy and the
specimen showed no nodal involve­
ment, but the other, who also had a 
modified radical mastectomy, was 
found to have disease in one node. 
She had adjuvant chemotherapy 
and radiotherapy added to her treat­
ment. Four patients had a total
mastectomy without axillary dissec­
tion, two because of patient choice, 
one because the breast was too
small to be treated by wide local 
excision and the other because she 
had previously had carcinoma of 
the contralateral breast; she and
one of the patients who had select­
ed the mastectomy as her preferred 
treatment had no residual disease. 
The patient whose breast was too 
small had minimal residual disease 
and received no further treatment; 
the fourth patient, who also had 
selected mastectomy as her treat­
ment, was found to have disease at 
the deep resection margin so she 
received chest wall irradiation as 
adjuvant therapy. The final patient 
in this group had a modified radical 
mastectomy since she had diffuse 
intraductal involvement and had 
previously had a primary malignant 
tumour of the breast.
In the group of women who had 
invasive disease discovered by fine- 
wire biopsy (Table VII), the one 
with lobular carcinoma underwent a 
wide local excision with axillary 
node dissection. Her nodes were not 
involved and therefore she had no 
further treatment.
The patients with infiltrating duc­
tal carcinoma were treated either by 
wide excision and axillary dissection 
or by modified radical mastectomy, 
except for three patients who, be­
cause of age or other disease, un­
derwent a course of radiotherapy
T a b le  V . Trea tm en t o f Five Patients W ith C om edocarcinom a
P r o c e d u r e R e s id u a l  d is e a s e N o  r e s id u a l  d is e a s e
Wide excision 0 1
Total m astectom y 3 0
M odified radical m astectom y 1 0
T a b le  V I .  Treatm ent o f 14 Patients W ith  In-situ  Ductal Carcinoma
P r o c e d u r e
N o .  o f  
p a t ie n t s
R e s id u a l  N o  r e s id u a l  
d is e a s e  d is e a s e
No fu rthe r treatm ent 1 _ _
Chemotherapy 1 - -
Wide excision 7 5 (2 invasive) 2
Total m astectom y 4 2 2
M odified radical m astectom y 1 1 0
T a b le  V I I .  T rea tm ent o f 14 Patients W ith  Invasive Carcinoma
W id e  e x c is io n M o d i f i e d
T y p e  o f N o a n d r a d ic a l
c a n c e r t r e a t m e n t R a d ia t io n a x i l l a r y  d is s e c t io n m a s t e c t o m y
Lobular _ _ 1 _
Ductal 1 2 5 6
instead of further surgery. Of the 
five patients who had wide excision 
and axillary dissection, none had 
nodal involvement, but one had the 
mastectomy completed because of 
disease at the margins of the ex­
cised specimen; another had radio­
therapy after her operation because 
of intramammary lymphatic involve­
ment within the diseased area. Only 
one of the women treated by modi­
fied radical mastectomy had nodal 
disease (1 node of 19 recovered). It is 
notable that only 1 of the 15 women 
who had invasive disease had tu­
mour in her axillary nodes.
Conclusions
Our yield of positive breast biop­
sies has improved over the last 6 
years, but the number of malignant 
lesions diagnosed has remained rel­
atively stable. As a result, the num­
ber of patients offered fine-wire bi­
opsies has decreased. We believe 
that mammograms should be re­
viewed by radiologists in continuing 
efforts to improve the accuracy of 
preoperative radiologic assessment.
The early diagnosis afforded by 
mammography has allowed a larger 
number of women to be treated by 
conservative surgery than would be 
the case if diagnosis depended on 
the discovery of a breast mass by 
physical examination. This is main­
ly because of the large proportion 
of in-situ carcinomas in our series, 
and also because of the small size 
of the invasive lesions at the time of 
diagnosis.
We believe that our patients’ sur­
vival has not been compromised 
because of our approach. We ex­
pect a significantly improved surviv­
al rate from breast carcinoma diag­
nosed by mammography because of 
the greatly increased number of 
cancers diagnosed earlier than 
would have been allowed by tradi­
tional methods.*
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of ceftizoxime.
Drug Interactions: The concomitant administration of some cephalosporins and amino­
glycosides has caused nephrotoxicity. The effect of administering CefizoxTM concomitantly 
with aminoglycosides is not known.
Pregnancy: The safety of CefizoxTM in pregnancy has not been established. The use of 
CefizoxTM jn pregnant women requires that the likely benefit from the drug be weighed 
against the possible risk to the mother and fetus. The pharmacokinetics of CefizoxTM in 
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Genitourinary: Vaginitis
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No disulfiram-like reactions have been reported with CefizoxTM
TREATMENT OF OVERDOSAGE j
No case of acute overdosage has been reported to date; consequently there is no specif 
information available on symptoms or treatment. In cases of suspected overdosag 
supportive therapy should be instituted according to symptoms. Serum ceftizoxime leve 
can be reduced by hemodialysis. |
DOSAGE AND ADMINISTRATION ]
CefizoxTM (sterile ceftizoxime sodium) may be administered either intramuscularly or intre 
venously after reconstitution.
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Frequency and Route
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continued on page 76
CANADIAN ASSSOCIATION OF CLINICAL SURGEONS
Diaphragmatic Resection in Association 
With Right Hepatectomy
C.H. Scudamore. MD. MSc. FRCSC, FRCS(Edin), FRCS, FACS;* C.R. Shackleton, MD, FRCPC, 
FRCSC;* J.S. Fache, MD. FRCPC;t A.D. Forward, MD, FACS, FRCSC;*
S.R. Erb, MD. FRCPCJ
Ten cases of combined diaphragmatic and hepatic resection for tumours involving 
both structures are described. A complete work-up, including ultrasonography and 
computed tomography, usually can predict potential direct spread to the diaphragm. 
Up to 50% of the diaphragm can be excised and reconstructed without the need for 
prosthetic mesh or tissue transfer. Diaphragmatic resection does not appear to cause 
long-term postoperative morbidity. Diaphragmatic invasion by primary or secondary 
tumours does not preclude resection for cure. Pulmonary function studies are not 
necessary if there is no serious pre-existing lung disease.
On decrit 10 cas de resections diaphragmatique et hepatique concomitantes pour 
atteinte tumorale de ces deux structures. Un examen complet, comprenant une 
echographie et une tomodensitometrie, peut habituellement predire la possibilite 
d’un envahissement direct du diaphragme. Jusqu’a 50% du diaphragme peut etre 
excise et reconstruit sans qu’il y ait necessity d’utiliser une toile prosthetique ou de 
transferer des tissus. La resection diaphragmatique ne semble pas etre la cause de 
morbidity postoperatoire a long terme. L’envahissement diaphragmatique de tu- 
meurs primitives ou secondaires n’empeche pas une resection a visee curative. Des 
examens de la fonction pulmonaire ne sont pas necessaires s’il existe pas de maladie 
pulmonaire preexistante serieuse.
H epatic resection for benign and malignant conditions has be­
come more common over the past 
20 years. Death rates for hepatic 
resection have fallen to approxi­
mately 5% in noncirrhotic pa­
tients.1-3 A number of large series 
describing hepatic resection for pri­
mary and secondary tumours have 
provided data for asssessing mortal­
ity and long-term morbidity.4-7
Not infrequently, a tumour aris­
ing in the right hepatic lobe ex­
tends beyond the capsule and be­
comes adherent to or invades the 
overlying diaphragm. For such con-
Accepted for publication Aug. 11, 1989
ditions, combined surgical resection 
of the diaphragm and liver is neces­
sary. Because little has been written 
about this combined procedure, we 
report our experience in 10 pa­
tients. Controversy exists regarding 
the surgical strategy when a malig­
nant tumor extends into the adja­
cent diaphragm.
Patients and Methods
All 10 patients (6 men, 4 women) 
were treated by the by the hepatobi­
liary team at the Vancouver General 
Hospital, University of British Co­
lumbia between 1983 and 1987. 
This series is a retrospective review, 
since no patient was excluded from 
exploratory laparotomy because of 
suspected diaphragmatic involve­
ment. The patients ranged in age 
from 30 to 76 years (mean 46 
years).
Preoperatively, all patients under­
went an extensive general medical 
and metastatic work-up, which in­
cluded chest roentgenography, real­
time ultrasonography and computed 
tomography. Specific investigations 
were added when indicated by the 
clinical situation. These included 
preoperative and postoperative lung 
function studies in three patients, 
laparoscopy in two and lung tomog­
raphy in two others. In nine pa­
tients fine needle aspiration was 
attempted for cytologic study; it 
confirmed the operative diagnosis in 
seven patients. Patients with large 
tumours underwent selective mes­
enteric angiography, including ve­
nous phase portography. Nine pa­
tients presented with malignant tu­
mours, four metastatic (three colon­
ic, one breast) and four primary 
(three hepatomas, one mesotheli­
oma). One had an echinococcal cyst 
invading the diaphragm.
Right hepatic lobectomy was per­
formed in five patients: extended 
right hepatic lobectomy in three 
and segmentectomy in two. Median 
sternotomy was required to control 
hepatic veins in one patient who 
had a hepatoma greater than 30 cm 
in diameter. With respect to dia­
phragmatic resection, four patients 
had central resection, three had 
peripheral resection, two had pe­
ripheral and central resection and
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only one had an extended resection 
to include the abdominal wall. Mesh 
repair was not necessary in any of 
the 10 patients, even though more 
than 50% of the diaphragm was 
resected in one case. Eight patients 
required tube thoracostomy. No pa­
tient required a right lateral thora­
cotomy.
When diaphragmatic extension of 
the tumour is evident, the operative 
technique should be modified so 
that en bloc resection can be per­
formed. The entire liver should be 
mobilized to determine the extent of 
disease and ensure that no other 
tumours are present in the remain­
ing liver. We routinely perform op­
erative ultrasonography as well as 
bimanual palpation. The lymph- 
node-bearing areas are carefully in­
spected and a biopsy is done if 
metastatic disease is suspected.
We open the diaphragm 2 to 3 
cm away from any adherent tissue 
and explore the thoracic aspect of 
the diaphragm. Adherence to lung, 
pleural spread, malignant effusion 
or mediastinal nodal spread pre­
cludes resection. If no contraindica­
tions exist, the tumour-bearing liver 
and diaphragm are dissected free, 
leaving a 2-cm margin of normal 
tissue. If the liver is mobile and the 
defect is small, we carry out repair 
immediately after a tube thoracosto­
my has been performed under direct 
vision. If the defect is large and 
access to the diaphragmatic edges 
is difficult, the hepatic resection is 
completed to allow adequate access 
for repair.
The follow-up in these 10 pa­
tients was from 3 months to 5 
years.
Results
Two patients required reopera­
tion in the early postoperative peri­
od because of bleeding; one had an 
arterial bleeder on the cut edge of 
the diaphragm, the second required
removal of a large hematoma as a 
result of a generalized oozing from 
the posterior-inferior diaphragmatic 
surface. One patient died on postop­
erative day 2 because of an ob­
structing mucous plug which pre­
vented reintubation. All patients 
suffered from atelectasis, but in 
only two was major atelectasis (col­
lapse of a lobe) or pneumonia diag­
nosed postoperatively. Two patients 
had a right pleural effusion after 
the chest tube was removed. There 
were no recorded wound infections 
or prolonged periods of endotrache­
al inhibition. There were no epi­
sodes of eventration or herniation 
through the diaphragm (Fig. 1). 
The mean hospital stay was 11 
days.
Ultrasonography was the most 
accurate preoperative investigation
FIG. 1. (Top) Preoperative chest film 
showing tumour elevating right dia­
phragm. (Bottom) On postoperative 
day 7 chest tube has been removed, but 
subphrenic drain remains.
for predicting diaphragmatic in­
volvement (in 8 of the 10 patients, 
Fig. 2). In one of the remaining two 
cases, proximity to the diaphragm 
could have been diagnosed, but was 
not reported. Computed tomogra­
phy is useful in predicting diaphrag­
matic involvement especially if a 
right pleural effusion is identified, 
but this study lacks the dynamic 
qualities that ultrasonography can 
provide (Fig. 3).
Aspiration cytology was almost 
routine before laparotomy, except 
when the tumour was small and 
inaccessible. No complications de­
veloped as a result of tumour aspi­
ration. In the patient who presented 
with a mesothelioma, the aspiration 
biopsy was interpreted as adenocar­
cinoma. The echinococcal cyst was 
not aspirated. Hepatic angiography 
was performed when a major hepat­
ic resection was anticipated. It pro­
vided valuable results in identifying 
anatomic variants preoperatively, 
thus adding to the safety and speed 
of the hepatic resection. Further­
more, angiography may identify 
vascular encasement by metastatic 
disease and so prevent a fruitless 
laparotomy. However, the need for 
preoperative angiography is contro­
versial.8
Spirometry was performed in 
three patients before and after oper-
FIG. 2. Real-time ultrasonography 
showing right hepatic lesion (white 
arrow) invading diaphragm (black ar­
row).
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ation. However, the results 7 days 
postoperatively were essentially the 
same as those preoperatively except 
for a minor decrease in the forced 
expiratory volume at one second 
(Fig. 4). This was thought to be 
secondary to pain and weakness in 
the abdominal wound. Spirometry 
performed 6 weeks after surgery 
gave normal results.
Recurrent disease resulted in two 
late deaths; one patient had system­
ic metastases and the other had 
recurrent tumour in the remaining 
liver. One patient with a large hepa­
toma is alive with brain metastasis.
Discussion
Despite notable advances in sur­
gical technique, major hepatic re­
section remains a therapeutic chal­
lenge. Patients left with residual 
disease do not do as well as those in
whom all recognized disease is re­
moved.2-’
Although many have reported en­
couraging results after hepatic re­
section for secondary malignant dis­
ease in selected patients,6 few have 
been specific about spread to the 
diaphragm. Since no large series of 
hepatic resections has addressed the 
problem of diaphragmatic exten­
sion, the prognosis of combined 
resection remains essentially un­
known. Many authors report ex- 
trahepatic spread as a contraindica­
tion for resection.15' 10
Adson6 reported that 18% of pa­
tients who underwent hepatic resec­
tion for colonic metastases had ex- 
trahepatic extension. These patients 
probably did poorly because Adson 
did not include those who had ex- 
trahepatic disease in the overall 
survival results. Fortner and col­
leagues2 reported only two patients 
with diaphragmatic extension in 
their series of 247 consecutive pa­
tients who had colonic hepatic me­
tastases treated by hepatic resec­
tion. Both patients died within 7 
months of operation.
One of the problems in attempt­
ing to analyse the experiences of 
others is the difficulty in staging 
hepatic metastases. Fortner and col­
leagues2 included anatomic and 
pathologic criteria in their staging 
system so that a small tumour 
isolated to a resectable portion of 
the liver, theoretically stage I, 
would be considered a stage II 
lesion if it involved a major vessel 
or the bile duct, or extended direct­
ly to the diaphragm. There did not 
seem to be a substantial difference 
in survival between patients who 
had stage I or stage II tumours in 
Fortner’s series, suggesting that di­
rect extension outside the liver cap­
sule does not have a negative im­
pact on survival if the tumour is 
resectable. The criteria for resection 
of Logan and colleagues1 would 
exclude tumours not confined to 
the liver, which would include tu-
FIG. 3. Scan shows tumour (arrow) invading posterior lateral diaphragm.
FIG. 4. Results of spirometry done on postoperative day 7 on 66-year-old woman in 
whom 80 cm2 of central diaphragm had been removed. (Left) Slightly decreased 
lung volumes as compared to control. FEV 1 = forced expiratory volume in one 
second, FVC = forced vital capacity. (Right) Mildly restrictive flows but no change 
in flow as compared with preoperative values. MMFR = maximal midexpiratory flow 
rate (L/s).
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mours with diaphragmatic exten­
sion. Earlier attempts at staging of 
metastatic liver tumours was simply 
an estimated percentage of liver 
occupied by tumour; however, Pack 
and Ariel11 added a (+) after each 
stage, signifying the presence of 
extrahepatic tumour. Since no relia­
ble data exist for direct diaphrag­
matic extension, these staging sys­
tems may be misleading.12'13
We believe that direct extension 
to the diaphragm has the potential 
of lymphatic spread into other 
channels. One patient had a solitary 
hepatic metastasis which was moni­
tored for 11 months. At the time of 
resection, there was extension into 
the diaphragm and diaphragmatic 
lymphatics, which was noted only 
after a portion of diaphragm was 
removed. This extension and lym­
phatic invasion likely resulted from 
this solitary metastasis. The lym­
phatic extension might have been 
prevented had the patient under­
gone excision earlier.
Hepatoma is one of the world’s 
commonest lethal malignant lesions 
and is infrequently seen in white 
persons.13 Although it has been 
mentioned anecdotally, diaphrag­
matic resection in combination with 
hepatectomy is not an absolute con­
traindication for resection of hepa­
toma,14 but few authors have de­
scribed the long-term results after 
diaphragmatic resection. Since most 
Asian patients with hepatoma have 
cirrhosis, diaphragmatic resection 
in combination with hepatectomy is 
seldom an option. In noncirrhotics, 
or those who have small hepatomas 
on the hepatic surface, diaphrag­
matic resection should be consid­
ered.
The fibrolamellar variant of hepa­
toma is most frequently seen in 
young, noncirrhotic white patients 
and is characterized by its slow 
growth. This variant should be ma­
naged aggressively. If the tumour 
involves the diaphragm, it should
be removed with the specimen with 
clear resection margins if possi­
ble.1516
Diaphragmatic resection has been 
described for mesothelioma, but for 
the thoracic rather than the perito­
neal type. Our patient who had 
mesothelioma was initially assessed 
2 years before operation; at that 
time the biopsy specimen was inter­
preted as showing adenocarcinoma. 
When a repeat biopsy was done, a 
mesothelioma was diagnosed and a 
combined hepatic and diaphragmat­
ic resection was performed. The 
patient is disease free 2 years lat­
er.17
Resection of the diaphragm for 
hydatid disease of the liver has been 
well described.18 We included this 
case only to illustrate that the full 
thickness of the diaphragm need 
not be excised. It is not established 
whether a full-thickness portion of 
diaphragm must be taken to pre­
vent regional spread if a tumour is 
partially invading the diaphragm. A 
frozen section of the resection mar­
gins should be obtained before dia­
phragmatic reconstruction is at­
tempted.19-21
Until prospective data are avail­
able, we believe that direct exten­
sion of a hepatic tumour into the 
adjacent diaphragm is not a contra­
indication for resection, provided 
the whole lesion can be removed en 
bloc.
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Follow-up of Patients Who Have 
Undergone Ileogastrostomy
C.K. Dingee, MD; I.G.M. Cleator, MB, ChB, FRCSC, FRCS(Edin), FRCS, FACS;
J.K. MacFarlane, MD, CM, MSc, FACS, FRCSC; R.M. Christensen, MD, FACS, FRCSC; 
C.L. Birmingham, MD, FRCPC; J. Appleby, MD; R.H. Gourlay, MD, FRCSC
Patients who have had ileogastrostomy for the treatment of morbid obesity require 
close, long-term follow-up. From a prospective study of a large number of variables 
in 12 consecutive patients, and from experience with more than 200 patients who 
have undergone this procedure since 1982, a protocol has evolved. The authors 
outline the associated morbid conditions, operative complications and biochemical 
alterations that are important in the management of these patients.
Les patients ayant subi une ileogastrostomie dans le cadre d’un traitement contre 
l’obesite morbide doivent etre suivis de pres sur une longe periode. II a ete possible 
d’etablir un protocole d’apres une etude prospective d’un grand nombre de variables 
realisee sur 12 patients de suite et grace aux enseignements pratiques tires de plus 
de 200 patients qui ont subi cette operation depuis 1982. Les auteurs decrivent les 
conditions associes morbides, les complications operatoires et les modifications 
biochimiques qui sont si importantes dans les soins et le traitement de ces patients.
I leogastrostomy for the treatment of morbid obesity has been de­
scribed by Cleator and Gourlay.12 
At St. Paul’s Hospital in Vancouver, 
the procedure has been performed 
in over 200 patients since its intro­
duction in 1982. Other surgeons as 
far away as Australia are now carry­
ing out this procedure. Close fol­
low-up of patients who undergo 
ileogastrostomy is essential, and 
their availability for long-term as­
sessment is a prerequisite for sur­
gery. The purpose of this paper is 
to introduce our protocol for the 
pre- and postoperative assessments 
of morbidly obese patients.
The Surgical Procedure
As previously described,1 an end-
to-end jejunoileal bypass is con­
structed, with the proximal jejunum 
measuring 25 cm and the distal 
ileum 50 cm (Fig. 1). The proximal 
end of the resultant blind loop is 
closed and a wide antecolic anasto­
mosis is carried out between the 
distal blind loop and the parietal 
cell mass area of the anterior stom­
ach.
Patients and Methods
Our protocol evolved from an 
analysis of the data from a series of 
12 consecutive morbidly obese pa­
tients who underwent ileogastrosto­
my. A large number of variables 
were measured pre- and postopera- 
tively (Table I). Long-term follow­
up of these and 200 other patients
who have undergone ileogastrosto­
my since 1982 has identified the 
late complications that may be ex­
pected.
Statistical analysis of the physio­
logic variables was carried out by 
constructing confidence intervals to 
bracket the true change in variables 
in the 12 patients.
Results
Significant changes (p < 0.05) 
were noted in a number of variables 
(Table I). There was a significant 
decrease in serum carotene, iron 
and blood urea nitrogen levels. 
There was a significantly (p < 0.05) 
large fall in cholesterol, LDL- 
cholesterol and triglyceride levels 
and a smaller but still significant 
decrease in the HDL-cholesterol 
level. The alkaline phosphatase, as­
partate aminotransferase and lactic 
dehydrogenase levels increased sig­
nificantly. However, there was a 
high incidence of hepatic steatosis
FIG. 1. Ileogastrostomy.
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preoperatively. Long-term follow-up 
showed that at 18 months 86.3% of 
the patients had normal liver func­
tion; the remainder had minimal 
disturbance of liver function, with 
less than 10% increase in liver en­
zyme levels. There was a mean 
weight loss of 22.9 kg (range from 
10.9 to 36.5 kg). The 3-day calorie 
counts demonstrated a postopera­
tive decrease in calorie consumption 
of 320 to 3870 kcal (mean 1975 
kcal) (1339 to 16 192 kJ [mean 
8263 kJ]).
The Protocol
A comprehensive computer form 
is used to enter data prospectively. 
Each patient is given a study num­
ber. Standard demographic data are 
recorded. Patients are defined as 
being morbidly obese according to 
the Metropolitan Life Insurance 
Company 1983 tables.3 The age of 
onset of obesity, the coexistence of 
obesity in parents and siblings and 
the qualitative calorie intake are 
included to stress the important 
contribution of heredity, environ­
ment and psychosocial factors.
Excess weight affects all organ 
systems and there is a direct rela­
tionship between the degree of mor­
bid obesity and the incidence of 
cardiovascular, pulmonary, locomo­
tor, endocrine, gastroenterologic 
and renal problems that shorten 
life.43 It is mandatory to recognize 
and assess serious coexisting condi­
tions in obese patients. In our pro­
tocol, the presence of coincidental 
disease is noted under each organ 
system. Not only are medical condi­
tions for which ileogastrostomy is 
contraindicated readily identified, 
but an accurate preoperative record 
is made of preexisting disease, 
which otherwise might later be in­
terpreted as a result of the opera­
tion (Table II).
The ideal candidate for bypass 
surgery is young (aged 18 to 50
years), intelligent, well motivated 
and psychologically stable6 Most of 
these patients have had repeated 
failures of attempts to reduce
weight medically with diet, behavi­
our modification and medication. 
Some have had surgical procedures 
previously. The salient features of
Table I. Blood Biochemistry: Deviations From Normal Values in St. Paul’s Hospital, Vancouver,
Laboratory
Variable
Test measured Preop Postop Significance
Malabsorption
Fat soluble vitamins
A Carotene, Mmol/L 1.92 0.33 <0.05
D Calcium, mmol/L 2.30 2.30
K Prothrombin time, s 12.32 12.72
Fat 72-h stool, g/d 34.2 143.4 <0.05
Carbohydrate Glucose, mmol/L 5.31 5.23
Liver function Albumin, g/L 40.2 40.2
Protein, g/L 67.3 67.0
Alkaline phosphatase, U/L 
Aspartate aminotransferase,
83.25 113.58 <0.05
U/L 32.33 55.18 <0.05
Lactate dehydrogenase, U/L 192.17 227.83 <0.05
Bilirubin, Mmol/L 9.58 10.6
Electrolytes Na, mmol/L 140.25 143.33
K, mmol/L 4.13 3.60 <0.05
Cl, mmol/L 106.33 108.17
Mg, mmol/L 0.81 0.68
Renal function Blood urea nitrogen, mmol/L
urea 4.00 2.95 <0.05
Creatinine, Mmol/L 75.14 73.37
Hematologic measurements Hemoglobin, g/L 139.10 135.30
Leukocytes, x  109 /L 7.57 6.66 <0.05
Platelets, x  109 /L 292.33 262.92 <0.05
Partial thromboplastin time, s 29.09 31.61
Thyroid function Thyroxine, pmol/L 
Thyroid stimulating hormone,
15.19 14.67
mU/L 2.71 2.14
Lipid studies Cholesterol, mm ol/L 5.65 3.08 <0.05
HDL-cholesterol, mm ol/L 1.01 0.65 <0.05
LDL-cholesterol, mm ol/L 3.56 1.71 <0.05
Triglycerides, mm ol/L 2.06 1.57 <0.05
Miscellaneous Iron, Mmol/L 16.97 11.95 <0.05
Uric acid, Mmol/L 375.32 347.96 <0.05
Phosphorus, mm ol/L 1.05 1.04
Table II. Information Obtained on the Preoperative Assessment Form
Date information taken Thrombophlebitis Other (specify)
Sex Other Renal-parenchymal
Date of birth Asthma (specify) Obstructive stones
Height in cm Chronic obstruction Other
Weight in kg Sleep apnea No. pregnancies
Bone structure (light Other (specify) Hysterectomy
medium, heavy) Osteoarthritic knees Previous admission to
Ideal weight Spinal pain psychiatry
Age onset of obesity Gout Lithium or major tranquillisers
Average daily caloric Other (specify) at any time
intake Diabetes mellitus Other (specify)
Mother/father obese (diet controlled) No. previous hospital
No. brothers Oral hypoglycemia admissions for obesity
No. brothers obese Insulin dependence No. previous hospital
No. sisters Cushing’s syndrome admissions for other
No. sisters obese Stein—Leventhal syndrome Previous surgery for obesity
Coincidental conditions Other (specify) Previous surgery for other
(yes =  1, no =  2) Cholelithiasis reasons
Cardiac Fatty liver
Hypertension Peptic ulcer
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the medical and psychiatric history 
are recorded on an assessment form 
(Table II). Although it has been 
used mainly for follow-up of ileo- 
gastrostomy patients, this form can 
also be used in the follow-up of 
patients who undergo gastroplasty 
or other obesity procedures.
All complications encountered in 
the postoperative period are tabulat­
ed (Table III). From our experience 
with 200 patients, the most fre­
quent complications are wound in­
fections (6.6%), respiratory compli­
cations (2.2%) and electrolyte dis­
turbances requiring correction 
(6.8%). Although 70% of patients 
had loose bowel movements at 3
months after operation, this prob­
lem subsequently resolved.
Milk and milk products are dis­
couraged in the early postoperative 
period. The only dietary supplement 
is one multivitamin tablet daily.
Patients are followed up by the 
attending surgeons at monthly in­
tervals until the bowel and blood 
biochemistry have stabilized, then 
at 3-monthly intervals for 1 year 
and every 6 months for 1 year. In 
addition, when the patient lives in a 
geographically remote area, the re­
ferring physician receives a copy of 
the protocol and checks on the 
patient between visits to the sur­
geon. At each visit, the patient is
weighed, and waist and hip mea­
surements are taken. A number of 
blood tests (those shown to change 
substantially postoperatively) are 
also done. They are: lipid profile, 
complete blood count, tests of liver 
and renal function, and selected 
tests to screen for malabsorption 
(Table IV). Persistent oxaluria has 
been noted in several patients. This 
is not corrected by the oral adminis­
tration of calcium. Vegetables, 
which are high in oxalates, for 
example, are discouraged.
At each follow-up visit, the pa­
tient is also questioned regarding 
any change in bowel habit, the 
frequency and consistency of stool 
and the presence of excessive flatus 
or bloating. Dietary indiscretion was 
the cause of bloating in some pa­
tients, and at 18 months after oper­
ation 35% experience bloating occa­
sionally. The bloating can be cor­
rected in many patients by the use 
of 250 mg of Flagyl daily.
Ileogastrostomy has been sug­
gested as an effective treatment for 
morbid obesity, and we have found 
this protocol to be effective in the 
management of these patients, both 
preoperatively and postoperatively.
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Tab le  III. Information Obtained on the Postoperative Assessment Form
Date of operation 
Postoperative complications
Pulmonary Gastrointestinal
Failure Stomal ulcer
Atelectasis Liver failure
Pneumonia Anastomotic leak
Embolism Other
Other Renal
Cardiac Stones
Failure Sepsis
Arrhythmia Other
Pericarditis Lower limb
Other Phlebothrombosis
Wound Other complications (list)
Sepsis Separation
Dehiscence Alive
Subphrenic abscess normal convalescence
Intra-abdominal abscess stay increased by complications 
Died in hospital 
date 
cause
T a b le  IV. Laboratory Information Obtained on Admission, at 3-Month Intervals fo r 1 Year and at 
6-M onth Intervals Thereafter
Date Blood urea nitrogen
Weight in kg Creatinine
Girth measurement Uric acid
waist Carotene
hips Iron
Average daily caloric intake Magnesium
last week Calcium
Cholesterol Vitamin B12
HDL-cholesterol Folic acid
LDL-cholesterol Urinalysis
Triglycerides normal
Glucose abnormal
Hemoglobin specify abnormality
Leukocyte count Bowel status
Alkaline phosphatase flatus and bloat
Aspartate aminotransferase no. formed bowel m ovem ents/d
Potassium no. loose bowel movements/d
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Hydatid Cyst Presenting As a Breast 
Lump
J.M. Radhi, MB, ChB, MRCPath; M.J. Thavanathan, MB, BS, FRCS(Edin)*
Cystic hydatid disease is caused by the parasite Echinococcus granulosus. 
Indigenous infections are seen among the Indians and Inuit. Man is an occasional 
intermediate host in whom the disease is manifested by the presence of one or more 
hydatid cysts, usually located in the liver or lung and rarely at other sites such as 
the breast, as in this case report. The cyst is usually asymptomatic; in this it case 
was discovered on routine mammography. On aspiration biopsy, 1 ml of clear fluid 
was removed, but there was a residual lump which was successfully excised.
L’hydatidose est causee par le parasite Echinococcus granulosus. On peut rencon- 
trer des infections indigenes parmi les Amerindiens et les Innus. L’homme est un 
hote intemediaire occasionnel chez qui la maladie se manifeste par la presence d’un 
ou plusieurs kystes hydatiques habituellement localises au foie ou aux poumons et, 
rarement, a d’autres endroits tels que le sein, comme on le signale dans cet article. 
Le kyste est habituellement asymptomatique. Dans le present cas, il fut decouvert 
lors d’une mammographie de pratique courante. A la ponction-biopsie, 1 ml de 
liquide clair fut retire, laissant une masse residuelle qui fut excisee avec succes.
C ompared with the European form, hydatid cysts in northern 
North America and Alaska are smal­
ler, more delicate in structure, 
cause fewer symptoms and compli­
cations and have an excellent prog­
nosis.1 We describe the case of a 
31-year-old woman who had a 
breast lump which, on pathological 
examination, was found to be a 
hydatid cyst. To our knowledge, 
this represents the first case of
Accepted for publication Jan. 16, 1989
hydatid disease of the breast report­
ed in Newfoundland and Labrador.
Case Report
A 31-year-old Inuit woman pre­
sented with a lump in the right 
breast which had been detected by 
her family doctor on routine exami­
nation. She did not have any pain 
or discharge from the nipple. There
was no family history of breast 
cancer. She was taking Triphasil 
contraceptive pills.
On examination, the left breast 
was normal. The right breast was 
slightly smaller and there was dif­
fuse, brownish speckling of the 
skin. A mobile lump, 2 X 1.5 cm in 
dimension, was palpable in the 12 
o’clock position. Both nipples were 
normal. There was no axillary or 
supraclavicular lymphadenopathy. 
Abdominal examination did not re­
veal any organomegaly. The chest 
x-ray film appeared normal. On nee­
dle aspiration of the lump in the 
right breast, 1 ml of clear fluid was 
obtained. Post-aspiration examina­
tion revealed a residual lump, so an 
excisional biopsy was done.
The mass appeared to be a cyst 
with thickened membranes. On 
gross examination, the specimen 
measured 4 X 3 X 3 cm and 
consisted of fibrofatty tissue, in 
which was included an open fibrous 
walled cyst measuring 2.5 cm in 
diameter with a semitranslucent, 
shiny inner surface (Fig. 1). Micro­
scopically, the fibrocollagenous wall 
was infiltrated by lymphocytes and 
eosinophils. Within the lumen were 
germinal layers, laminated mem­
branes, scolices and hooklets, char­
acteristic of a hydatid cyst.
Discussion
Echinococcosis is an infection by
From the Charles S. Curtis Memorial Hospital, Grenfell Regional Health Services, St. Anthony, 
Nfld.
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larval tapeworms of the genus Echi­
nococcus. Echinococcus granulosus 
is the most common species, but 
Echinococcus multilocularis and 
Echinococcus olgarthrus also infect 
man.
This disease used to be a serious 
problem in sheep-raising regions, 
especially Australia, New Zealand 
and Iceland. Today, it is most prev­
alent in East Africa, Mediterranean 
countries, some parts of the USSR 
and Middle East, South America, 
Uruguay, Chile and Argentina. In­
fections are seen among Indians in 
the southwestern United States and 
in Indians and Inuit in the northern 
regions of North America.1
The definitive host includes many 
species of carnivores, the most im­
portant being the dog. Gravid pro- 
glottids pass in the feces and rup­
ture, releasing eggs that are swal­
lowed by the intermediate host 
mammal. The eggs hatch in the 
intestine, releasing oncospheres 
that penetrate the intestinal muco­
sa, enter the blood stream and 
develop into hydatid cysts in vari­
ous organs and tissue. The life
FIG. 1. Thick-walled cyst having semi- 
translucent inner surface.
cycle is completed when a cyst is 
ingested by a definitive host.
Hydatid disease of the breast is 
extremely rare.2 In our patient, the 
breast lump was noted incidentally 
on a routine medical examination. 
Typically, the patient presents with 
a long history of a breast lump, and 
mammography reveals an opacity 
with calcification which must be 
differentiated from that of a calci­
fied fibroadenoma. Immunologic 
tests such as intradermal and indi­
rect hemagglutination tests are 
rarely performed and vary in degree 
of reliability.3
From the clinical standpoint, the 
differences between E. granulosus 
of northern North America and the 
standard European type are out­
standing. The laminated membrane 
is delicate, bluish and semitranslu- 
cent, reminiscent of waxed paper, in 
the North American hydatid cyst 
but, in the European type, it resem­
bles the white of a boiled egg.1 
Some of the peculiarities recognized 
by Cameron4 led Wilson and associ­
ates5 to propose that the North 
American form be designated a vari­
ety of E. granulosus and called E. 
granulosus var. canadiensis. The 
larval stage of this form has adapt­
ed to development in large deer, 
especially moose, reindeer and cari­
bou. The wolf is the natural defini­
tive host and dogs can become 
infected; domestic animals such as 
sheep, cattle and pigs are resistant 
to the parasite. In the European 
type, the cysts most commonly 
occur in the liver, whereas the lung 
is the most commonly affected
organ in the North American type. 
The size of the cyst in the latter 
type rarely exceeds 6 cm in diame­
ter, but in the former, cysts may be 
much larger. Cyst rupture and 
other complications are less fre­
quent in the North American type. 
If the cysts do rupture, the risk of 
secondary growth of germinal ele­
ments or anaphylaxis is not great, 
and the prospect of spontaneous 
cure without complications seems 
excellent.
It has been suggested that the 
clinical differences between the Eu­
ropean and North American forms 
of E. granulosus may be explained 
by the fact that man is apparently 
not as suitable a host for the North 
American type of the parasite as he 
is for the European type.5
We thank Dr. M. Gillett for his com­
ments, Mrs. Cora Snow for typing the 
manuscript and Mr. Anthony Cronhelm 
for the photography.
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Action
In vitro studies indicate that the bacterial action ol Claforan (cefotaxime sodium) a semi synthetic cephalosporin 
antibiotic, results from inhibition of cell wall synthesis.
Indications and Clinical Uses
Treatm ent: Claforan (cefotaxime sodium) may be indicated for the treatment of infections caused by susceptible 
strains of the designated micro organisms in the diseases listed below.
Lower respiratory tract in fe c tio n s : pneumonia and lung abscess caused by Streptococcus pneumoniae 
(formerly Diplococcus pneumoniae), other streptococci (excluding enterocci, e.g. S. faecalis), Straphylococcus 
aureus (penicillinase and non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including 
ampicillin resistant strains) and unspecified Klebsiella species.
Urinary tract in fec tions : caused by Escherichia coli, unspecified Klebsiella species (including K. pneumoniae), 
Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated 
gonorrhea caused by N. gonorrhoeae including penicillin resistant strains.
B acterem ia /S e pticem ia : caused by Escherichia coli, unspecified Klebsiella strains and Serratia marcescens 
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non-penicillinase producing, S. epidermidis, 
Group A streptococci, Escherichia coli, Proteus mirabilis and indole positive Proteus 
Intra-abdominal in fec tions : caused by Escherichia coli, and unspecified Klebsiella species.
Gynecological in fec tions : including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by 
E. coli, Group A streptococci and Staphylococcus epidermidis, anaerobic bacteria including unspecified Peptococcus 
and Peptostreptococcus strains and some strains of Bacteroides fragilis. In several cases, although clinical cures 
were achieved, bacteriological follow up was not available.
Clinical experience with Claforan in anaerobic infections is limited. Claforan has been used with some success in 
wound and intra-abdominal infections against some strains of unidentified Bacteroides and anaerobic cocci. 
Claforan has been shown to be active against some strains of Pseudomonas
In the treatment of infections encountered in immunosuppressed and granulocytopenic patients, results of therapy 
with Claforan have not been impressive.
Claforan should not be considered in the treatment of enterococcal infections, i.e. Streptococcus faecalis. 
Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify the causative 
organisms and to determine their susceptibilities to Claforan. Therapy may be instituted before results of susceptibility 
studies are known; antibiotic treatment should be re evaluated once these results become available.
Prophylactic U se : The administration of Claforan perioperatively (preoperatively, intraoperatively and postoperatively) 
may reduce the incidence of certain infections in patients undergoing elective surgical procedures (e.g. abdominal 
or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or 
potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased risk of infection, intraoperative 
(after clamping the umbilical cord) and postoperative use of Claforan may also reduce the incidence of certain 
postoperative infections.
Effective use for elective surgery depends on the time of administration (see Dosage and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as 
with a non absorbable antibiotic (e.g. neomycin) is recommended.
If there are signs of infection, specimens for culture should be obtained for identification of the causative organism 
so that appropriate therapy may be instituted.
Contraindications
Claforan is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, the cephalosporin 
or the penicillin groups of antibiotics.
Warnings
Before therapy with Claforan is instituted, it must be carefully determined whether the patient has had previous 
hypersensitivity reactions to cefotaxime, cephalosporins, penicillins or other drugs. Claforan should be given with 
caution to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including Claforan should be 
administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs. If an 
allergic reaction to Claforan occurs, the drug should be discontinued and the patient treated with the usual agents 
(e.g. epinephrine, antihistamine, pressor-amines or corticosteroids).
Pseudomembranous co litis  has been reported w ith  the use of cephalosporins (and other broad spectrum 
antib io tics); therefore, i t  is im portan t to consider its diagnosis in patients who develop diarrhea during 
the adm inistration of Claforan. This co litis  can range from  m ild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as Claforan, alters the normal flora of the colon and may permit 
overgrowth of Clostridium difficile or other Clostridia. It has been established that a toxin produced by Clostridium 
difficile is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of Claforan and replacement with a suitable specific antibiotic. 
Moderate to severe cases should be managed with fluid, electrolyte and protein supplemntation as indicated.
When the colitis is not relieved by discontinuance of Claforan administration or when it is severe, an antibiotic 
specifically effective in antibiotic-associated pseudomembranous colitis (e.g. vancomycin) or other suitable therapy 
may be indicated. Other possible causes of colitis should also be considered (see Adverse Reactions).
Precautions
Claforan (cefotaxime sodium) should be prescribed with cauton in individuals with a history of lower gastro­
intestinal disease, particularly colitis.
The safety of Claforan in pregnancy has not been established. Consequently, use of the drug in pregnant women 
requires that the likely benefit from the drug be weighed against the possible risk to the mother and fetus.
Use of Claforan in women of child-bearing potential requires that the anticipated benefits be weighed against the 
possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be exercised when the drug is 
administered to nursing mothers.
Prolonged use of Claforan may result in the overgrowth of nonsusceptible organisms. Constant evaluation of the 
patient's condition is essential. If super-infection occurs, therapy should be discontinued and appropriate measures 
taken.
Although Claforan rarely produces alterations in kidney function, evaluation of renal status is recommended, 
especially in severely ill patients receiving high doses.
Patients with markedly impaired renal function should be placed on the special dosage schedule recommended 
under Dosage and Administration, because normal dosage in these individuals is likely to produce excessive and 
prolonged serum antibiotic concentrations.
Positive direct Coomb's test is known to develop in individuals during treatment with the cephalosporin group of 
antibiotics, including cefotaxime sodium.
In laboratory tests a (also positive reaction to glucose may occur with reducing substances but not with the use 
of specific glucose oxidase methods.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with Claforan, no specific information on symptoms or 
treatment is available. Treatment of overdosage should be symptomatic.
Dosage and Administration
Claforan (cefotaxime sodium) may be administered intramuscularly or intravenously after reconstitution (see Table 
with recommended mode of reconstitution according to route of administration).
Adults
The dosage of Claforan should be determined by susceptibility of the causative organisms, severity of the infection 
and condition of the patient.
Guidelines for Dosage of Claforan (cefotaxime sodium)
Type of Infection
Daily Dose
(g) Frequency and Route
Uncomplicated Gonorrhea 1 1 g IM (single dose)
Uncomplicated infections 2 1 g every 12 hours IM or IV
Moderately severe to severe infections 3-6 1-2 g every 8 hours IM or IV
Very severe infections (e.g. septicemia) 6-8 2g every 6-8 hours IV
Life-threatening infections up to 12 2 g every 4 hours IV
To prevent postoperative infection in contaminated or potentially contaminated surgery, recommended doses are 
as follows.
(a) 1 g IM or IV administered 1/2 to 1-1/2 hours prior to the initial surgical incision to ensure that adequate 
antibiotic levels are present in the serum and tissues at the start of surgery
(b) 1 g IM or IV administered 1-1/2 to 2 hours following the first dose; for lengthy operative procedures, additional 
intraoperative doses may be administered, if necessary, at appropriate intervals (1-1/2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery 
The total cumulative prophylactic dose should not exceed 6g in a 12 hour period
Caesarian Section Patients
The first dose of 1 g is administered IV as soon as the umbilical cord is clamped. The second and third doses 
should be given as 1 g IM or IV at 6 and 12 hours after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended 
Neonates: 0-1 week of age 50 mg / kg IV q 12 h
1-4 weeks of age 50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg, the recommended daily dose is 
50 to 100 mg / kg IM or IV of body weight divided into 4 to 6 equal doses, or up to 180 mg / kg / day for severe 
infections.
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of Claforan should be continued for a minimum of 48 to 72 hours after the patient defervesces or 
after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended for 
infections caused by Group A beta-hemolytic streptococci in order to guard against the risk of rheumatic fever or 
glomerulonephritis; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic urinary 
tract infections and may be required for several months after therapy has been completed; persistent infections may 
require prolonged treatment. Doses less than those recommended should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2 the dose of Claforan should be 
halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on sex, weight, and age of the patient) 
may be used to convert these values into creatinine clearance.
Males: Weight (kg) x  (140 -  age)
72 x  serum creatinine 
Females: 0.85 x  above value
Administration
In tra m uscu la r: Claforan should be injected well within the body of a relatively large muscle such as the upper 
outer quadrant of the buttock (i.e. gluteus maximus); aspiration is necessary to avoid inadvertent injection into a 
blood vessel.
In travenous: The intravenous route is preferable for patients with bacteremia, bacterial spticemia, or other severe 
or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from 
such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if 
shock is present or impending.
For bolus administration a solution containing 1 or 2 g of Claforan can be injected over a period of 3 to 5 minutes. 
Using an infusion system, it may also be given over a longer period of time through the tubing system by which 
the patient may be receiving other intravenous solutions. Butterfly* or scalp vein type needles are preferred for this 
type of infusion. However, during infusion of the solution containing Claforan, it is advisable to discontinue 
temporarily the administration of other solutions at the same site.
ADD-Vantage* Vial
When administering Claforan using the ADD-Vantage* Drug Delivery system, Claforan powder is added directly to a 
single-dose flexible plastic ADD-Vantage* diluent container. Claforan 1 g or 2 g may be reconstituted in 50 mL or 
100 mL of 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP.
Stability
Solutions of Claforan reconstituted in 5% Dextrose Injection USP or 0.9% Sodium Chloride Injection USP in the 
ADD-V&ntage* flexible containers maintain satisfactory potency for 12 hours at room temperature.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder, in vials containing 500 mg,
1.0 and 2.0 g of cefotaxime sodium and in ADD-Vcintage* vials containing 1.0 and 2.0 g of cefotaxime sodium 
(expressed as acid on a dry basis).
S tora ge: Claforan in the dry state should be stored at room temperature protected from light and heat.
Product monograph available on request.
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Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
Hypersensitiv ity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflammation with intravenous 
administration. Pain, induration and tenderness after intramuscular injection. Gastrointestinal (1.7%): Colitis, 
diarrhea, nausea and vomiting. Symptoms of pseudomembranous colitis can appear during or after Claforan 
treatment. Hemic and Lymphatic System ( <  1%): Mild, reversible leukopenia, granulocytopenia and thrombo­
cytopenia have been reported. Some patients developed positive direct Coomb's test during treatment with 
Claforan. Genitourinary System ( <  1%): Moniliasis, vaginitis. Liver ( <  1%): Transient elevations in SGOT, SGFT, 
serum LDH and serum alkaline phsphatase levels have been reported Kidney ( <  1%): Increased serum creatinine 
and BUN have occasionally been observed. Central Nervous System (0.2%); Headache.
•Reg’d TM of Abbott Laboratories.
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Desmopressin Acetate in Uncomplicated 
Coronary Artery Bypass Surgery: a 
Prospective Randomized Clinical Trial
Giles S. Hedderich, MD; Dimitri J. Petsikas, MD; Bernard A. Cooper, MD, FACP, FRCPC;
Mavis Leznoff, RT; Albert J. Guerraty, MD, FRCSC; Normand L. Poirier, MD, FRCSC;
James F. Symes, MD, MSc, FRCSC; Jean E. Morin, MD, FACS, FRCSC
Bleeding in coronary artery bypass procedures increases morbidity and exposes 
patients to the risks associated with blood transfusion. Desmopressin acetate 
(DDAVP), a synthetic vasopressin analogue, may limit bleeding during cardiac 
surgery. In a prospective randomized trial, the authors evaluated the ability of 
DDAVP to reduce perioperative bleeding during uncomplicated coronary bypass 
operations.
Sixty-two patients who underwent coronary artery bypass grafting were 
randomized to receive intraoperatively either a placebo or DDAVP. Both groups 
were similar with respect to operative characteristics and preoperative hematologic 
profiles, von Willebrand factor levels increased postoperatively in both placebo (2.77 
± 1.06 versus 2.17 ± 1.51 U) and DDAVP groups (2.75 ± 0.94 versus 1.80 ± 0.88 
U). Only the increase in the DDAVP groups was significant (p < 0.001). There was 
no difference in total blood loss between the placebo (1826 ± 849 ml) and DDAVP 
groups (1716 ± 688 ml). Total red cell transfusions were similar in placebo (3.4 =t 
1.3 units of blood) and DDAVP groups (3.6 ± 0.8 units).
These results do not support the intraoperative use of DDAVP to reduce 
perioperative bleeding in routine coronary artery bypass surgery.
Les pertes sanguines peroperatoires lors de pontages coronariens augmentent la 
morbidity et exposent les patients aux complications des transfusions. L’acetate de 
desmopressin synthetique (DDAVP) peut possiblement diminuer les pertes sangui­
nes. Dans cette etude, les auteurs evaluent de fafon prospective la valeur de son 
usage pour diminuer les pertes sanguines peroperatoires lors de pontages 
aortocoronariens conventionnels.
Soixante-deux patients ont re?u soit un placebo ou du DDAVP. Les deux groupes 
avaient des profiles hematologiques semblables. Le niveau du facteur von Wille­
brand augmenta dans les deux groupes; placebo (2.77 ± 1.06 versus 2.17 ± 1.51 U) 
et DDAVP (2.75 ± 0.94 versus 1.80 ± 0.88 U). Seulement l’augmentation dans le 
groupe DDAVP etait significative (p < 0.001). II n’y a pas de difference dans les 
pertes sanguines entre le groupe placebo (1826 ± 849 ml) et DDAVP (1716 ± 688 
ml). La quantite de sang transfusee n’est pas differente entre les deux groupes — 
placebo (3.4 ± 1 .3  unites de sang) et DDAVP (3.6 ± 0.8 unites).
Cette etude ne supporte pas l’usage de DDAVP lors d’operations pour pontages 
coronariens de routine en vue de diminuer les pertes sanguines.
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Oncology, Royal Victoria Hospital, McGill University, Montreal, PQ
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A lthough the morbidity and mortality after coronary artery 
bypass have been reduced, perioper­
ative bleeding continues to pose 
problems. Most patients who re­
quire re-exploration because of he­
morrhage have bleeding due to the 
surgical procedure, 12 but others 
have diffuse hemorrhage due to 
abnormal hemostasis. Coagulopa­
thies associated with cardiopulmo­
nary bypass include thrombocyto­
penia, qualitative platelet defects, 
decreased clotting-factor concentra­
tions and fibrinolysis.3-5 Excessive 
protamine sulfate, unneutralized 
heparin,6 heparin rebound7 and anti­
platelet agents may also contribute.
It has also been suggested that 
cryoprecipitate-thrombin glue,8 fi­
brin glue,9 the serine protease in­
hibitor aprotinin, 10 and the synthet­
ic vasopressin analogue desmo­
pressin acetate (DDAVP)11 all mini­
mize blood loss after cardiopulmo­
nary bypass procedures. Desmo­
pressin acetate may act by releasing 
endogenous Factor VIILvon Wille­
brand factor1213 and increasing 
platelet aggregation. 1415 A previous 
study11 demonstrated a substantial 
reduction in blood loss when 
DDAVP was administered during a 
variety of cardiac procedures. To 
assess the effect of intraoperative 
DDAVP administration on perioper­
ative bleeding and transfusion re­
quirements after uncomplicated cor­
onary artery bypass operations, we
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undertook a randomized prospec­
tive clinical trial.
Patients and Methods
Sixty-two consecutive patients 
(47 men, 15 women) who under­
went uncomplicated coronary artery 
bypass grafting were entered into 
the study. Patients were assigned to 
either treatment (31) or placebo 
(31) groups using a computer­
generated random number table. 
Preoperative intake of antiplatelet 
agents (within 7 days) was noted. 
Immediately after administration of 
protamine sulfate, patients received 
a 100-ml saline infusion over 15 
minutes containing a placebo or 
desmopressin acetate (Ferring Phar­
maceuticals, Malmo, Sweden) (0.3 
Mg/kg). Blood was collected before 
the induction of anesthesia, and at 
1 and 24 hours postoperatively, to 
measure hemoglobin concentration, 
platelet count, prothrombin time 
(PT), partial thromboplastin time 
(PTT), fibrinogen concentration and 
plasma Factor Vllhvon Willebrand 
factor activity. All samples were 
obtained from a flushed arterial 
catheter.
Platelet-poor plasma was pre­
pared by centrifugation from blood 
collected in vacutainer tubes (Bec- 
ton-Dickinson Canada Ltd., Missis­
sauga, Ont.) containing buffered so­
dium citrate. Aliquots were stored 
in polypropylene tubes at -20°C . 
von Willebrand factor antigen was 
assayed by ELISA assay (Diagnos- 
tica, Stago Co., Asniere-sur-Seine, 
France) using micro-ELISA plates 
(Linbro Scientific Co., Hamden, 
Conn.) and a Behring ELISA II 
reader (Behring Diagnostics, Ho- 
echst Canada Inc., Montreal, PQ). 
Values obtained with this method 
correlated well when compared with 
those determined using Laurel 
rockets and commercial antiserum. 
Fibrinogen levels were determined
using a commercial version of the 
Clauss technique (Fibriquick; Orga­
non Teknika Corp., Oklahoma City, 
Okla.). Prothrombin time and PTT 
were determined automatically 
using a Coag-a-Mate X-2 (Organon 
Teknika Corp.). Intraoperative 
blood loss was determined by tabu­
lating suction drainage and by 
weighing sponges. Postoperatively, 
mediastinal sump and chest-tube 
drainage were measured hourly for 
18 hours. The volume of red cell 
transfusion was tabulated intraoper- 
atively and for 48 hours postopera­
tively. Perioperative myocardial in­
farctions were diagnosed if new 
characteristic changes were present 
on the electrocardiogram.
The data are expressed as the 
mean ±  standard deviation. Statisti­
cal analysis was by Student’s f-test 
(two-tailed) for the comparison of 
sample means and by the x2 test for 
comparison of nominal data.
Results
The mean age of the patients was 
59 ± 9 years in the placebo group 
and 61 ± 10 years in the DDAVP 
group. Calculated body surface area 
was 1.88 ± 0.19 m2 in the placebo 
group and 1.90 ± 0.19 m2 in the 
DDAVP group. Thirteen patients in 
the placebo group and 12 in the
DDAVP group took antiplatelet 
agents in the 7 days preceding 
surgery. Both groups had similar 
preoperative hemoglobin concentra­
tions, platelet counts, fibrinogen 
and Factor VIILvon Willebrand fac­
tor plasma levels and prothrombin 
and partial thromboplastin times 
(Table I). There were no significant 
differences between the groups with 
respect to the number of coronary 
bypasses performed, previous coro­
nary bypass surgery, unilateral or 
bilateral internal mammary grafts, 
and the duration of extracorporeal 
circulation (Table II). Three patients 
(10%) in the placebo group and two 
(6.5%) in the DDAVP group suf­
fered perioperative myocardial in­
farction. There were no periopera­
tive deaths.
Four patients were re-explored 
for postoperative bleeding of more 
than 200 ml/h; three were in the 
DDAVP group. One of the three 
had diffuse oozing while the other 
two had identifiable bleeding points, 
as did the fourth patient in the 
placebo group. The three patients 
with surgical bleeding were exclud­
ed from further study.
There were no significant differ­
ences in total blood loss or in the 
number of units of red cell transfu­
sion. Blood loss intraoperatively 
and at each postoperative interval 
were similar (Table III).
Table 1. Preoperative Hematologic Profile (Mean ± SD)
Measurement Placebo DDAVP
Platelets, x  109/L 247 ± 75 242 ± 61
Hemoglobin, g/L 136 ± 18 141 ± 20
Prothrombin time, % of control 100.22 ±9.47 97.03 ±7.15
Partial thromboplastin time, % of control 99.61 ± 19.51 100.75 ±26.62
Fibrinogen, g/L 3.22 ± 1.13 2.88 ± 0.83
von Willebrand factor, U (arbitrary units) 2.17 ± 1.51 1.80 ±0.88
Table II. Operative Characteristics (Mean ± SD)
Characteristic Placebo DDAVP
Duration of extracorporeal circulation, min 89 ± 24 92 ± 21
No. of coronary artery bypasses per patient 3.4 ± 1.3 3.6 ± 0.8
No. of redo operations 3 4
No. of single mammary artery procedures 13 15
No. of double mammary artery procedures 16 16
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Postoperatively there was only a 
small, but significant, reduction in 
the platelet count in the DDAVP 
group (Table IV). Factor Vllhvon 
Willebrand factor levels were similar 
between the groups; however, the 
levels before operation (1.80 ± 0.88 
U [arbitrary units]) and 1 hour 
postoperatively (2.75 ± 0.94 U) in 
the DDAVP group were significant­
ly different (p < 0.001). Although 
factor Vllhvon Willebrand factor 
plasma levels increased similarly in 
the placebo group (2.77 ± 1.06 
versus 2.17 ± 1.51 U), the differ­
ence was not significant.
Comment
Desmopressin acetate has benefi­
cial effects in various congenital 
and acquired hemostatic disorders, 
including hemophilia,816 von Wille- 
brand’s disease,8-17 uremia,15 as well 
as intrinsic and Aspirin-induced 
platelet defects.18 Its use has also 
limited blood loss associated with 
cardiopulmonary bypass.11-19 The 
primary mechanism of action seems 
to be the release of endogenous 
stores of Factor Vllhvon Willebrand 
factor (specifically, the high mole­
cular weight forms of Factor VIII- 
related antigen).13-15-16-20 Additional, 
indirect effects on platelets and the 
blood vessel wall have been sug­
gested.18-21 Increases in Factor VIII- 
:von Willebrand factor levels corre­
late with shortening of the bleeding 
time in various hemorrhagic disor­
ders.18
A previous prospective study as­
sessed the prophylactic use of 
DDAVP in various open-heart surgi­
cal procedures.11 The drug was also 
administered immediately after prot­
amine sulfate was given. Total 
blood loss was significantly de­
creased in the DDAVP group com­
pared with controls. Red cell trans­
fusions in the first 3 postoperative 
days, however, were not statistically 
different. Czer and colleagues19 
noted attenuation of bleeding and a 
reduction in the use of blood pro­
ducts after the administration of 
DDAVP to patients who had exces­
sive bleeding after cardiac surgery.
In our study, both groups of 
patients were similar with respect to 
patient characteristics, preoperative 
hematologic profile and operative 
procedures. Most patients had one 
or both internal mammary arteries 
utilized. Platelet counts decreased 
in both groups postoperatively, but 
this difference may not be clinically 
important. The postoperative plate­
let count, however, was lower in the 
DDAVP group than in the controls. 
After DDAVP administration, Ko- 
brinsky and colleagues18 noted simi­
lar decreases in platelet counts and
T a b le  I I I .  B lood  L o ss  (M e a n  ±  SO)
Blood loss Placebo D D A VP
T o ta l, m l 182 6  ±  8 4 9 1 7 1 6  ±  688
In traope ra tive 7 7 5  ±  4 7 4 8 4 5  ±  4 4 0
0 - 6 h 6 4 2  ±  421 5 4 4  ±  3 9 0
6 - 1 2  h 2 4 3  ±  176 2 6 3  ±  3 2 0
12 - 1 8  h 148  ±  89 1 5 6  ±  95
T o ta l red ce ll t ra n s fu s io n s , u n its 3 .4  ±  1.3 3 .6  ±  0 .8
Tab le  IV . P o s to p e ra tiv e  H e m a to lo g ic  P ro file  (M ean  ±  S D )
M easu rem en t P lacebo D D A VP p va lue
P la te le ts  at 1 h, x  109/ L 1 7 9  ±  39 147  ± 4 3 < 0 .0 5
P ro th ro m b in  t im e  a t 1 h, s 1 3 .9  ±  1.1 1 4 .5  ±  1 .3 NS
P artia l th ro m b o p la s t in  t im e  a t 1 h, s 4 2 .3  ±  13 .9 4 3 .2  ±  14.1 NS
von  W ille b ra n d  fa c to r  at 1 h, U 2 .7 7  ±  1 .06 2 .7 5  ±  0 .9 4 NS
von  W ille b ra n d  fa c to r  at 24  h, U 4 .0 5  ±  1 .28 3.81 ±  0 .9 4 NS
volume. The underlying mechanism 
may be the drug-induced release of 
an abnormal platelet aggregating 
factor.14
The intraoperative administration 
of DDAVP did not alter total blood 
loss or red cell transfusion require­
ments in our patients who under­
went uncomplicated coronary by­
pass procedures. Similar results 
have been reported by Rocha and 
associates22 in patients who under­
went valvular and congenital heart 
surgery. Moreover, no significant 
differences were observed in in­
traoperative blood loss or during 
any postoperative interval. The 
1-hour postoperative Factor VIII: 
von Willebrand factor levels were 
significantly increased compared 
with preoperative levels in the treat­
ment group. A similar rise was 
noted in the control group. This 
difference, although not statistically 
significant, parallels changes seen 
with major surgery,23 including 
open-heart procedures,1 and other 
stressful stimuli.24 It is thought to 
be mediated by catecholamines and 
other vasoactive drugs.25 In con­
trast, Salzman and associates11 
noted no change in Factor Vllhvon 
Willebrand factor levels after 
DDAVP administration, but de­
creased levels in the control group.
In this study, we assessed the 
effects of DDAVP, given intraopera- 
tively, on blood loss and red cell 
transfusion requirements in patients 
who had uncomplicated coronary 
artery bypass grafting. Operative 
procedures consisted exclusively of 
coronary revascularization, in con­
trast to previous studies of DDAVP 
in cardiac surgery.1119-22 In addition, 
the duration of extracorporeal cir­
culation was up to 44% shorter 
than that reported in previous 
studies.1119 This is highly signifi­
cant since platelet factors are pro­
gressively depleted with the dura­
tion of extracorporeal circulation,26 
resulting in decreased platelet ag-
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gregation,26-27 hemostatic defects 
and increased bleeding. Beurling- 
Harbury and Galvan28 found signifi­
cant depletion of releasable platelet 
adenosine diphosphate when their 
patient group was categorized by 
bypass times more than and less 
than 90 minutes. Platelets that 
have undergone release reaction 
when given to a thrombocytopenic 
animal are less effective in reducing 
bleeding times than are normal 
platelets.29 Desmopressin acetate in­
fusion in normal subjects will in­
crease Factor Vllhvon Willebrand 
factor levels, but will change bleed­
ing times only slightly18 or not at 
all.12 Shorter pump times in our 
study may have preserved intrinsic 
clotting mechanisms, making 
DDAVP unnecessary, and resulting 
in no differences between the 
groups.
Prophylactic intraoperative use of 
DDAVP may contribute to prema­
ture vein graft thrombosis after 
coronary bypass.1119 Perioperative 
myocardial infarction rates (10% 
and 6.5% in the placebo and 
DDAVP groups, respectively) in the 
present study were less than in the 
control group of a recent study.19 
Nevertheless, this possibility and 
the failure to demonstrate therapeu­
tic benefit in the present study 
serve to discourage the intraopera­
tive use of DDAVP in uncomplicat­
ed coronary bypass surgery.
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ORIGINAL ARTICLES
Acute Abdomen in the Patient With a 
Ventriculoperitoneal Shunt
D. Patrick, MD;* P. Marcotte, MD;t G.E. Garber, MD, FRCPC
When patients who have a ventriculoperitoneal shunt present with an acute 
abdomen, shunt infection may be the cause. The authors relate the cases of three 
such patients. Two underwent a laparotomy which failed to show any abnormality 
and which in retrospect might have been avoided. They review the literature and 
present a systematic approach to the diagnosis and management of this problem. 
Specific clues from the patient’s history, physical examination and further 
investigation may clarify the diagnosis. When shunt infection cannot be excluded 
and the clinical setting does not warrant immediate laparotomy, shunt 
externalization, cerebrospinal fluid culture, empiric antibiotic therapy and close 
observation of the patient are recommended.
Quand un patient porteur d'une derivation ventriculoperitoneale est vu en abdomen 
aigu, on doit soupgonner une infection de derivation. Les auteurs decrivent trois cas 
de ce type. Deux patients subirent une laparotomie qui ne revela aucune anomalie et 
qui, en retrospective, aurait pu etre evitee. Les auteurs passent la presse medicale 
en revue et proposent une approche systematique du diagnostic et du traitement de 
cette affection. Des indices specifiques issus de l’anamnese du patient, de l’examen 
physique et d’autres examens peuvent permettre de clarifier le diagnostic. Quand la 
possibilite d’une infection de derivation ne peut etre eliminee et que le tableau 
clinique ne commande pas une laparotomie immediate, la mise a nu de la derivation, 
la culture du liquide cephalorachidien, la mise en route d’une antibiotherapie 
empirique et une etroite observation du patient sont recommandees.
The ventriculoperitoneal (VP) shunt is a therapeutic modality 
that effectively relieves the symp­
toms and signs of hydrocephalus of 
diverse causes. However, this device 
is a foreign body and its use is often 
complicated by such problems as 
infection (5% to 27% of cases12) or 
mechanical malfunction.
tResident in neurosurgery, University o f  Ottawa 
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When the VP shunt becomes 
infected, the patient will often show 
signs of fever and have a headache 
and neurologic dysfunction. Howev­
er, in some instances, the infection 
may be insidious and affect the 
peritoneal membrane and may 
mimic the presentation of a variety 
of intra-abdominal disorders.3 The
clinician is then faced with a diag­
nostic dilemma.
In this paper, we describe the 
cases of three patients with a VP 
shunt who presented with the signs 
and symptoms of peritonitis. In re­
trospect, two of these patients un­
derwent potentially avoidable ab­
dominal surgery because the acute 
abdomen was precipitated by the 
VP shunt infection. We review the 
literature on this interesting clinical 
problem and suggest a systematic 
approach to its diagnosis and man­
agement.
Case Reports
Case 1
A 57-year-old man presented in 
May 1986 with a ruptured right 
middle cerebral artery aneurysm. 
After evacuation of the hematoma 
and clipping of the aneurysm, his 
full recovery was impaired by hy­
drocephalus, requiring lumbar-per­
itoneal and ventriculoperitoneal 
shunt insertion, associated meningi­
tis and ventriculitis. At the end of 
September, he was discharged to a 
rehabilitation facility.
On Oct. 15, he returned to the 
emergency room complaining of 
right lower quadrant pain, anorexia, 
nausea and vomiting. On examina­
tion he was alert, oriented and had 
a supple neck. Head and neck, 
chest and cardiovascular examina­
tions were unremarkable. His 
scaphoid abdomen was rigid and
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there was right lower quadrant 
guarding and rebound tenderness. 
Bowel sounds were present but di­
minished. The leukocyte count was 
10.3 X 109/L  with 8.9 X 109/L  
granulocytes. The remaining labo­
ratory results were unremarkable. 
Because the patient had recently 
been on tetracycline, it was felt that 
he possibly had a masked acute 
appendicitis. A slightly inflamed ap­
pendix was removed at surgery. 
Pathological examination of the ap­
pendix showed a well-preserved mu­
cosa with no evidence of appendici­
tis. Culture of a peritoneal swab 
grew Staphylococcus epidermidis. 
Postoperatively, the patient had a 
persistent low-grade fever which ap­
peared to be resolving at the time 
he was discharged from hospital on 
Oct. 22. Five days later he returned 
to hospital with fever and an im­
paired level of consciousness. He 
was unresponsive and had a temper­
ature of 39.5°C. His bone flap was 
bulging but not tense. Chest, car­
diovascular system and abdominal 
findings were unremarkable. Lum­
bar puncture gave negative results 
and computed tomography showed 
mild ventricular dilatation. The leu­
kocyte count was 17.3 X 109/L  
with 15.9 X 109/L  granulocytes. 
The diagnosis was presumed to be 
shunt infection, so vancomycin hy­
drochloride and rifampin were start­
ed. The lumbar-peritoneal shunt 
was removed and the ven­
triculoperitoneal shunt external­
ized, then revised. The patient's 
sensorium gradually cleared over 
the week after externalization. Cul­
ture of the removed lumbar perito­
neal shunt showed heavy growth of 
S. epidermidis with the same sensi­
tivity pattern as that grown from 
the swab of the patient’s appendix 
during the previous hospitalization.
Case 2
A 74-year-old Roman Catholic
priest with a history of severe ath­
erosclerosis presented in September
1986 with a subarachnoid hemorrh­
age. His course was complicated by 
normal-pressure hydrocephalus, 
which was managed by inserting a 
ventriculoperitoneal shunt.
He returned to hospital Feb. 1,
1987 complaining of right lower 
quadrant pain and anorexia. He was 
afebrile. Head, neck, chest and neu­
rologic examinations showed no ab­
normalities. The right lower quad­
rant was tender, but there were no 
firm peritoneal signs. The leukocyte 
count was 12 X 109/L  with 8.3 X 
109/L  granulocytes. Abdominal 
x-ray films were noncontributory. 
Because the patient’s condition 
worsened, he was taken to the 
operating room with a presumptive 
diagnosis of appendicitis. A normal­
appearing appendix was removed 
surgically. Pathological examina­
tion confirmed that the appendix 
was only mildly infected, and there 
was no evidence of luminal inflam­
mation to suggest appendicitis. The 
patient recovered and was dis­
charged.
He was readmitted on Feb. 23 
because of abdominal pain, head­
ache and confusion. On examina­
tion, he was febrile (body tempera­
ture 38.6°C) and exhibited mild 
photophobia. There was now right 
upper quadrant tenderness. The 
leukocyte count was 16.9 X 109/L  
with 14.0 X 109/L  neutrophils. 
The serum levels of alkaline phos­
phatase, alanine aminotransferase 
and aspartate aminotransferase 
were 332 U/L, 103 U/L and 47 
U/L, respectively. Ultrasonography 
of the abdomen revealed fluid 
around the gallbladder. A HIDA 
scan showed patent cystic and com­
mon bile ducts. Barium enema ex­
amination gave normal results. Pe­
rihepatic fluid was drained and grew 
no bacteria.
Because of the patient’s decreas­
ing mental status, we consulted a
neurosurgeon. Cerebrospinal fluid 
was sampled from the shunt reser­
voir. The fluid contained 640 X 
109/L  leukocytes with 83% neutro­
phils and was cultured for S. epider­
midis.
Vancomycin was initially adminis­
tered pending final culture results. 
Removal of the shunt resulted in 
rapid improvement. Once sensitivi­
ties were known, treatment was 
continued with penicillin G and 
when the shunt was reinserted 2 
weeks later, vancomycin was used 
again to cover methicillin-resistant 
strains.
Case 3
In 1979, a 39-year-old man pre­
sented to another hospital with su­
barachnoid hemorrhage from intra­
cranial aneurysm. After surgical 
clipping, he was left with substan­
tial neurologic deficits and required 
insertion of a ventriculoperitoneal 
shunt to relieve communicating hy­
drocephalus. Over the next 4 years 
he required numerous revisions of 
his shunt because of recurrent mal­
function and infection.
In November 1986, he presented 
to the emergency department with a 
4-day history of right lower quad­
rant pain and nausea. His neck was 
supple, findings on chest and car­
diovascular examinations were un­
remarkable and normal bowel 
sounds were present. He had right 
lower quadrant guarding. The 
erythrocyte sedimentation rate was 
47 mm/h and the leukocyte count 
was 11.4 X 109/L .
Because the cause of the pain 
was uncertain, he was admitted for 
investigation. Computed tomogra­
phy findings of the brain were nor­
mal. Ultrasonography of the abdo­
men and small-bowel barium study 
suggested thickening of small- 
bowel wall. Barium enema examina­
tion gave normal findings. The dif­
ferential diagnosis included appen-
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dicitis, ischemic colitis and focal 
inflammation due to the shunt. 
Symptoms appeared to clear sponta­
neously over the next 2 weeks; then 
the patient experienced neurologic 
decompensation and right lower 
quadrant pain. There was also pain 
over the shunt reservoir. The eryth­
rocyte sedimentation rate was 42 
mm/h, leukocyte count 10.4 X 
109/L  and repeated computed to­
mography of the head demonstrated 
hydrocephalus.
The shunt was externalized and 
cerebrospinal fluid cultures grew S. 
epidermidis. He was treated with 
cloxacillin, and a new shunt was 
inserted 8 days later, leading to 
resolution of symptoms and hydro­
cephalus.
Discussion
These three cases illustrate the 
difficulties in diagnosis and choice 
of therapy when patients who have 
a VP shunt present with peritonitis. 
Although this problem is addressed 
to a limited extent in the pediatric 
literature, this presentation in 
adults has seldom been reported 
and there is no clear consensus on 
its management. We have reviewed 
the relevant literature and examined 
our own experience to arrive at a 
proposed approach.
Certain clues from the patient’s 
history, physical examination, labo­
ratory testing and imaging investi­
gations (Table I) may implicate the 
shunt as the cause of the present­
ing symptoms. These patients com­
monly present with nausea, vomit­
ing and abdominal pain.134 Such 
symptoms are entirely nonspecific. 
A history of headache, stiff neck, 
declining level of consciousness or 
photophobia would suggest con­
comitant meningeal irritation or hy­
drocephalus and thus implicate the 
shunt. As revealed in our three 
cases and in another series by Re- 
kate and colleagues,3 a history of 
recent shunt revision substantially 
increases suspicion that the shunt 
is the likely cause. Most shunt 
infections are a result of intraopera­
tive seeding by gram-positive micro­
organisms at the time the shunt is 
inserted.5
Unless there are clear signs of 
neurologic decompensation, menin- 
gismus or hydrocephalus, the local­
ized or generalized peritoneal signs1 
on physical examination will not be 
helpful in localizing the problem. A 
palpable abdominal mass may indi­
cate a shunt-associated pseudocyst.4 
This entity is thought4 to represent 
a chronic inflammatory response to 
the presence of the shunt tip and 
to be associated with colonizing 
organisms of low virulence in the 
peritoneal cavity. Most patients in 
whom a shunt pseudocyst develops 
after VP shunt insertion have a 
clear history of infection; the cyst 
fluid will often be positive for S. 
epidermidis or other organisms.4 6'7
General laboratory investigations 
are often not helpful in making the 
diagnosis. An elevated leukocyte 
count or erythrocyte sedimentation 
rate are frequently consistent with 
ongoing inflammation but have no 
discriminating value. The presence 
of bacteremia is rare but if gram­
positive bacteria such as staphylo­
cocci are isolated, primary shunt 
infection is highly likely.8-9 Gram­
negative bacteremia may be seen in 
both primary abdominal emergen­
cies and shunt-related peritonitis, 
especially in infants. The series of 
Reynolds and associates,1 describ­
ing 19 children with shunt-associat­
ed peritonitis, reported that 90% of 
shunt cultures gave positive results; 
65% grew gram-positive and 23% 
gram-negative organisms.
Cerebrospinal-fluid sampling has 
yielded variable results. Cultures 
are more frequently positive when 
drawn from the shunt reservoir or a 
pseudocyst than from ventricular or 
lumbar puncture.8 Although 
Hubschmann and Countee8 reported 
100% of reservoir cultures positive 
for S. epidermidis, Rekate and col­
leagues3 revealed that it is not un­
usual to have negative reservoir 
cultures and that infection may 
seem to be limited to the peritoneal 
end of the shunt.
Both ultrasonography and com­
puted tomography appear to have 
some diagnostic merit.10 When a 
pseudocyst is demonstrable, symp­
toms of peritonitis are likely related 
to its presence. Worsening hydro­
cephalus suggests shunt blockage, 
which often may be precipitated by 
infection.
Shunt externalization, collection 
of cerebrospinal fluid for culture 
and sensitivity, and empiric antibiot­
ic therapy are indicated when the 
clinical picture clearly implicates 
shunt infection. In cases of shunt- 
associated peritonitis,13'8 external­
ization of the peritoneal tip of the 
catheter combined with parenteral
T a b le  1. C lin ic a l Fea tu res  U se fu l in D is tin g u is h in g  S h u n t In fe c tio n  F ro m  P rim a ry  In tra -a b d o m in a l
D isease
F e a tu re N o n s p e c ific S u p p o rt in g  s h u n t in fe c tio n
H is to ry N ausea, vo m itin g , fe ve r, 
a b d om ina l pa in
R ecen t s h u n t re v is io n , 
c o n fu s io n , headache
P hys ic ia l e x a m in a tio n Loca l o r  genera lized  p e rito n e a l 
s ig n s
D im in ish e d  m e n ta l s ta tus , 
p a lp a b le  a b d o m in a l 
p s e u d o c y s t
General la b o ra to ry  te s ts L e u ko cy te  coun t, e ry th ro c y te  
se d im e n ta tio n  rate
B lood cu ltu re s G ram -nega tive  b a c te re m ia G ra m -p o s it iv e  ba c te re m ia
C e reb rosp ina l flu id  c u ltu re s N egative P os itive
Im ag ing  (u ltra s o n o g ra p h y  o r 
co m p u ted  to m o g ra p h y )
P s e u d o c ys t
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antibiotic therapy usually leads to 
resolution of clinical symptoms in 
less than 24 hours. The antibacteri­
al agent should have a spectrum 
sufficient to cover methicillin-resist- 
ant staphylococci (i.e., vancomycin), 
pending results of culture and sen­
sitivity studies.
When the clinical picture does 
not distinguish between a primary 
peritoneal and a shunt-associated 
source of symptoms, the clinician 
may face a dilemma. Should he 
proceed with a potentially “negative 
laparotomy” or should he external­
ize the peritoneal end of a normal 
shunt, necessitating future revision?
We advocate externalization as 
an early diagnostic and therapeutic 
maneuver. Fluid from the distal end 
of the shunt can then be sent for 
Gram’s staining and culture. If the 
results of these investigations are 
positive, shunt infection is strongly 
implicated. If negative, they are less 
helpful and one must rely on the 
clinical course of events. Since clini­
cal symptoms usually resolve within 
24 hours after externalization of an 
infected shunt, residual symptoms 
after this time are more likely at­
tributable to primary intra-abdomi­
nal disease, and laparotomy should 
be considered.
Physicians are understandably re­
luctant to tamper with what may be 
a functioning and uninfected shunt. 
We believe there are two compelling 
reasons to favour shunt externaliza­
tion, even when primary intra­
abdominal disease may be present. 
First, the shunt is at grave risk of
becoming secondarily infected, thus 
requiring removal anyway. Second, 
sound surgical principles dictate 
that removal of a foreign body such 
as the shunt may be a necessary 
prerequisite to the resolution of a 
closed-space infection, whatever the 
primary cause. Hence, shunt exter­
nalization is rational for both shunt 
infection and primary intra-abdomi­
nal sepsis.
Recommendations
In summary, when a patient who 
has a VP shunt presents with fever 
and evidence of peritoneal inflam­
mation, a careful clinical work-up 
should take place. When a shunt 
infection is strongly implicated as 
the source of the problem, shunt 
externalization, cerebrospinal fluid 
culture, empiric antibiotic therapy 
against methicillin-resistant staphy­
lococci and close clinical observa­
tion are indicated. When the diag­
nosis is still in doubt, however, and 
laparotomy is not immediately indi­
cated by a precipitous clinical de­
cline, we strongly recommend these 
same steps. In the latter case, exter­
nalization is both a diagnostic and 
therapeutic procedure and may 
avert unnecessary laparotomy. Sub­
sequent clinical decline or lack of 
improvement within 24 hours 
should lead to consideration of a 
primary intra-abdominal source of 
infection, in which case laparotomy 
and broader spectrum antimicrobial 
therapy are indicated.
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Management of Duodenal Injuries
G. Cuddington, MD, FRCSC; C.H. Rusnak, MD, FRCSC; R.D.A. Cameron, MD, FRCSC; 
J. Carter, MD, FRCSC
Between 1975 and 1986, 42 patients with duodenal trauma were seen at six major 
hospitals serving the province of Saskatchewan. Twenty-six patients had blunt 
trauma and 16 penetrating trauma. The mean age of the patients was 25 years and 
38 were male. An assessment of patient management revealed an unacceptable rate 
of duodenal fistulas (17%) and death (14%). Detailed analysis suggests that duodenal 
injuries must be diagnosed early with prompt and appropriate surgical correction.
De 1975 a 1986, 42 patients souffrant de traumatisme duodenal ont ete admis dans 
six hopitaux importants desservant la province de Saskatchewan. Vingt-six patients 
souffraient de traumatismes fermes, alors que les 16 autres presentaient des plaies. 
L’age moyen des patients etait de 25 ans et 38 etaient des hommes. L’evaluation du 
traitement des patients a revele un taux inacceptable de fistules duodenales (17%) et 
de deces (14%). Une analyse approfondie indique la necessity de diagnostiquer tot 
les lesions duodenales et de proceder rapidement a la correction chirurgicale 
appropriee.
Duodenal injuries, although rela­tively infrequent, remain an im­
portant cause of morbidity and mor­
tality in the trauma patient. The 
retroperitoneal location of the duo­
denum offers protection, and duo­
denal injuries are found in only 3% 
to 5% of laparotomies performed for 
trauma.1' 3 Duodenal injuries are fre­
quently associated with injuries to 
the pancreas, colon, liver, aorta and 
inferior vena cava. In addition, the 
injured site is exposed to the gastr­
ic, duodenal and pancreatic secre­
tions which may interfere with heal­
ing. These factors contribute to a 
reported mortality of 6.5% to 
20%,2-6 even in recent series, and to 
a similarly high morbidity.
We have studied retrospectively 
42 patients with duodenal trauma,
seen, between 1975 and 1986, at 
six major hospitals serving Regina 
and Saskatoon. The objective was 
to review patient management and 
to identify the factors associated 
with morbidity and mortality. Pa­
tients whose initial treatment was 
performed elsewhere were excluded.
Medical records were reviewed to 
identify the type and mechanism of 
injury, associated injuries and treat­
ment given, complications and out­
come.
Duodenal injuries were classified 
according to the system proposed 
by Roman and colleagues.1 Types I 
and II are partial and full-thickness 
injuries, respectively, with no asso­
ciated pancreatic trauma. Type III 
injuries are full thickness with a 
minor associated pancreatic injury.
Type IV injuries are full thickness 
with a severe pancreatic injury, in­
cluding ductal disruption or exten­
sive devitalization of tissue.
Findings
The 42 patients in this study 
ranged in age from 1 to 78 years 
(mean 25 years). There were 38 
males and 4 females. The mecha­
nism of injury (Table I) was blunt 
trauma in 26 patients and penetrat­
ing trauma in 16.
Presentation
Seven patients (17%) had isolated 
duodenal injuries and 35 (83%) had 
associated injuries (Table II).
Associated injury No. (% of total)
Intra-abdominal
Liver 11 (26)
Pancreas 9(21)
Colon 7(17)
Small bowel 6 (14)
Stomach 7(17)
Biliary tract 5(12)
Major blood vessel 5(12)
Other
Musculoskeletal 8(19)
Chest 7(17)
Spinal cord 2 (5)
Head 2 (5)
F rom  the D epartm ent o f  Surgery, U n ivers ity  o f  Saskatchewan, U nivers ity  H ospita l, Saskatoon, 
Sask.
Table I. Mechanism of Duodenal Injury
Mechanism No. of patients
Blunt trauma 26
Motor vehicle accident 18
Fall 2
Crush injury 5
Child abuse 1
Penetrating trauma 16
Gunshot wound 11
Knife wound 4
Shotgun wound 1
Table II. Associated Injuries (35 Patients)
Accepted fo r  pub lica tion  M ay 15, 1989
R eprin t requests to: Dr. C. Cuddington. D epartm ent o f  Surgery. P la ins H ea lth  Centre, 4500  
Wascana Pkw y., Regina, Sask. S4S 5 W 9
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Twelve patients (29%) presented in 
shock (systolic blood pressure less 
than 90 mm Hg).
Peritoneal lavage was performed 
in eight patients who had blunt 
trauma and was positive in seven of 
them. Of these seven patients, three 
had isolated duodenal injury and 
four associated intra-abdominal in­
juries. There was only one false­
negative peritoneal lavage; it oc­
curred in a patient who had a 
partial-thickness duodenal injury.
The serum amylase level was ele­
vated in 20 (67%) of 30 patients in 
whom it was measured; 5 had as­
sociated pancreatic injury. Twenty- 
four (56%) of the 42 patients had 
an elevated leukocyte count.
Radiologic Findings
Plain abdominal x-ray films were 
obtained in 34 patients. Fifteen 
showed nothing abnormal, 11 
showed nonspecific signs of in- 
traperitoneal injury (free air, fluid 
or displacement of bowel) and 8 
showed retroperitoneal gas in the 
right upper quadrant, highly sug­
gestive of a specific duodenal inju­
ry. In two of these eight patients, 
the finding of retroperitoneal gas 
was not identified by the surgical 
team, but was subsequently report­
ed by the radiologist.
Contrast studies of the upper 
gastrointestinal tract, performed in 
five patients, were diagnostic of 
duodenal hematoma in two and 
showed a leak in only one of the 
three patients with full-thickness 
injuries.
Computed tomography was used 
in only one patient, several days 
after a motor vehicle accident. This 
patient had persistent pain but neg­
ative results of upper gastrointesti­
nal series. The investigation was 
performed with the aid of oral con­
trast medium, but failed to demon­
strate the injury in the second part 
of the duodenum.
Injury Classification
This series included 7 type I 
injuries (hematoma or serosal tear), 
26 type II injuries (transmural inju­
ry), 8 type III injuries (full thick­
ness with pancreatic contusion or 
hematoma) and 1 type IV injury 
(with major pancreatic ductal dis­
ruption).
Timing o f Surgery
Figure 1 shows the interval be­
tween injury and operative repair in 
the 35 patients who had a full­
thickness duodenal injury, divided 
into those with and without compli­
cations (abscess or duodenal fistula) 
or death related to the duodenal 
injury. The time to repair was not 
known in one patient and another 
died at the time of anesthetic induc­
tion, 9 hours after injury.
Treatment o f the Injury
Of the seven patients with a type 
1 injury, five sustained duodenal 
hematoma and, although three of 
these underwent laparotomy for 
other reasons, none required specif­
ic treatment for this injury. Two 
other patients had seromuscular 
lacerations, which were simply over­
sewn.
Eighteen of the 26 patients with 
type II injury were treated by
FIG. 1. Time interval from injury to 
repair in 33 patients with full-thick­
ness injuries who underwent opera­
tion. Shaded bars =  without complica­
tions, dotted bars =  with complica­
tions.
debridement and suture closure. 
Three of these patients also had a 
feeding jejunostomy and two had 
decompressive gastrostomy. Five 
other patients had primary closure 
accompanied by tube duodenostomy 
(or a nasogastric tube threaded into 
the duodenum in one patient). The 
remaining three patients were treat­
ed by the pyloric exclusion proce­
dure.7 This consists of oversewing 
the pylorus with an absorbable su­
ture followed by gastrojejunostomy, 
after the injury has been repaired.
Five of the type III injuries were 
treated by primary repair and drain­
age of the lesser sac. Of the remain­
ing three patients, one underwent a 
pyloric exclusion procedure, one pa­
tient died upon induction of anes­
thesia before the injury was re­
paired and the last patient had a 
completely transected duodenum 
which was managed with an end-to- 
side duodenojejunostomy and over­
sewing of the distal duodenum.
One patient sustained a type IV 
injury. A stab wound to the head of 
the pancreas caused disruption of 
the main pancreatic duct and an 
associated duodenal injury. This 
was managed by a Whipple’s proce­
dure.
All patients with full-thickness 
duodenal injuries had drainage of 
the periduodenal area with either a 
Penrose or a closed-suction drain. 
Nine patients had a feeding jejunos­
tomy inserted.
Complications (Table III)
A duodenal fistula developed in 
six patients (17% of those with 
full-thickness injuries). In four the 
injury resulted from blunt trauma. 
The interval from injury to opera­
tive repair was longer than 24 
hours in four of these six patients. 
In two this was because the duode­
nal injury was not recognized at the 
initial laparotomy; in one case the
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more obvious injuries were orthope­
dic, so no general surgery consulta­
tion was obtained until several days 
later when intra-abdominal sepsis 
was evident; the final patient did 
not seek medical attention until 4 
days after a motor vehicle accident.
All fistulas followed type II inju­
ries and were repaired by primary 
closure and drainage, with a tube 
duodenostomy being used as ad­
junctive treatment in only one pa­
tient, despite the prolonged interval 
to repair in four of the patients.
Two patients died of sepsis relat­
ed to their duodenal fistulas. Two 
required reoperation, and in the 
other two patients the fistula was 
well controlled by drains placed at 
the initial operation, and they re­
quired only supportive care. The 
average length of stay for the survi­
vors with fistulas was 47 days as 
opposed to 18 days for the remain­
der of the group without fistulas.
Although late (post-discharge) 
complications were not sought, one 
patient who underwent a pyloric 
exclusion procedure had a serious 
gastrointestinal hemorrhage caused 
by a stomal ulceration 1 year after 
injury. This was managed by opera­
tion with reversal of the pyloric 
exclusion.
Mortality
There were six deaths (14%), 
three being directly related to the 
duodenal injury. The three deaths 
not directly related included two
T a b le  II I .  Complications (Full-Thickness 
Injuries)
C om plication No. of pa tien ts
Duodenal fistula 6
Intra-abdominal abscess 2
Wound infection 3
Pancreatic fistula 2
Leak from  feeding 
jejunostomy 2
Diagnosis missed at 
laparotomy 2
from hemorrhage and one due to 
myocardial infarction.
Of the patients who died of 
causes related to the duodenal inju­
ry, one, whose injury was missed at 
the initial laparotomy, was operated 
on 6 days later, with only suture 
closure and drainage. The second 
patient’s injury was not identified 
for 4 days, after initial treatment of 
orthopedic injuries, and again re­
pair was only simple suture closure 
and drainage. The final patient sus­
tained a rupture of the duodenum 
in a motor vehicle accident, but 
intra-abdominal injury was not iden­
tified during resuscitation and he 
died during induction of anesthesia, 
when the injury manifested itself 9 
hours later. In retrospect, the radi­
ologist identified retroperitoneal air 
on the plain abdominal x-ray film, 
but this finding was not appreciated 
by the surgical team.
Discussion
Injuries to the duodenum are not 
commonly seen by the busy trauma 
surgeon.8 This 12-year review of 
the six major hospitals servicing 
Saskatchewan revealed only 42 du­
odenal injuries. This series reaf­
firms that predominantly rural areas 
have a greater incidence of blunt 
duodenal trauma (62% in this re­
view).910
Duodenal injury, when discov­
ered, is of paramount importance 
due to the extraordinarily high 
rates of serious complications and 
of death. The most common compli­
cation is that of duodenal fistula, 
reported as occurring in 3% to 22% 
of cases.27911 Duodenal fistulas 
(17% in this series) were more com­
mon with blunt injuries and with 
delayed treatment. Four out of six 
duodenal fistulas were from blunt 
abdominal trauma, and four were 
treated more than 24 hours from 
the time of injury.
The death rates for duodenal in­
juries range from 6.5% to 12.5%2“5-7 
The death rate in our series was 
14%. The main determinant of mor­
bidity and mortality in many series, 
particularly in blunt abdominal 
trauma, is related to delayed diag­
nosis or delayed surgical repair 
from the time of the injury. Roman 
and colleagues1 identified 10 pa­
tients in their series in whom the 
diagnosis was delayed over 24 
hours; 4 of the 10 died and 3 of the 
10 had duodenal fistulas. Snyder 
and colleagues11 found four patients 
whose surgery for blunt abdominal 
trauma was delayed more than 24 
hours. Two of them died and in the 
other two fistulas developed. Flint 
and associates12 noted that duode­
nal lacerations would not have been 
discovered in 6 of 19 patients were 
it not for the policy of mobilizing 
the duodenum at all laparotomies 
for blunt trauma.
In our series, the three deaths 
directly related to duodenal injury 
were all due to delayed diagnosis; in 
one, the diagnosis was missed at 
the initial laparotomy, the second 
injury was not detected at initial 
assessment (retroperitoneal air was 
noted on the abdominal film retro­
spectively), and the final injury re­
mained undetected for 4 days while 
the patient was being treated for 
orthopedic injuries.
Acute awareness is needed to 
make an early diagnosis together 
with early operative intervention to 
prevent unnecessary morbidity and 
mortality.
Hasson and colleagues5 demon­
strated the value of tube decom­
pression in duodenal injuries. The 
overall mortality of duodenal repair 
was clearly less with decompression 
(9% versus 19.4%). The primary 
repair with tube decompression ver­
sus primary repair without tube 
decompression showed a fistula rate 
of 2.3% versus 11.8%. The rate of 
tube duodenostomy fistula in this
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collected series was an alarming 
19.4%.
In our series there was no single 
method used for repair with which 
to make a statistical analysis. The 
pyloric exclusion procedure was 
used in four patients, three times in 
patients whose injury was over 12 
hours old. There were no complica­
tions in these patients; however, in 
one patient stomal ulceration devel­
oped later at the gastrojejunostomy 
site and required reoperation. Ka- 
shuk and colleagues13 in their study 
favoured pyloric exclusion over 
tube decompression in types III and 
IV duodenal injuries. In their trau­
ma centre they decreased the occur­
rence of duodenal fistulas from 13% 
to 4% and the postoperative death 
rate by a similar percentage.
The surgeon, having made an 
early diagnosis and discovered a 
duodenal injury, should determine 
the mechanism of injury, the time 
from injury and extent of duodenal 
and associated injuries to decide on 
the appropriate method of repair.
Most type I injuries (intramural 
hematomas), obstructive or nonob­
structive, can be successfully ma­
naged conservatively with nutrition­
al support.14 If hematoma does not 
resolve in 12 to 14 days, then 
reassessment using a gastrointesti­
nal series may lead to the recom­
mendation that surgical evacuation 
is necessary.
The uncomplicated type II (full­
thickness) injury can be managed 
by primary repair. The pyloric ex­
clusion procedure should be used 
for type II injuries when the duode­
nal repair is tenuous and when 
repair is delayed beyond 12 hours. 
Omental and serosal patches have 
also been used but no clear benefit 
has been shown.15 In our series, 
drainage was instituted for type II 
injuries. However, Stone and Fabi­
an16 suggested that drainage is un­
necessary in this circumstance.
A type III injury may be treated
by primary repair and pancreatic 
drainage if the injury is less than 12 
hours old and the duodenum is not 
extensively devitalized. For the 
more extensive duodenal injury or 
delayed repair, the pyloric exclusion 
procedure is indicated. Type III in­
juries require drainage to decrease 
the potential morbidity of a pancre­
atic fistula.6
Type IV injuries are full thick­
ness with a severe pancreatic injury, 
including extensively devitalized tis­
sue or major ductal disruptions. If 
the pancreatic injury is in the neck, 
body or tail, then distal pancreatec­
tomy, primary duodenal repair and 
diversion of the gastroduodenal 
stream is the procedure of choice. 
If, however, there is a severe injury 
to the head of the pancreas, then 
pancreatoduodenectomy may be 
preferable. The death rate is high in 
this group because of the frequent 
presence of major associated inju­
ries.
In types II, III and IV injuries, 
the extent of the duodenal injury 
may preclude primary reconstruc­
tion, so the surgeon will need to 
use his ingenuity to restore gas­
trointestinal continuity (e.g., Roux- 
en-Y anastomosis, duodenojejunos­
tomy). At our centre, we believe 
that threading the nasogastric tube 
into the duodenum is an acceptable 
method of tube decompression for 
these injuries. All these patients 
(particularly those with types III 
and IV injuries) should be consid­
ered candidates for a feeding jeju- 
nostomy.
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Effect of Hypothermia and Cardioplegia 
on Intramyocardial Voltage and Myocardial 
Oxygen Consumption [Republication]
R.W. Landymore, MD, FRCSC; A.E. Marble, PhD, PEng
Intramyocardial voltage and myocardial oxygen consumption were measured in the 
fibrillating heart between the temperatures of 37°C and 25°C and in the arrested 
heart after infusion of potassium cardioplegic solution in 10 adult mongrel dogs. 
Electrical activity from the myocardium was recorded using specially designed 
plunge electrodes, and intramyocardial voltage was monitored by an in-line 
voltmeter. Myocardial oxygen consumption gradually decreased from 5.8 ± 0.6 ml 
0 2/m in at 37°C to 2.3 ± 0.5 ml 0 2/min at 25°C. In contrast, hypothermia did not 
cause a similar decrease in intramyocardial voltage which remained within a range of 
1.8 ± 0.5 mV to 2.4 ± 0.5 mV between the temperatures of 37°C and 25°C. The 
infusion of potassium cardioplegic solution resulted in a dramatic decrease in 
voltage to 43 ± 5 gV, and myocardial oxygen consumption fell to 0.5 =t 0.3 ml 
0 2/m in. Our data demonstrated that the mean voltage of the fibrillating heart 
remains constant between the temperatures 37°C and 25°C and myocardial oxygen 
consumption decreases with hypothermia, which suggests that voltage does not 
correlate with the level of myocardial oxygen consumption. Myocardial oxygen 
consumption and intramyocardial voltage, however, decrease dramatically when 
cardioplegia is instituted.
Chez 10 chiens batards adultes, on a mesure le voltage intramyocardique et la 
consommation d’oxygene du myocarde sur le coeur en fibrillation maintenu a des 
temperatures de 37°C et de 25°C et sur le coeur a l’arret apres perfusion d’une 
solution cardioplegique de potassium. L’activite electrique du myocarde a ete 
enregistree a l’aide d'electrodes de conception speciale, et le voltage intramyocardi­
que a ete monitorise a l’aide d’un voltmetre en ligne. La consommation myocardique 
d’oxygene a baisse progressivement de 5.8 ± 0.6 ml d’0 2/m in a 37°C jusqu’a 2.3 ± 
0.5 ml d’0 2/m in a 25°C. Par opposition, l’hypothermie n’a pas cause une baisse 
similaire du voltage intramyocardique, lequel est demeure dans l’intervalle de 1.8 ± 
0.5 mV a 2.4 ± 0.5 mV entre les temperatures de 37°C et de 25°C. La perfusion 
d’une solution cardioplegique de potassium a entralne une baisse spectaculaire du 
voltage de 43 ± 5 g\, et la consommation myocardique d’oxygene a chute de 0.5 ± 
0.3 ml d’0 2/min. Ces resultats demontrent que le voltage moyen du coeur en 
fibrillation demeure constant entre 37°C et 25°C et que la consommation d’oxygene 
du myocarde s’abaisse dans des conditions d’hypothermie; ceci indique que le 
voltage n’est pas relie au niveau de consommation d’oxygene du myocarde. La 
consommation myocardique d’oxygene et le voltage intramyocardique baissent 
toutefois de fa?on spectaculaire quand une cardioplegie est mise en route.
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I nduction of myocardial arrest with cold potassium cardioplegic 
solution decreases myocardial ener­
gy requirements by lowering myo­
cardial temperature and preventing 
electromechanical activity. Al­
though cardioplegia initiates a rapid 
electromechanical arrest, small- 
amplitude electrical potentials may 
be recorded from the myocardium, 
using specially designed plunge 
electrodes, within 10 to 15 minutes 
after the infusion of potassium car­
dioplegic solution when there is no 
visual mechanical activity and when 
the electrocardiogram is isoelec­
tric.12 These small-amplitude elec­
trical potentials have a fundamental 
frequency of 3.0 Hz and may persist 
for more than 30 minutes before 
electromechanical activity resumes.1 
Although the importance of small- 
amplitude electrical activity during 
cardioplegic arrest is uncertain, pre­
liminary investigations in our labo­
ratory suggest that such activity is 
associated with impaired functional 
recovery of the myocardium after 
90 minutes of ischemia.3 To estab­
lish the relationship between in­
tramyocardial voltage and myocar­
dial metabolism we designed a 
study to measure oxygen consump­
tion (a) in the fibrillating heart 
between the temperatures of 37°C  
and 25°C, (b) during small-ampli­
tude electrical activity and (c) in the 
cardioplegic-arrested heart.
Materials and Methods
Ten, adult, mongrel dogs, weigh­
ing between 21 and 25 kg, were
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sedated with 1 ml of Innovar. Anes­
thesia was induced and maintained 
with Somnutol. Ventilation was pro­
vided with a Bird Mark 7 (Bird 
Corp., Palm Springs, Calif.) pres­
sure-regulated ventilator.
The left femoral artery was can- 
nulated with a no. 14F USCI arteri­
al cannula (C.R. Bard Inc., Billerica, 
Mass.) for cardiopulmonary bypass, 
and venous return was provided by 
two 34 USCI cannulas. The cavae 
were snared and the left ventricle 
was vented. Cardiopulmonary by­
pass was established with a Med­
tronic impellar pump (model 
1835-00U) driven by a Medtronic 
circulatory assist console (model 
1810) that would deliver nonpul- 
satile flow at a rate of 2.5 
L/min-m~2 (Medtronic Inc., Circu­
latory Systems Division, Roseville, 
Miss.).
The right atrium was opened 
while the dog was on bypass and a 
no. 12F USCI catheter was inserted 
into the coronary sinus and brought 
out directly through the wall of the 
atrium for measurement of coro­
nary sinus flow. A snare was passed 
externally around the coronary 
sinus to prevent migration of the 
catheter and to ensure that the 
effluent from the catheter repre­
sented the entire coronary sinus 
flow. Coronary sinus blood was col­
lected in a graduated cylinder for 
60 seconds, the total flow being 
used for the calculation of myocar­
dial oxygen consumption. An aver­
age of three measurements of coro­
nary sinus flow was used for each 
calculation of myocardial oxygen 
consumption.
Plunge electrodes were posi­
tioned over the anterior wall of the 
left ventricle and connected to re­
cording and signal conditioning 
equipment. Intramyocardial voltage 
was measured with an in-line RMS 
voltmeter (John Fluke Manufactur­
ing Co., Everett, Wash.). The tech­
nical details related to the recording
of small-amplitude electrical poten­
tials from the myocardium during 
cardioplegic arrest have already 
been detailed.1 Myocardial tempera­
ture was measured and recorded on 
chart paper with specially con­
structed plunge electrodes. The 
thermistor probes were calibrated 
before each experiment with a mer­
cury thermometer.
Oxygen saturation was monitored 
continuously with two Oxy-Sat me­
ters (SM-0100; Bentley Laborato­
ries, Irvine, Calif.). Oxygen-sensing 
equipment was positioned in the 
arterial circuit and also placed in 
line with the coronary sinus drain­
age. Myocardial oxygen consump­
tion (MV02) was measured at two- 
degree intervals between the tem­
peratures of 37°C and 25°C and 
was calculated from measurements 
of oxygen saturation, coronary 
sinus flow (CSF) and hemoglobin 
(Hb) according to the following for­
mula: MV02 (ml/min) = (% arterial 
saturation -  % venous saturation) 
X Hb X 1.34 X CSF (ml/min).
Myocardial temperature was then 
increased to 30°C and cardiac ar­
rest was initiated by infusing potas­
sium cardioplegic solution directly
into the oxygenator.4 Crystalloid 
cardioplegic solution containing 25 
mmol/L of potassium3 was infused 
directly into the oxygenator until 
complete cardiac arrest was ob­
tained. Cardiac arrest was defined 
by the absence of visual mechanical 
activity and loss of electrical activity 
on the surface electrocardiogram 
and from the plunge electrodes. 
Intramyocardial voltage and myo­
cardial oxygen consumption were 
measured in the arrested heart and 
were monitored continuously until 
gross electromechanical activity re­
sumed.
The results are reported as the 
arithmetic mean ± the standard 
error of the mean.
Results
Intramyocardial voltage and myo­
cardial oxygen consumption are il­
lustrated in Fig. 1. Intramyocardial 
voltage during ventricular fibrilla­
tion varied between 1.8 ± 0.5 mV 
and 2.4 ± 0.5 mV between the 
temperatures of 37°C and 25°C. 
The mean intramyocardial voltage 
did not decrease as the core temper-
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FIG. 1. Mean intramyocardial voltage and myocardial oxygen consumption (MV02) 
during hypothermia and cardioplegic arrest. ± =  standard error of mean.
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ature was lowered. In contrast, 
myocardial oxygen consumption 
gradually decreased from 5.8 ± 0.6 
ml 0 2/m in at 37°C to 2.3 ± 0.5 ml 
0 2/m in at 25°C. The infusion of 
cardioplegic solution resulted in a 
dramatic decrease in both the in- 
tramyocardial voltage and myocar­
dial oxygen consumption. Voltage 
recorded in the arrested heart mea­
sured 43 ± 5 mV and myocardial 
oxygen consumption decreased to 
0.5 ± 0.3 ml 0 2/min. Intramyocar- 
dial voltage and myocardial oxygen 
consumption remained low until the 
onset of ventricular fibrillation.
Small-amplitude electrical poten­
tials were recorded from the myo­
cardium just before the onset of 
ventricular fibrillation. However, 
the transition from a complete ar­
rest to ventricular fibrillation was so 
rapid that we could not measure 
coronary sinus flow, and, thus, 
could not calculate myocardial oxy­
gen consumption during the pres­
ence of the small-amplitude fibrilla­
tion waveforms.
Discussion
Infusion of potassium cardiople­
gic solution into the ascending 
aorta will initiate a rapid electrome­
chanical arrest but may not main­
tain a complete electrical arrest. 
Independent investigators12 have 
recorded small-amplitude electrical 
potentials from the myocardium 
with specially designed plunge elec­
trodes after the infusion of the 
cardioplegic solution when the 
heart is quiescent and the elec­
trocardiogram is isoelectric. Small- 
amplitude electrical activity origi­
nates in the HIS bundle and is 
conducted to the ventricles within a 
few minutes.5 This activity is char­
acterized by the onset of small- 
amplitude fibrillation waveforms 
which have a mean voltage two to 
three times greater than the cardio­
plegic arrest potential, which usual­
ly lies between 10 and 40 mV .6 
These small-amplitude electrical po­
tentials are usually recorded within 
5 to 15 minutes after the infusion 
of cardioplegic solution and may be 
present for more than 30 minutes 
before electromechanical activity re­
sumes.6 Earlier investigations in our 
laboratory suggested that the pres­
ence of small-amplitude electrical 
activity may be associated with im­
paired recovery of myocardial func­
tion after ischemic arrest.3 To ex­
plore further the relation between 
intramyocardial voltage and myo­
cardial metabolism, we measured 
myocardial voltage and oxygen con­
sumption in the fibrillating heart 
between the temperatures of 37°C 
and 25 °C in the cardioplegic arrest­
ed heart and, finally, we attempted 
to measure myocardial oxygen con­
sumption and intramyocardial volt­
age during small-amplitude electri­
cal activity.
Our observations indicate that 
myocardial oxygen consumption 
gradually decreases as the tempera­
ture of the fibrillating heart is low­
ered from 37°C to 25°C. Because 
Buckberg and colleagues7 8 demon­
strated that hypothermia decreased 
myocardial energy requirements by 
lowering myocardial oxygen con­
sumption, we expected that moder­
ate hypothermia would have similar 
effects on the magnitude of the 
fibrillation waveforms, since hypo­
thermia is known to reduce the 
contractile force of the myocardi­
um. However, moderate hypo­
thermia did not reduce the mean 
voltage of the fibrillation waveforms 
between the temperatures of 25 °C 
and 37°C, indicating that the volt­
age of the fibrillating heart does not 
correlate directly with the level of 
myocardial oxygen consumption.
Cardiac arrest was initiated by 
infusing the cardioplegic solution 
into the oxygenator rather than 
into the ascending thoracic aorta.
This was necessary in order to 
preserve coronary sinus flow, so 
that myocardial oxygen consump­
tion could be calculated. Cardio­
plegia induced an electrical and me­
chanical arrest in all animals. Ven­
tricular fibrillation and plunge-elec­
trode activity ceased after the car­
dioplegic solution was infused and 
intramyocardial voltage decreased 
from 2.1 mV in the fibrillating heart 
at 30°C to 40 mv. The cessation of 
electromechanical activity was asso­
ciated with a marked reduction in 
myocardial oxygen consumption, 
and both voltage and myocardial 
oxygen consumption remained low 
until the spontaneous onset of ven­
tricular fibrillation. Small-amplitude 
electrical potentials were recorded 
from the plunge electrodes just be­
fore ventricular fibrillation resumed, 
but because the transition between 
the arrested state and electrome­
chanical activity was so short that 
we could not measure coronary 
sinus flow and thus calculate myo­
cardial oxygen consumption during 
small-amplitude electrical activity.
Brandt and associates4 monitored 
the electrical status of the myocar­
dium during cardioplegic arrest 
using an identical experimental 
model. They never recorded electri­
cal activity from the plunge elec­
trodes after the infusion of the 
cardioplegic solution, which led 
them to conclude that cardioplegia 
always initiated and maintained a 
complete electrical arrest. Our data 
and Brandt’s observations4 comple­
ment each other but are in contrast 
to numerous earlier investiga­
tions,1”3-56910 which indicated that 
small-amplitude electrical potentials 
may be recorded from the myocardi­
um within 10 to 15 minutes after 
infusion of the cardioplegic solu­
tion. Cardiac arrest for these ex- 
periments1”3-5-6-9-10 was induced by 
infusing potassium directly into the 
aortic root. Infusion of cardioplegic 
solution into the clamped ascending
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thoracic aorta almost completely 
abolishes coronary flow, which pre­
vents rapid fluctuations of intracel­
lular potassium. The gradual de­
cline of intracellular potassium as­
sociated with this technique results 
in a slow transition between the 
arrested myocardium and the onset 
of gross electromechanical activity. 
Thus, small-amplitude electrical po­
tentials may develop and persist for 
more than 30 minutes before ven­
tricular fibrillation resumes. In con­
trast, infusion of cardioplegic solu­
tion into the oxygenator preserves 
coronary flow and presumably 
causes rapid washout and decline of 
intracellular potassium, leading to 
the sudden onset of ventricular ex­
citation.
The metabolic significance of 
small-amplitude electrical activity is 
not fully understood, although an 
earlier investigation3 suggested that 
such activity was associated with 
postischemic depression of left ven­
tricular function. Unfortunately, we 
were unable to calculate myocardial 
oxygen consumption during small- 
amplitude electrical activity. Howev­
er, we measured the voltage of the 
fibrillating heart during hypo­
thermia and following the induction 
of potassium cardioplegia. Interest­
ingly, the mean voltage of the myo­
cardium during ventricular fibrilla­
tion remained relatively constant as 
myocardial temperature was low­
ered. Considering that myocardial 
oxygen consumption progressively 
decreases with hypothermia, one 
must assume that voltage does not 
correlate directly with the level of 
myocardial oxygen consumption. 
Therefore, the increase in the rest­
ing potential associated with the 
onset of small-amplitude activity 
may indicate increased myocardial 
oxygen consumption but may not 
directly reflect the level of myocar­
dial metabolism. The significance of 
small-amplitude electrical activity 
during cardioplegic arrest remains
uncertain, requiring further clarifi­
cation to determine its effects on 
myocardial metabolism and preser­
vation.
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American Society for Bariatric Surgery
The 7th annual meeting of the Ameri­
can Society for Bariatric Surgery will be 
held at the Royal York Hotel, Toronto, 
Ont., June 7-9, 1990. For further in­
formation concerning this important 
meeting for obesity surgeons, for ab­
stract forms and for information regard­
ing membership, please write to: Thom­
as J. Blommers, PhD, Executive Manag­
er, American Society for Bariatric Sur­
gery, Box 639, 633 Post St., San 
Francisco, CA 94109, USA.
Progress in Cancer Surgery
The Department of Surgery, University 
of Minnesota Medical School is spon­
soring the 54th Annual Course “Prog­
ress in Cancer Surgery” from June 20- 
22, 1990 at Willey Hall, University of 
Minnesota, Minneapolis, Minn. The 
course is accredited for 20.5 hours in 
Category 1 by the American Medical 
Association. The registration fee is 
$425. US ($200. US for medical resi­
dents). For information contact: Office 
of CME, University of Minnesota, Box 
202 UMHC, 420 Delaware St. SE, Min­
neapolis, MN 55455; (612) 626-5525.
Royal College Abstracts
The 1990 Royal College meeting will be 
held in Toronto, Ontario, from Sept. 
14-17, 1990. The Annual Meeting 
Committee is inviting all Fellows and 
members of participating societies to 
submit abstracts of scientific papers for 
consideration by the specialty review 
panels for the 1990 program.
The abstract submission forms were 
distributed to all Fellows as an insert to 
the January 1990 Annals.
Please note that the deadline for 
receipt of the abstracts, accompanied by 
the processing fees is Mar. 9, 1990.
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Inflammatory Abdominal Aortic 
Aneurysms and Ureteric Obstruction
S.B. Radomski, MD;* F. Michael Ameli, MB, ChB, FRCS(Edin), FRCSC, FACS;* 
M.A.S. Jewett, MD, FRCSCt
Inflammatory abdominal aortic aneurysms are rare, but when they occur the ureters 
may be involved in the perianeurysmal fibrosis. Treatment of this ureteric 
involvement is controversial. The authors present one such case, review the 
literature and describe what they believe is the appropriate method of diagnosis and 
treatment. This includes the use of computed tomography, retrograde pyelography, 
ureteral stenting, repair of the aneurysm and ureterolysis.
Les anevrismes inflammatoires de l’aorte abdominale sont rares mais, quand ils 
surviennent, il peut y avoir atteinte des ureteres par la fibrose perianevrismale. Le 
traitement de l’atteinte ureterale est conteste. Les auteurs en signalent un cas, font 
la revue de la litterature et decrivent ce qu’ils croient etre la methode appropriee de 
diagnostic et de traitement. Elle fait appel a la tomodensitometrie, a la pyelographie 
retrograde, a la pose d’un manchon ureteral, a la reparation de l’anevrisme et a 
l’ureterolyse.
Inflammatory abdominal aortic aneurysms represent 2.5% to 
10% of all infrarenal aortic aneu­
rysms.1-4 In the past, the diagnosis 
was difficult to make preoperative- 
ly, but with the introduction of 
computed tomography and ul­
trasonography, the diagnosis is 
being made earlier. The first report­
ed case of ureteric obstruction sec­
ondary to an inflammatory reaction 
around an aortic aneurysm was 
made in 1935 by James.5 Since then 
there have been many case reports 
of perianeurysmal fibrosis and uret­
eric obstruction. However, contro­
versy regarding the management of
ureteric obstruction still remains. In 
this report we present a case of 
ureteric obstruction associated with 
an inflammatory abdominal aortic 
aneurysm and describe what we 
believe is the appropriate method of 
diagnosis and management.
Case Report
A 73-year-old woman was admit­
ted for elective repair of an abdomi­
nal aortic aneurysm diagnosed by 
ultrasonography. She complained of 
dizziness and upper abdominal dis­
comfort. She had no back or flank
pain and no claudication. She was a 
nonsmoker and had no history of 
diabetes or heart disease. The re­
mainder of her history was nega­
tive. She was on no medications.
On physical examination, the 
only notable finding was a tender 
5-cm abdominal aortic aneurysm 
and a right popliteal Baker’s cyst. 
All of her peripheral pulses were 
palpable and she had no bruits. She 
had no flank tenderness.
Results of urinalysis and urine 
culture, and the serum electrolyte 
levels were normal. Her erythrocyte 
sedimentation rate and serum creat­
inine level were mildly elevated at 
26 m m/h (normal 0 to 20 mm/h) 
and 132 mmol/L (normal 50 to 
110 mmol/L) respectively. The 
electrocardiogram and chest x-ray 
film appeared normal. Her VDRL 
test result was negative.
Computed tomography demon­
strated an infrarenal abdominal aor­
tic aneurysm, measuring 5.5 cm, 
with a thickened wall. There was a 
right hydronephrosis and the right 
ureter was involved in the wall of 
the aneurysm (Figs. 1 and 2). An 
intravenous pyelogram confirmed 
the presence of a moderate right 
hydronephrosis with medial devia­
tion of the right ureter, but the 
level of obstruction was not clearly 
defined (Fig. 3). As a result, right 
retrograde pyelography was carried 
out and a right ureteric stent insert­
ed (Fig. 4).
At operation, a thick-walled shiny 
abdominal aortic aneurysm was
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found and the level of obstruction 
was just above the left sacroiliac 
joint. The left ureter was easily
identified and not involved in the 
inflammatory aneurysm. However, 
ureterolysis of the right ureter was
FIG. 1. Computed tomogram reveals infrarenal abdominal aortic aneurysm, 
measuring 5.5 cm, with thickened wall. Note right ureter involved in wall of 
aneurysm.
FIG. 2. Computed tomogram shows right hydronephrosis.
necessary as it was involved in the 
wall of the aneurysm. In addition, 
the duodenum was adherent to the 
aorta and there was a severe inflam­
matory reaction around the iliac 
vessels. A 16-mm Dacron graft was 
inserted and the aneurysm repaired 
without difficulty.
Postoperatively, the ureteral 
stent was kept in place for 7 days.
FIG. 3. Intravenous pyelogram shows 
right hydronephrosis.
FIG. 4. Right retrograde pyelogram. 
Note level of obstruction at right sa­
croiliac joint.
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During this time the patient re­
ceived antibiotics. Her postoperative 
course was smooth and she was 
discharged from hospital 11 days 
after surgery. At that time, her 
urine culture was negative and her 
serum creatinine level normal at 98 
mmol/L.
Three months after surgery she 
was well and an intravenous pyelo- 
gram appeared normal (Fig. 5).
Discussion
This woman clearly had an in­
flammatory abdominal aortic aneu­
rysm with ureteric obstruction. 
Only 23% of patients with inflam­
matory aneurysms will have ureteric 
encasement due to perianeurysmal 
fibrosis.4 In the past, diagnosis has 
been missed, resulting in increased 
morbidity and mortality.6 Medial 
displacement of the ureter can be 
an early radiologic sign of perianeu­
rysmal fibrosis7 but is not patho­
gnomonic.78 In a large review by 
Pennell and associates,9 10% of 
those with inflammatory aneurysms 
had lateral deviation of the ureters.
FIG. 5. Intravenous pyelogram 3 
months after aneurysm repair and 
ureterolysis. Note resolution of right 
hydronephrosis.
Computed tomography has signifi­
cantly improved the detection of 
inflammatory aneurysm and ureter­
al obstruction. In Pennell’s review,9 
computed tomography and ul­
trasonography were 70% and 60% 
accurate, respectively, in diagnosing 
inflammatory aneurysms. Ureteral 
obstruction secondary to an abdom­
inal aortic aneurysm often goes 
undetected because symptoms are 
nonspecific. Findings such as ure­
mia or anuria are seen in only 14% 
to 21% of cases.1011 In 1961, Culp 
and Bernatz12 at the Mayo Clinic 
reported that only 10% of 400 
patients surgically treated for ab­
dominal aortic aneurysms presented 
with urologic symptoms, most com­
monly pain.
The course of treatment for ure­
teral obstruction and inflammatory 
aneurysm remains highly controver­
sial. Some4-613 suggest that in the 
absence of complete ureteric ob­
struction aneurysm repair alone is 
sufficient. They believe that this 
promotes resolution of the inflam­
matory process and relieves the 
ureteric obstruction.13 However, 
many others101114-17 recommend 
both aneurysm repair and ureterol­
ysis for definitive treatment of the 
ureteric obstruction. Darke and col­
leagues16 reported that the only 
patient in their series who did not 
initially undergo ureterolysis re­
quired it 18 months later. Further­
more, Loughlin and associates14 in 
1984 reported that their only pa­
tient who did not undergo ureterol­
ysis had persistent left hydrone­
phrosis. Steroids have been advo­
cated to treat the inflammatory 
changes and ureteral obstruction. 
However, Pennell and colleagues9 
had five patients who had been on 
long-term prednisone therapy be­
fore surgery who still had severe 
inflammatory changes.
Thus, we believe it is crucial to 
perform computed tomography pre- 
operatively to assess both the aorta
and genitourinary system. We per­
form computed tomography on all 
patients who have an abdominal 
aortic aneurysm in order to define 
the nature of the aneurysm (i.e., 
inflammatory, dissecting). Comput­
ed tomography is noninvasive, 
highly predictive of aneurysmal 
size, gives no false-negative results 
and can localize the proximal extent 
of the aneurysm.1819 Furthermore, 
it provides a modified form of an 
intravenous pyelogram, so that hy­
dronephrosis can be detected. Al­
though in our opinion computed 
tomography is the investigation of 
choice for evaluating an abdominal 
aortic aneurysm, we recognize that 
the scanner may not be available in 
all hospitals in Canada. In these 
circumstances, ultrasonography can 
be used, although it does not give 
as much information. If there is any 
evidence of ureteric involvement we 
then carry out retrograde pyelogra­
phy, which, in our opinion, provides 
more information than intravenous 
pyelography. We can define the 
exact location and cause of obstruc­
tion. Furthermore, it allows us to 
insert a ureteral stent if the ureter 
is intimately involved in the inflam­
matory aneurysm with or without 
ureteric obstruction. The insertion 
of a ureteral stent allows easier 
identification of the ureter and 
hence prevents injury to the ureter 
during repair of the aneurysm and 
ureterolysis. Ureteral stents are also 
useful in case of injury to the 
ureter; they can act as a splint once 
the ureter is repaired.
Conclusions
The diagnosis and management 
of ureteric obstruction secondary to 
inflammatory abdominal aortic an­
eurysms have been variable and 
controversial. The diagnosis can be 
made initially by computed tomog­
raphy followed by retrograde pye-
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lography. Once the diagnosis is 
established, the ureteral obstruction 
can be managed by insertion of a 
ureteral stent and ureterolysis, 
which can be performed safely and 
effectively during repair of the in­
flammatory abdominal aortic aneu­
rysm.
Although inflammatory aortic an­
eurysms are rare, possible ureteral 
involvement should always be sus­
pected by both the vascular surgeon 
and urologist.
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Hinged Total Knee Replacement 
Indications and Results
H.U. Cameron, MB, ChB, FRCSC;* Y.B. Jung, MDt
Twenty-seven hinged (Guepar II) knee replacements were performed on 26 patients 
with a follow-up of 1 to 7 years (mean 3 years). Indications for the procedure were 
bone loss (nine cases) nonunion of tibial or femoral fractures (four), anteroposterior 
instability (five), mediolateral instability (eight) and recurvatum instability (one).
Results were good or excellent in 66.6%. Two patients required revision and there 
were three other implant-related complications. All press-fit stems were radiolucent 
to some extent and some radiolucency was present close to the knee in all revisions 
of stem components. No radiolucency was present in revisions of non-stem cemented 
components.
Although the introduction of variable stem length, semi-constrained knees has 
reduced the need for implants such as the Guepar II prosthesis, the results, 
especially in terms of radiolucency, are surprisingly good. The authors conclude 
that a hinged knee remains of value in desperate situations.
Vingt-sept protheses a charniere du genou (Guepar II) ont ete posees chez 26 
patients. La periode de surveillance des suites therapeutiques va de 1 a 7 annees 
(moyenne de 3 ans). L’intervention avait ete rendue necessaire a cause d’une 
degenerescence osseuse (neuf cas), de l’absence de soudure d’une fracture du tibia 
ou du femur (quatre), d’une instability anteroposterieure (cinq), mediolaterale (huit) 
ou de la courbure posterieure (une).
Les resultats on ete bons ou excellents dans 66.6% des cas. Deux patients ont eu 
besoin d’une revision et il y eut trois autres complications reliees aux protheses.
Toutes les tiges ajustees sous pression avaient une transparence relative aux rayons 
X et une certaine opacite etait presente a proximite du genou dans tous les cas de 
revision de la tige. Aucune transparence radiologique n’etait presente lors des 
revisions de protheses cimentees, sans tige.
Meme si la venue de protheses semi-contraintes a tiges de longueur variable a 
reduit l'utilisation des protheses de type Guepar II, leurs resultats, surtout au plan 
de la transparence radiologique, sont etonnamment bons. Les auteurs concluent que 
les protheses a charniere du genou ont encore leur place dans les cas desesperes.
H inges of various types have been used for total knee re­
placement since the 1950s, and the 
reported results have not been par­
ticularly good (Fig. I).1-8 Currently, 
there are few indications for a stabi­
lized knee prosthesis. Most cases 
can be handled by a semi-con-
From the Department o f  Surgery, University o f  Toronto, Toronto, Ont.
* Assistant Professor, Department o f  Surgery, Department o f  Pathology and Department o f  
Engineering, University o f  Toronto. Staff orthopedic surgeon. Orthopaedic and Arthritic  
Hospital. Toronto
strained condylar type prosthesis.
In an attempt to determine the 
indications for a hinged implant and 
the results that can be achieved, all 
cases of Guepar II (Howmedica Inc., 
Rutherford, NJ) hinge replacements 
carried out by the senior author 
were reviewed.
Methods
All patients with Guepar II re­
placements carried out by the se­
nior author were followed up pro­
spectively at 6-month intervals 
using the Hospital for Special Sur­
gery rating system9 and radiologi- 
cally, using 3-foot standing films, 
lateral and skyline views. The 
bone-cement interface was studied 
after the fashion of Bargar and 
colleagues1 and DeLee and Charn- 
ley.10
Because it became apparent that 
radiolucency starts at the knee and 
extends proximally and distally 
along the stems, we found it conve­
nient to divide the stems into three 
parts in both planes: a type I lucen- 
cy extending over one-third of the 
stem closest to the knee, a type II 
lucency over two-thirds of the stem 
closest to the knee and a type III 
lucency over the whole stem. Grade 
1 means that the width of the 
radiolucent line is 1 mm or less, 
grade 2, 2 mm or less and grade 3 
greater than 2 mm.
tAssociate Professor, Chung-Ang University, Seoul, South Korea 
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Technical Aspects
We limited our study to the Gue­
par II prosthesis because the Gue-
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par I stems were manifestly too 
small and the cementing technique 
was inadequate. In all cases in this 
series in which the prostheses were 
cemented in place, canal brushing, 
plugging, pressure lavage, cement 
injection and pressurization were 
carried out.
When a patella had been re­
placed, the original was left in situ. 
The patella was replaced if a lateral 
release was not carried out. When a 
wide lateral release was necessary, 
fears of further devascularizing the 
patella precluded replacement.11 Re­
placement, when done, was with an 
inset, non-cemented, plastic button 
(Tricon P; Richards Manufacturing 
Co., Memphis, Tenn.).
Findings
Twenty-seven Guepar II knee 
prostheses were inserted in 26 pa­
tients (11 men, 15 women) who
ranged in age from 48 to 86 years 
(mean 68 years). The follow-up was 
from 1 to 7 years (mean 3 years). 
Two patients had died by the time 
of this review, but since they had 
been followed up for more than 3 
years they were included. Knee re­
placement was done in one patient 
who had had poliomyelitis and had 
never undergone knee surgery, in 
four who had nonunion of bones 
around the knee, in three who had 
failure of knee fusion and in the 
remainder (19) as revision. Of the 
19 who had knee revision, 7 had 
one revision, 9 two, 1 three and 2 
five or more.
Complications at surgery includ­
ed two longitudinal tibial shaft frac­
tures, from attempting to insert too 
large a tibial component into too 
small a tibia. Only one size of tibial 
component is available and the com­
ponent had to be customized in- 
traoperatively in the machine shop. 
Both patients were treated with
FIG. 1. Tibial component in this original Guepar prosthesis has loosened, resulting 
in substantial osteolysis of surrounding bone. Cementing in new stem prosthesis 
will result in rapid development of radiolucency around new stem in area of old 
stem.
screw closure of the split and bone 
grafting. The tibial component was 
simply press-fitted in these cases.
Postoperative Complications
One patient had a severe stroke 
but recovered completely. One pa­
tellar tendon ruptured 3 months 
postoperatively and had to be wired 
back in place (Fig. 2). One patient, 
who had a 30° quadriceps lag be­
fore revision due to a patellar ten­
don rupture, continued to have a 
20° lag in spite of tendon repair at 
the time of surgery. One patella 
that had been dislocated for years 
required a huge lateral release for 
recentering; it subsequently became 
avascular and disintegrated. The 
original patellar component, which 
had been left in place, had to be 
removed along with the necrotic 
bone.
FIG. 2. Patellar tendon ruptured, 3 
months after surgery. Patient had 
avascular necrosis after initial total 
knee replacement. Patella was wired 
back using three multiphase wires 
(stainless steel wires tend to break 
under these circumstances). These 
components have been press-fitted. Ob­
vious radiolucency surrounds femoral 
component but is minimal on tibial 
side.
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Two patients had severe patella 
Baja (i.e., a low-riding patella). 
Their range of movement was 0° to 
30° and 0° to 60° only, but be­
cause they were pain free they did 
not wish to undergo revision. In 
one patient, removal of the previous 
femoral component resulted in such 
severe bone loss that in spite of 
three allografting procedures the 
femoral tube remained unsatisfacto­
ry.12 Her postoperative course was 
complicated by infection which 
cleared with debridement, but the 
femoral component was in too short 
a segment of femur and loosened 
within 6 months. She has subse­
quently undergone revision and 
more bone graft was added.
One patient who had a tibial 
shaft fracture and a press-fitted 
stem continued to have “end pain” 
at the stem tip. When the fracture 
had healed she underwent revision, 
and a new tibial component was 
cemented in place. She required a 
further 2.5 cm of allograft to build 
up the tibia to gain sufficient 
length.
Knee ratings were difficult. The 
majority of these patients were sal­
vage cases and had other problems. 
The majority had had at least one 
other joint replaced; 60% used 
walking aids and although some did 
not strictly require it, all were en­
couraged to use them.
Twenty-one patients had no pain, 
5 had some aching on use of the 
limb, including 1 who had recently 
undergone another revision. Pain is, 
of course, activity related, and if 
activities have been reduced it is 
difficult to tell how pain free these 
patients would be if their other 
limbs were normal. For example, 
one patient used a wheelchair most 
of the time not because of the knee 
problem but because of feet, back, 
neck and shoulder problems.
Range of motion was usually 
over 100° except in the two pa­
tients with patella Baja and two 
who had knee-fusion takedown. 
The latter two had flexion to 50° 
and 75° respectively. Two patients, 
including the one who had had 
poliomyelitis, had a quadriceps lag.
Using the Hospital for Special 
Surgery rating system, 1 knee 
scored poor, 8 fair and 18 good or 
excellent.
Of great interest is the radiologic 
review, which considered press-fit 
and cemented components; the ce­
mented group was subdivided into 
those who had revision of a previ­
ous stem component and those who 
did not.
Of patients who were press-fitted 
(four), all showed some degree of 
radiolucency. Only one patient, 
however, had symptoms severe 
enough to require revision. All the
revisions of previously cemented 
stem knees (six) showed some ra­
diolucency, although interestingly 
in the tibial stems a type I and 
grade 1 only (Table I). The femoral 
side showed more radiolucency but, 
with the exception of a patient who 
had undergone revision, none 
showed a type III radiolucency.
In the remaining 17 cases there 
was no radiolucency (Fig. 3).
Discussion
The radiologic findings are the 
most interesting aspect of this 
study. Over the short term (i.e., less 
than 7 years), added constraints did 
not appear to result in early loosen­
ing of a well-fixed stem. These 
findings are contrary to all previous 
studies1 and require an explanation. 
Previous hinged prostheses had rel­
atively short stems and were insert­
ed with original cement techniques. 
In hips, the universal use of short 
stems such as the Charnley-Muller 
have been abandoned and this study 
suggests that short stems in con­
strained knee prostheses should 
also be abandoned.
A short stem means that the 
interface loads are concentrated on 
a small area while a longer stem 
allows better stress distribution. 
Furthermore, from experience with 
hip prostheses, it is known that 
loosening rates are higher if the 
metal stem does not fill at least 50% 
of the canal. The distal femoral 
canal is so big that it is difficult to 
do this and the Guepar II stem fails 
to fulfil this criterion, even though 
it is much bigger than any other 
stem available.
Improved cementing techniques 
with brushing, canal plugging, la­
vage and pressure injection also 
help in stabilizing the implant and 
should be used routinely in cement- 
ed-stem knees as they are in hips.
The press-fit components func-
Table 1. Type* and Gradet of Radiolucency
Non-cement Cem ent revision of stem Non stem
AP Lat AP Lat AP Lat
Femoral stem 11-2 II-2 1-1 1-1 Nil Nil
111-1 III-2 11-1 11-1
III-2 III-2 11-1 1-1
1-1 111-1 III-3 1-1
Tibial stem 111-1 II-3 1-1 1-1 Nil Nil
1-1 1-1 1-1 1-1
III-2 III-2 1-1 1-1
0-0 0-0 1-1 1-1
0 0
1-1 1-1
*1 =  radiolucency around 1/3 of the prosthesis closest to the knee, II =  radiolucency around 2 /3  
of the prosthesis closest to the knee, III =  complete radiolucency.
t1 =  radiolucency less than 1 mm, 2 =  radiolucency less than 2 mm, 3 =  radiolucency greater 
than 2 mm.
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tioned well, although all loosened 
to some extent. Only one patient 
had symptoms severe enough to 
require revision. The absence of 
pain in the other cases is remark­
able because the Guepar II stem is 
not designed for press-fitting. This 
provides clinical proof of the find­
ings of Andriacchi and Galante’s13 
recent study which suggest that 
rotatory loads on the knee are not 
as high as was feared.
The fact that all cemented stems 
revised from previous cemented 
stems show some degree of radiolu- 
cency is cause for concern. It sug­
gests, as in hips, that cemented 
revision may not be particularly 
durable and that there is a role for a 
noncemented long-stem prosthesis 
in such cases.14
The infection rate in this series
was low compared with that report­
ed in other series,1 but this may 
merely be a statistical anomaly re­
sulting from small numbers. We 
used antibiotic-loaded cement rou­
tinely in addition to prophylactic 
antibiotics.
There were two main indications 
for use of the Guepar II — the 
length of the stem and the need for 
stability.
Stem Length
The Guepar II has the longest 
and heaviest stem of all knee pros- 
theses available in Canada. It was 
used when there was extensive bone 
loss requiring massive allografting 
(six cases), when revision of a previ­
ous long stem component such as 
the Guepar I was required (three
cases) and when there was nonun­
ion of the proximal tibia (two cases) 
and distal femur (two cases) (Fig. 
4) .
The knee in some cases could 
have been handled with a semi-con- 
strained prosthesis with a custom 
long stem, but custom implants are 
extremely expensive.
Instability
Three types of instability exist: 
post-patellectomy, mediolateral and 
recurvatum instability.
•  Post-patellectomy instabili­
ty.1516 Patellectomy results in re­
moval of an important anteropost­
erior knee stabilizer. If both cruci­
ate ligaments have also been re­
moved, it is necessary to use a 
stabilized prosthesis, either a true 
hinge such as the Guepar or a 
posterior stabilized knee prosthesis.
FIG. 4. This patient had nonunion of 
supracondylar femoral fracture which 
had been plated and grafted. Knee was 
ankylosed. One year after implantation 
union has occurred.
FIG. 3. Five years after implantation, no radiolucency can be seen. Had this been 
operated on today, distal femur would have been rebuilt with allograft bone.
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This was the reason for using the 
Guepar II in five cases in this series, 
two being knee-fusion takedowns.17
•  Mediolateral instability. It is 
now universally accepted that liga­
ment balancing is required in total 
knee replacement for a semi-con­
strained implant to be successful. In 
ligament balancing, the tight side is 
loosened until the tension in the 
collateral ligaments is the same. 
Ligament tightening on the loose 
side has not been successful.2 In 
primary knee replacement when the 
deformity is intra-articular, liga­
ment balancing is always possible, 
but this is not necessarily the case 
when the deformity is extra-articu­
lar because ligaments may have to 
be over-lengthened, and for this 
they have a limited capacity.18
In a revision situation, ligament 
balancing is more difficult, but is 
usually possible. If, however, a 
loose tibial component sinks down 
on one side and remains there for 
some time, intense ligament scar­
ring may result. Removal of the 
component slightly loosens the liga­
ments on the loose side and, in 
spite of the most extensive release 
possible of the sleeve on the tight 
side, correction occasionally cannot 
be achieved — hence, the use of a 
Guepar II prosthesis in this situa­
tion in eight cases.
•  Recurvatum instability. Sig­
nificant recurvatum deformity in 
the arthritic knee can usually be 
handled by inserting a semi-con­
strained knee so tightly that the 
patient ends up with a 10° fixed 
flexion deformity. However, when 
neurologic problems exist as they 
may after poliomyelitis because the 
patient has stretched out the cap­
sule and ligaments, the same thing 
will likely happen if a semi-con- 
strained knee prosthesis is used. 
Indeed, in these rare instances when 
this type of surgery is necessary, 
the knee is painful, not from arthri­
tis but from a global instability due
to stretching of all the ligaments. 
This is only likely to occur if there 
are no functioning muscles below 
the hip, so the knee must be capa­
ble of a little hyperextension. It is 
also more likely to occur if the hip 
or ankle have been fused.
Although a range of stem sizes 
would be of value, technical prob­
lems in this series were surprisingly 
few. The biggest problem was cor­
recting previous rotatory deformity. 
If the knee had been replaced and 
the leg left in external rotation with 
a dislocated patella, it was difficult 
to correct even when the proximal 
tibia was skeletonized. A frighten­
ing amount of force sometimes had 
to be used to connect the two 
components, often coupled with a 
wide lateral release. It is for this 
reason that two patellas remained in 
a significantly Baja position. After a 
medial parapatellar approach and a 
lateral release, a tibial tubercle 
transfer was not attempted for fear 
of totally devascularizing the patel­
la.19
Considering the complexity of 
the cases, the results achieved were 
reasonably acceptable. It should be 
emphasized, however, that the indi­
cations for hinged total knee re­
placement are few. The recent intro­
duction of variable stem length im­
plants virtually negates one of the 
main indications used in this series 
(i.e., bone loss). Furthermore, it is 
becoming apparent that a posterior 
stabilized knee gives adequate an­
teroposterior stability when the pa­
tella and cruciate ligaments have 
been removed. Whether there is any 
real load difference between a true 
hinge such as the Guepar II and a 
rotating platform hinge and a non- 
linked hinge18 remains to be deter­
mined.
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andConcurrent Poland’s Syndrome 
Gynecomastia: a Case Report
James Mahoney, MD, FRCSC, FACS; Brian Hynes, BSc, MD
Gynecomastia (enlargement of the male breast) is a common occurrence during 
puberty and usually resolves. Poland’s syndrome or hypoplasia of the chest wall is a 
rare congenital anomaly associated with hypoplasia of the ipsilateral extremity. 
Simultaneous presentation of gynecomastia and Poland’s syndrome in a 26-year-old 
man increased the extent of asymmetry and the perception of each deformity. 
Surgical reduction of the enlarged breast greatly reduced the asymmetry, giving a 
satisfactory result.
La gynecomastie (le developpement de la poitrine chez l’homme) est frequemment 
observee a la puberte et se corrige habituellement d’elle-meme. Le syndrome de 
Poland, ou hypoplasie de la paroi thoracique, est une anomalie congenitale rare qui 
est associee a une hypoplasie des membres ipsilateraux. Le developpement, chez un 
homme de 26 ans, d’une gynecomastie et d’un syndrome de Poland exagera 
l’etendue de l’asymetrie et la perception de chacune des difformites. Une reduction 
chirurgicale de la poitrine reduisit l’asymetrie, laissant un resultat satisfaisant.
Poland’s syndrome (hypoplasia of the chest wall and ipsilateral 
extremity) and gynecomastia (en­
largement of the male breast) repre­
sent two distinct chest-wall deformi­
ties. We describe the simultaneous 
appearance of Poland’s syndrome 
and gynecomastia on opposite sides 
of the chest wall in a 26-year-old 
man. The conditions produced pro­
found asymmetry, offering an un­
usual challenge. Treatment of the 
gynecomastia greatly reduced the 
asymmetry and gave a satisfactory 
result in this patient.
Case Report
A healthy 26-year-old man pre­
sented with persistent unilateral 
right gynecomastia, which had been 
present for approximately 11 years. 
His main concern was the obvious 
asymmetry due to the enlarged
right breast which was accentuated 
by contralateral chest-wall hypopla­
sia.
His medical history revealed that 
he was born at term after an un­
complicated pregnancy. At the age 
of 2 years he was seen by the family 
doctor because of an absent left 
nipple. Examination had revealed a 
very small nipple on the left com­
pared with the right. The left pec- 
toralis muscle was deficient, caus­
ing a sunken appearance to the left 
side of the chest.
During puberty, unilateral clinical 
right gynecomastia presented. 
Other male secondary sexual cha­
racteristics developed normally.
Our examination revealed obvi­
ous chest-wall asymmetry. An en­
larged right breast, which was non­
tender, ptotic and of moderate size 
with a firm consistency, was present 
(Fig. 1). There was a large areola
and nipple. The left anterior chest 
wall had a hollow, sunken appear­
ance. The sternal head of the pec- 
toralis major and the left anterior 
axillary fold were absent. The sub­
cutaneous tissue appeared deficient. 
The clavicular portion of the pector- 
alis major muscle was intact. A 
2-mm hypoplastic left nipple with­
out an areola was visible. Otherwise 
the hands and arms on both sides 
were similar. Laboratory tests in­
cluding measurement of adrenocor­
ticotropic hormone, follicle- 
stimulating hormone, thyroid- 
stimulating hormone, prolactin, tes­
tosterone, cortisol and estradiol lev­
els as well as a chest x-ray film were 
all within normal limits.
Treatment was directed toward 
the enlarged right breast. The uni­
lateral right gynecomastia was re­
sected through an inferior periareo- 
lar incision. Fibroadipose tissue, 
weighing 180 g and measuring 11 
X 8 X 3 cm, was excised. Care was 
taken to maintain the nipple projec­
tion. His postoperative course was 
uncomplicated. Examination 3 
months postoperatively revealed im­
proved symmetry between the two 
sides (Fig. 2). The patient was very 
pleased with the result and did not 
request any further surgery.
Discussion
Our case represents an unusual 
clinical situation in which two dif­
ferent types of chest-wall abnormal­
ity presented simultaneously, em­
phasizing the abnormalities of each 
deformity. The left hypoplastic nip­
ple and pectoralis muscle, repre­
senting an incomplete expression of 
Poland’s anomaly, accentuated the 
contralateral enlarged right breast,
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the patient’s main complaint.
Hypoplasia of the chest wall sec­
ondary to Poland’s syndrome can 
result in serious chest-wall deformi­
ty. It was first described in 1841 by 
Alfred Poland1 and involves a spec­
trum of congenital anomalies, all of 
which may or may not be present. 
The classic features of the anomaly 
are unilateral absence of the sterno­
costal head of the pectoralis major 
muscle, a hypoplastic hand and ipsi- 
lateral syndactyly, but considerable 
variation has been reported,2-4 in­
cluding hypoplasia or absence of 
the breast, hypoplasia of the chest 
subcutaneous tissue, ipsilateral bra- 
chysyndactyly, costocartilage and 
vertebral defects, winged scapulas, 
posterior shoulder girdle anomalies, 
renal anomalies and even herniation 
of the lung. For the patient, the 
emotional stigma is often great, 
especially in women. Poland’s 
anomaly is thought to occur ap­
proximately once in 25 000 births.2 
The right side is affected more 
frequently than the left. Although 
most reports of the Poland anomaly 
and its variants have been sporadic, 
there is a handful of familial cases 
suggesting autosomal dominant in­
heritance.5 Minor manifestations of 
the syndrome will easily be over­
looked without careful examination 
of the relatives. Various hypotheses 
have been put forth regarding the 
pathogenesis of the syndrome, in­
cluding an intrauterine vascular in­
sult causing hypoxia, arising from
FIG. 1. Right gynecomastia and con­
tralateral Poland’s syndrome in 
26-year-old man.
arterial spasm or poor collateral 
circulation.6-8 The developmental 
insult is thought to occur between 
6 and 8 weeks’ gestation, the peri­
od during which upper extremity, 
hand and pectoral development 
takes place. Anomalies associated 
with other organ systems have also 
been reported. Treatment of the 
chest deformity depends on the ex­
tent of the anomaly and may re­
quire the use of split rib or bone 
grafts if there is a significant defect. 
Breast reconstruction is commonly 
requested. Soft-tissue augmentation 
of the chest wall with the latissimus 
dorsi island myocutaneous flap 
combined with a prosthesis can pro­
vide a very satisfactory result.910 
Reduction or augmentation of the 
opposite breast can also improve 
breast symmetry.
Gynecomastia or excessive devel­
opment of the male mammary gland 
is the most common breast disorder 
of males. An early historical de­
scription was provided by Herodo­
tus, who noted it amongst the Scy­
thians. Paulus of Aegina (635 to 
690 AD), the last of the great 
physicians of Byzantium, clearly 
recommended a surgical approach 
to this disorder when the “deformi­
ty had the reproach of effemina­
cy”.11 Although the size of the 
breast will vary, clinical diagnosis 
requires that a 2-cm diameter of 
subareolar mammary tissue be pres­
ent.
Histologically, early gyneco-
FIG. 2. Postoperative appearance fol­
lowing surgical removal of breast tis­
sue.
mastia is characterized by ductules 
embedded in loose connective tis­
sue. Later, ductular structures be­
come less conspicuous in a dense 
hyaline stroma.12 Gynecomastia can 
be either physiologic, as in the 
majority of cases, or pathological, 
resulting from one of three basic 
mechanisms: deficiency of testoster­
one production or reduced respon­
siveness to its action, increase in 
estrogen production, and secondary 
to the effects of drugs.13 As a 
clinical entity, gynecomastia is seen 
frequently.14 It is especially com­
mon among males at puberty and 
usually regresses spontaneously. 
Gynecomastia persisting into man­
hood is rare and is related to persis­
tent breast or fatty tissue, or both. 
Our patient gave a history of true 
gynecomastia with enlargement of 
the breast at puberty.
In the majority of instances the 
cause of gynecomastia is unknown, 
but it is thought to be a physiologic 
response to the ratio of circulating 
estrogens and androgens.14 Gyneco­
mastia again increases in frequency 
in later life as the amount of circu­
lating androgen decreases. Male 
breast enlargement associated with 
mainly adipose tissue is seen at this 
time and is not related to any 
endocrine abnormality. Often a 
cause cannot be identified. History 
and physical examination should 
include the drug history and exami­
nation of the testes. Laboratory 
investigations of liver function and 
endocrine status (serum andros- 
tenedione or 24-hour urinary 
17-ketosteroids, plasma estradiol, 
luteinizing hormone and testoster­
one) should be performed when the 
drug history is negative, the breast 
is tender (indicating rapid growth) 
or palpable breast tissue is greater 
than 4 cm in diameter, or when 
based on the clinical findings.13
In Poland’s anomaly, develop­
mental arrest of ectodermal and 
mesodermal elements results in the
CJS, VOL. S3. NO. 1. FEBRUARY 1990 59
MAHONEY & HYNES
absence of pectoralis muscle, sub­
cutaneous tissue and breast tissue. 
End-organ response secondary to 
hormone-tissue receptor interac­
tion is not possible. This patient’s 
disposition to gynecomastia was 
manifested on the right side where 
the ectodermal-mesodermal deriva­
tives were intact. We hypothesize 
that the left side could not mount a 
similar end-organ response second­
ary to a developmental lack of re­
ceptor-sensitive tissues and subse­
quently less tissue was present on 
that side and the asymmetry was 
accentuated.
The object of surgical treatment 
of gynecomastia, once an underly­
ing cause has been ruled out, is to 
restore the normal male contour of 
the chest with minimal scarring.15 
Different operations have been rec­
ommended, depending on the size 
of the affected breasts. A classifica­
tion of the deformity, based on the 
size of the breast and the recom­
mended operation is available.16 Re­
moval of the tissue, usually 
through an inferior periareolar inci­
sion, preserving adequate tissue be­
neath the nipple to prevent retrac­
tion, has been the usual approach. 
In larger men who have redundant 
skin, excision of the skin is neces­
sary.12 Recently, suction lipolysis 
has been used as an adjunct to 
excision in some patients and can 
effectively treat the problem alone 
in patients with mildly to moderate­
ly enlarged breasts, especially when 
the deformity consists mainly of 
adipose tissue.17 From the experi­
ence of the senior author, complica­
tions appear to be fewer with this 
technique.
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Femorodistal Bypass Using the 
Chemically Processed Human Umbilical 
Vein Graft: 9-Year Experience
Michel Batt, MD;* Georges Avril, MD;*t Jean-Marie Gagliardi, MD; Randy Guzman, MD;t 
Robert Guidoin, PhD;t Norbert Boas, MD;* Bruno Daune, MD;* Reda Hassen-Khodja, MD;* 
Pierre Le Bas, MD;*
To evaluate patency, limb salvage rates and complications associated with the use of 
human umbilical vein as an arterial substitute, the authors carried out a 
retrospective review of 52 femorodistal bypasses performed over 9 years using 
human umbilical vein. Indications for operation included acute ischemia, rest pain 
and nonhealing ulceration or gangrene. There were 28 early occlusions, which 
resulted in a 1-month primary patency rate of 46% and a secondary patency rate of 
52%. The primary and secondary patency rates at 1 year were 18% and 19% 
respectively. The mean limb salvage rate at 1 month was 57% and at 1 year 34%. 
Three aneurysms occurred (two anastomotic, one graft). Factors found to have a 
significant effect on patency rates were indication for operation and state of distal 
runoff. Infection occurred in 6% of grafts and led to amputation in every case. These 
disappointing results have caused the authors to discontinue use of human umbilical 
vein as an arterial substitute.
Cette etude retrospective concerne 52 pontages femoro-jambiers realises a 1’aide de 
la veine ombilicale humaine sur une periode de 9 ans. Les indications operatoires 
ont ete une ischemie aigue, l’existence de douleurs de decubitus et l’existence 
d’ulcerations ou de gangrene. Vingt-huit occlusions precoces sont survenues 
donnant une permabilite primaire a 1 mois de 46% et une permabilite secondaire de 
52%. Les taux de permabilite primaire et secondaire a 1 an etaient respectivement de 
18% et 19%. Le taux de sauvetage de membre etait de 57% a 1 mois et de 34% a 1 an. 
Trois anevrysmes ont ete constates (deux anastomotiques, un prothetique). Les 
facteurs ayant une incidence sur le taux de permabilite ont ete l’indication 
operatoire et le lit d’aval. L’infection est survenue dans 6% des greffes et toutes ont 
conduit a une amputation. Ces resultats decevants ont conduit les auteurs a 
suspendre l’utilisation de la veine ombilicale comme substitut arteriel pour les 
revascularisations de jambe.
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The concept of a readily avail­able graft of biologic origin and 
the outstanding early patency rates 
reported by several authors popu­
larized the use of glutaraldehyde- 
treated human umbilical vein (HUV) 
as an arterial substitute. 1-3 
Over the last decade, we have 
routinely used this graft if the au­
tologous saphenous vein was ab­
sent or unsuitable for lower-limb 
revascularization.
Bypass grafting to the tibial or 
peroneal level has also gained ac­
ceptance in limb salvage operations, 
and many of the grafts used for 
revascularization at these sites have 
been HUV.4 The inferior patency 
rates with bypasses to these levels 
compared with more proximal levels 
and the continuing controversy of 
the ultimate fate of HUV grafts, 
particularly with respect to aneu­
rysm formation, have prompted us 
to examine our own experience 
with HUV grafts in femorodistal 
bypasses.5'6
Our objectives were to evaluate 
the patency rate, the limb salvage 
rate and the complications associat­
ed with the use of HUV for femoro­
distal bypass grafting over a 9-year 
period.
Patients and Methods
During the 9 years from January
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1978 to April 1987, 551 femoropo- 
pliteal or femorodistal bypass grafts 
were inserted by surgeons in the 
Vascular Surgery Department of 
the Hopital Annexe Republique in 
Nice, France. Of these, 279 were 
femorodistal bypass grafts; autolo­
gous saphenous vein was used in 
227 and the HUV graft in 52 cases 
in which the saphenous vein was 
absent (17) or unsuitable (35). 
These 52 femorodistal HUV grafts 
and the accompanying data regard­
ing patients, operations and follow­
up formed the basis of this study.
Patients
There were 48 patients (28 men, 
20 women). The average age was 
74 years (range from 43 to 94 
years). Most (44) underwent unilat­
eral bypass; 2 patients had two 
successive bypasses on the same 
limb and 2 others required bilateral 
bypass.
Associated diseases and risk fac­
tors are shown in Table I. Twenty- 
two patients had previously under­
gone vascular procedures (Table II).
The indications for operation 
were acute reversible ischemia 
(acute ischemia grade II7) in 21 
cases; rest pain (chronic ischemia 
grade II7) in 5 cases and nonhealing 
ulceration or gangrene (chronic 
ischemia grade III7) in 26 cases. All 
patients underwent angiography 
preoperatively so that we could de­
termine the rate of runoff and select 
the distal site of anastomosis. If the 
angiogram was unsatisfactory, an­
other angiogram was obtained in 
the operating room immediately be­
fore revascularization; the site was 
selected by examining late films of 
contrast injected either into the 
common or deep femoral arteries or 
films of contrast injected directly 
into the distal popliteal artery. Run­
off was considered acceptable if at 
least one tibial or peroneal artery 
was patent and there was a demon­
strable pedal arch (not necessarily 
in continuity). Runoff was termed 
poor when one of the tibial or 
peroneal arteries was not patent or 
when the pedal arch was not dem­
onstrated.
The Operation
All operations were performed by 
the same surgical team using the 
same technique. The HUV graft was 
prepared according to manufactur­
er’s instructions.1'6 The distal anas­
tomosis was performed first. In six 
cases, a short segment of autoge­
nous vein was interposed between 
the graft and the distal anastomotic 
site to facilitate the reconstruction. 
The levels of proximal and distal 
anastomoses are shown in Table III. 
The grafts followed either a subcu­
taneous (43 cases) or anatomic (9 
cases) route. Clamps were never 
applied to the graft and each anas­
tomosis was performed using two 
running monofilament propylene 
sutures. The integrity of all distal 
anastomoses was verified by angi­
ography; any technical errors were 
corrected immediately. Adjunctive 
procedures are shown in Table IV. 
Antibiotics were used prophylacti- 
cally only in 21 patients who had 
ulcers or gangrene. Postoperatively, 
all patients were placed on antivita­
Table 1. A sso c ia te d  D isease and R isk 
F a c to rs
Disease %
Heart d is e a s e 40
H yp e rte n s io n 31
D iabetes 21
C e re b ro va scu la r in s u ffic ie n c y 3
S m o k in g  h is to ry 60
Table II. P re v iou s  V a s cu la r P rocedures
Procedure
No. of 
cases
F e m o ro p o p lite a l b yp a ss 12
F e m o ro d is ta l b yp a ss 10
A o rto ilia c  re va s cu la r iz a tio n 7
A x illo fe m o ra l b yp a ss 5
P ro fu n d o p la s ty 6
L u m b a r s y m p a th e c to m y 24
min K drugs unless these were 
contraindicated.
Follow-up
Follow-up examinations were per­
formed 1 and 3 months postopera­
tively and every 6 months thereafter 
during 9 years of follow-up. Graft 
patency was confirmed by a palpa­
ble graft pulse and by measurement 
of distal pressures. Angiography 
was performed if an abnormality 
was detected.
Statistical Analysis
The actuarial method was used to 
estimate graft patency and survival 
rates. The confidence interval was 
calculated using Student’s f-test. 
Survival curves were compared 
using the log rank test. Comparison 
of results by period were made by 
the x2 test.
Results
Patient Survival
The actuarial survival curve is
Table III. S ite  o f P ro x im a l and D is ta l 
A n a s to m o se s
Site
No. of
cases
P ro x im a l
C o m m o n  fe m o ra l a rte ry 25
S u p e rfic ia l fe m o ra l a rte ry 13
D eep fe m o ra l a rte ry 1
P ro x im a l re va scu la r iza tio n 11
E x te rna l il ia c  a rte ry 2
D is ta l
P o s te r io r t ib ia l a rte ry 9
A n te r io r  t ib ia l a rte ry 29
P eronea l a rte ry 14
Table IV. A d ju n c tiv e  P rocedu res  to  
F e m o ro tib ia l R e co n s tru c tio n
Procedure No.
P ro x im a l re va scu la r iza tio n 1
P ro fu n d o p la s ty 8
T h ro m b e c to m y  o f leg a rte ries 2
L u m b a r s y m p a th e c to m y 3
S e q u e n tia l b yp a sse s 2
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shown in Fig. 1. Three patients died 
within 30 days of operation — one 
of a cerebrovascular accident, one 
of pelvic ischemia and one because 
of deterioration in general condi­
tion. During the follow-up period,
17 patients died. Survival at 3 years 
was 59%.
Graft Patency
Primary patency is shown in Fig.
Fig. 1. Actuarial survival curve.
Fig. 2. Actuarial curve of primary patency.
Fig. 3. Actuarial curve of limb salvage.
2. There were 28 occlusions within 
30 days of operation, giving a pri­
mary patency rate of 46%. Restora­
tion of patency by thrombectomy 
was possible in 3 of the 28 cases, 
giving a secondary patency rate of 
52% at 1 month. These differences 
are not statistically significant.
Of the 27 grafts that remained 
patent for more than 1 month, 15 
became occluded, but thrombecto­
my was successful in two of six 
cases. Primary and secondary pat­
ency rates at 12 months were 18% 
and 19% respectively. At 1 month, 
the 27 limbs with poor runoff pre- 
operatively had a significantly (p < 
0.01) higher rate of graft occlusion 
(21 of 27) than the 25 limbs with 
acceptable runoff (7 of 25). This 
trend persisted after 1 month, with 
higher rates of occlusion in limbs 
with poor runoff (6 of 6 versus 8 of 
18 respectively), but the numbers 
were too small to be statistically 
significant.
Operations for acute ischemia 
were also associated with a higher 
rate of occlusion (16 of 21) than 
those performed for chronic isch­
emia (12 of 31).
Limb Salvage
The 25 grafts that became oc­
cluded within 30 days of operation 
and remained occluded despite 
thrombectomy led to 22 above-knee 
amputations. The limb salvage rate 
at 1 month was 57% (Fig. 3). At 1 
year, 15 of the 27 grafts that 
remained patent at 1 month had 
become occluded and led to 10 
above-knee amputations. Unsuc­
cessful thrombectomy in this group 
(four out of six cases) uniformly led 
to above-knee amputation. This was 
performed immediately upon graft 
occlusion in five cases. In one case, 
an above-knee amputation was per­
formed after a new graft on another 
leg artery had failed. Overall, limb 
salvage at 1 year was 34%.
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Infection
Two cases of infection within the 
first month led to above-knee ampu­
tation and one of the amputations 
was preceded by a failed extra-ana­
tomic bypass. An infection at 3 
months led to graft removal and 
replacement which failed and subse­
quently led to amputation.
Stability of HUV
One graft aneurysm occurred 
during the second month after op­
eration; at reoperation mural thin­
ning was found. An HUV replace­
ment graft subsequently occluded, 
necessitating above-knee amputa­
tion. Two cases of anastomotic an­
eurysm at the femoral level ap­
peared within an average of 30 
months. One was a small aneurysm; 
the other, larger aneurysm was re­
sected without complication (Fig. 
4).
One case of distal embolization 
was suspected 1 week postopera- 
tively, because a previously docu­
mented peripheral pulse disap­
peared despite a patent graft pulse. 
Angiography revealed distal occlu­
sion by an embolism which presum­
ably had originated from the graft. 
Thrombectomy failed and subse­
quently amputation was necessary.
There was one case of mural
thrombosis of an HUV graft; the 
graft was replaced with HUV (Fig. 
5). The patient’s postoperative 
course was uncomplicated. Another 
graft failed 24 hours postoperative- 
ly when the proximal portion of the 
graft rupured. At reoperation, the 
wall had ruptured in an area of 
mural thinning, but the Dacron 
mesh was intact. The zone of rup­
ture was resected and an interposi­
tion polytetrafluoroethylene (PTFE) 
graft implanted; unfortunately this 
lasted only 6 months before occlud­
ing.
Two cases of sterile serous effu­
sion were documented. Despite re­
currence after aspiration, they dis­
appeared spontaneously over 6 
months and both grafts remained 
patent.
Discussion
There is general acceptance of 
the rate of femorodistal bypass in 
patients with rest pain, ulceration 
or gangrene.8-10 The preferred graft 
material, if available, is autogenous 
saphenous vein, either reversed or 
in situ.10 Five-year patency rates as 
high as 70% and a limb salvage rate 
of 65% can be achieved by experi­
enced surgeons.4-10 Alternatives, if 
the vein is not available or suitable, 
are PTFE, composite grafts or, as
in this series, HUV. Among the best 
results using HUV for femorodistal 
bypass grafts are those reported by 
Dardik and colleagues1 who 
achieved a 1-year patency rate of 
62% and a 3-year rate of 58%.8 
Cranley and Hafner3 reported 1- and 
3-year patency rates of 55% and 
38% respectively. At the other end 
of the spectrum, more disappoint­
ing results have been reported by 
Harris and colleagues11 who had a 
1-year patency of 34% and a 2-year 
patency of 18%. The patency rate 
reported in our series was 46% at 1 
month and 18% at 1 year. Factors 
found to be associated with de­
creased patency were poor runoff 
and operative indications (acute ver­
sus chronic), similar to those of 
other reports.8'12 Sites of distal 
anastomosis, graft type and tobacco 
use are also important determinants 
of patency although we did not 
investigate these factors in this 
study.12 No effect of patency could 
be demonstrated by comparing one 
versus two operations; this finding 
corresponded with that of Dalsing 
and associates.9 A particular prob­
lem in our study was the rate of 
early occlusion (53%), which was 
higher than that of most other 
reports.2-3'5'1013-15 Potential causes 
of this high rate were differences in 
patient selection, distal runoff and a 
discrepancy in the size of the graft
Fig. 4. Anastomotic aneurysm occurring in human umbilical 
vein graft after 30 months’ implantation. Fig. 5. Mural thrombus in graft after 3 months.
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versus the host artery, the presence 
of free glutaraldehyde,15 irregulari­
ties of the luminal surface of the 
graft and persistence of air bubble 
after rinsing.16 One report, which 
examined virgin HUV grafts, 
showed several structural defects, 
including folds, which may predis­
pose to thrombosis.17 We believe 
that the high rate of early occlusion 
in our study could be explained by a 
relatively large number of patients 
with far-advanced ischemia. In such 
cases, a few authors have suggested 
immediate amputation with no at­
tempt at revascularization. Howev­
er, our limb salvage rate of 34% at 
1 year suggested that we should 
pursue this treatment for ischemic 
limbs.18 Nevertheless, the grafts 
that suffered early occlusion did 
have a higher rate of amputation 
(22 of 25) than grafts that suffered 
late occlusion (10 of 15).
Infection was documented in 6% 
(3 of 52) of cases, which is consis­
tent with the reported range (1% to 
6%) for prosthetic grafts.19 All three 
cases eventually led to amputation. 
Kikta and associates19 reported an 
amputation rate of 79% (in 32 pa­
tients with limb infection) and noted 
that for the four largest individual 
series the amputation rates ranged 
from 36% to 75%. The structural 
defects already noted,17 such as ir­
regularities and folds not only rep­
resent potential areas for thrombo­
sis formation but also privileged 
sites for bacteremic colonization. 
Pathological findings of bacteria in­
vading the wall of some infected 
grafts would lead us to encourage 
complete excision of the graft in 
cases of clinical infection.20
Finally, two cases of anastomotic 
aneurysm and one case of prosthet­
ic aneurysm were documented in 
our series. In a series of 907 cases 
reported by Dardik and associates,21 
there was a 1.4% incidence of anas­
tomotic aneurysm and 30% inci­
dence of aneurysmal formation (af­
ter 5 years), but operation was 
required in only 6% of cases.
Conclusions
A 1-month primary patency of 
only 46% and 1-year patency of 
18% are disappointing results. This, 
combined with the potential phe­
nomenon of biodegradation, have 
led us to discontinue the use of 
HUV grafts as an arterial substitute 
for lower-limb revascularization.
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ORIGINAL ARTICLES
L angioplastie au laser: une nouvelle 
approche dans le traitement de l’occlusion 
iliaque
J. Laliberte, MD;* Y-M. Dion, MD, MSc, FRCSC;* G. Dionne, MD, FRCPCt
L’angioplastie thermique au laser est une technique nouvelle. Le suivi le plus long 
date de 3 ans. Elle est presentement de plus en plus employee en vue du traitement 
de la maladie vasculaire atheromateuse au niveau du segment femoro-poplite. Les 
auteurs decrivent un cas de recanalisation fructueuse d’une artere iliaque externe 
gauche completement obstruee, grace a la technique d’angioplastie thermique au 
laser. L’abord chirurgical de l’artere s’est effectuee par une incision femorale 
gauche. La patiente a eu son conge de l’hopital au 4e jour postoperatoire alors 
qu’elle ne presentait plus de claudication intermittente. Les indications actuelles de 
cette procedure, ses avantages et ses complications potentielles sont discutes.
Laser thermal angioplasty is a new technique. The longest follow-up is 3 years. It is 
used increasingly for the treatment of atheromatous disease of the femoropopliteal 
segment. The authors describe a case of successful recanalization of a completely 
occluded left external iliac artery using laser thermal angioplasty. The artery was 
approached through a left femoral dissection. The patient was discharged from the 
hospital on postoperative day 4 without claudication. The present indications and 
potential benefits and complications of this procedure are discussed.
A u cours des dernieres annees, nous avons assiste au deve- 
loppement de nouvelles methodes 
moins invasives de traitement de la 
maladie vasculaire atheromateuse. 
La plus connue et la plus repandue 
est l’angioplastie de dilatation. Plus 
recemment, la technologie du laser 
a ete appliquee aux maladies vas- 
culaires comme adjuvant a la dilata­
tion,1 pour la recanalisation des
Accepte pour publication le 28 septembre 1988
vaisseaux obliteres.2 Deja, sans 
toutefois en faire un usage courant, 
certains groupes ont utilise avec 
succes l’angioplastie au laser pour 
les obstructions femoro-poplitees.1 
Son utilisation pour les obstruc­
tions iliaques est beaucoup moins 
repandue.1 Nous presentons un cas 
d’obliteration iliaque symptoma- 
tique ou Tangioplastie au laser fut 
utilisee avec succes.
Presentation de cas
II s’agit d’une patiente de 45 ans, 
obese, fumant un paquet par jour, 
hypertendue et angineuse depuis 3 
ans, qui consulte pour claudication 
du membre inferieur gauche. Le 
questionnaire revele que ses pro- 
blemes ont commence il y a plus de 
2 ans. En janvier 1988, elle notait 
l’apparition soudaine d’une douleur 
suivie de decoloration bleutee du 5e 
orteil du pied gauche, le tout ayant 
rentre dans l’ordre en moins de 2 
semaines. De plus, elle se plaignait 
d’une claudication a la marche 
apres environ 100 pieds sur terrain 
plat, avec douleur au niveau du 
mollet gauche. Depuis avril 1988, 
elle accuse une exacerbation de la 
claudication qui survient apres envi­
ron 50 pieds avec une douleur qui 
progresse du mollet a la cuisse si 
elle persiste a marcher. Par ailleurs, 
elle ne presente aucune douleur de 
repos.
A l’examen vasculaire des mem- 
bres inferieurs, les pouls sont tres 
bien per$us a tous les niveaux du 
cote droit. Du cote gauche, il y a 
absence de pouls femoral et de tous 
les pouls distaux avec cependant 
une tres bonne coloration du mem­
bre distalement.
Investigation
L’evaluation a l’echo duplex cou-
Du *Departement de chirurgie et du fDepartement de radiologie, Hopital St-Frangois d'Assise, 
Universite Laval, Quebec, PQ
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leur des membres inferieurs est nor- 
male du cote droit mais, du cote 
gauche, il y a obstruction complete 
de l’artere iliaque externe sur plus 
de 10 cm avec un arbre arteriel 
distal normal.
L’arteriographie demontre l’obs- 
truction complete sur environ 10 
cm de 1’iliaque externe gauche avec 
un arbre arteriel normal des deux 
membres inferieurs (Fig. 1).
FIG. 1. Arteriographie preoperatoire 
demontrant l’obstruction complete de 
l'artere iliaque externe gauche des son 
origine. Vascularisation de l’artere 
femorale commune gauche par les col­
laterals venant de l’artere iliaque in­
terne.
FIG. 2. Arteriographie peroperatoire 
demontrant la complete recanalisation 
de l’artere iliaque externe gauche.
Procedure
Sous anesthesie generate, la pa- 
tiente ayant ete drapee comme pour 
un pontage, les arteres femorale 
commune, profonde et superficielle 
gauches sont dissequees. Apres 
heparinisation systemique (5000 
unites intra-veineuses), les femora- 
les superficielle et profonde sont 
clampees. Par la suite, l’artere 
femorale commune est ponctionee, 
puis dilatee jusqu’a un calibre 8 de 
French pour y faire penetrer 1’intro- 
ducteur (Cordis Corp., Miami, Fla.) 
par lequel un guide Bentson (Cook 
035; Cook Co., Bloomington, Ind.) 
est passe jusqu’au travers de [’obs­
truction, sous controle fluoroscopi- 
que. Enfin, une sonde du laser 
(Trimedyne 775-2.5; Trimedyne, 
Santa Ana, Calif.) est introduite sur 
le guide et l’obstruction recanalisee 
sous controle fluoroscopique en 
delivrant 13 W de faqon continue 
au laser YAG.
Une fois l’artere recanalisee, un 
catheter a ballonnet (10 cm -  7 
mm) est introduit pour dilater le 
segment nouvellement recanalise. 
Suite a la dilatation, l’arteriographie 
revele la complete recanalisation du 
segment anterieurement obstrue 
(Figs. 2 et 3). Puis, l’introducteur
FIG. 3. Detail de l’arteriographie pe­
roperatoire demontrant l’origine de 
l’artere iliaque externe gauche nou­
vellement recanalisee.
est retire, l’artere femorale refermee 
par un seul point de Prolene 4-0 et 
la patiente heparinee de faqon sys­
temique pour maintenir un temps 
de cephaline activee de 2.5 fois la 
normale durant 24 heures. Par la 
suite, elle est mise a 1’Entrophen- 
10, a la dose de 1 comprime par 
jour.
Evolution postoperatoire
En postoperatoire immediat, le 
pouls de l’artere pedieuse et celui de 
l’artere tibiale posterieure gauche 
sont bien per?us et la patiente est 
gardee a l’unite des soins intensifs 
pendant 24 heures, puis mobilisee 
le lendemain de l’operation. Quaran- 
te-huit heures apres l’operation, la 
patiente marche sans aucune claudi­
cation. L’index cheville-bras du cote 
gauche est de 0.83. L’echographie 
duplex couleur ne demontre aucune 
stenose residuelle au niveau de l’i- 
liaque externe gauche et presente 
des ondes velocimetriques triphasi- 
ques normales au niveau de la femo­
rale commune gauche. La patiente 
est done liberee le 4e jour posto­
peratoire, completement asympto- 
matique.
Discussion
Classiquement, l’approche thera- 
peutique d’une claudication handi- 
capante secondaire a une occlusion 
iliaque d’origine atheromateuse est 
soit la thrombo-endarteriectomie, 
soit le pontage aorto-bifemoral, aor- 
to-femoral unilateral ou femoro- 
femoral.
L’interet pour des methodes 
moins invasives du traitement de la 
claudication secondaire a la maladie 
iliaque a vu nattre, a la fin des 
annees 70, l’angioplastie percutanee 
de dilatation par ballonnet qui, 
maintenant, est tres largement utili- 
see avec de tres bons resultats.
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Le succes de la dilatation translu- 
minale a sans doute contribute forte- 
ment au developpement d’autres 
techniques non invasives, dont l’an- 
gioplastie au laser qui est applicable 
a l’obstruction complete.
Actuellement, la technique la 
plus repandue en clinique utilise la 
fibre optique par laquelle l’energie 
du rayon laser est convertie en 
chaleur sur une pointe metallique. 
C’est done par un processus thermi- 
que que les plaques d’atherome 
sont vaporisees et liquefiees sous 
Taction du laser, permettant ainsi la 
recanalisation d’une obstruction 
avec un risque minimal d’embolisa- 
tion peripherique.3
L’utilisation de Tangioplastie au 
laser comme adjuvant a la dilatation 
dans le traitement des occlusions 
arterielles femoro-poplitees a deja 
ete rapportee comme efficace et 
securitaire.1’2 4-6 Sanborn et collabo- 
rateurs1 rapportent un taux de suc­
ces initial de 83% chez des patients 
avec obstructions femoro-poplitees 
et Cumberland et collaborateurs6 
avec des malades ayant des obstruc­
tions iliaques ou femoro-poplitees, 
rapportent un taux de recanalisa­
tion de 89%. Les indications actuel- 
les de Tangioplastie au laser sont la 
presence d’une stenose tres serree 
(difficilement dilatable) ou d’une oc­
clusion sur un segment relative- 
ment court. Les arteres fortement 
calcifiees et les occlusions longues 
(plus de 12 cm) sont plus difficile­
ment repermeabilisables.2
Les complications potentielles de 
Tangioplastie au laser sont la perfo­
ration, la reocclusion, la formation 
d’anevrisme et Tembolisation peri­
pherique. Comme nous Tavons 
mentionne plus haut, la vaporisa­
tion de la plaque d’atherome par le 
laser reduit au minimum le risque 
d’embolisation. La reocclusion et la 
thrombose a court terme peuvent 
etre prevenues par une anticoagula­
tion systemique lors de Tinterven- 
tion et durant les premieres 24 
heures. Un traitement a long terme 
aux anti-plaquettaires est par la 
suite institue. Finalement, la perfo­
ration qui, lors des premieres etu­
des, etait frequente peut etre preve- 
nue de deux manieres: en limitant 
Tenergie delivree par le laser7 et en 
irriguant de fa?on continuelle le 
vaisseau lors de la procedure.8
Bien que plusieurs articles aient 
ete publies concernant les oblitera­
tions femoro-poplitees la litterature 
est plus silencieuse quant a [’utilisa­
tion du laser comme adjuvant a la 
dilatation pour les obstructions ilia­
ques. Le cas que nous avons 
preserves demontre la possibility 
d’application de cette methode au 
niveau iliaque, avec un tres bon 
resultat a court terme. Les avanta- 
ges de Tangioplastie au laser au 
niveau iliaque sont evidents. En 
effet, elle est moins morbide qu’un 
pontage aorto-femoral ou ilio-femo- 
ral ou qu’une thrombo-endarterec- 
tomie iliaque, reduisant ainsi le 
sejour hospitalier au minimum 
(moins de 1 semaine). De plus, le 
patient peut retourner a ses activi- 
tes normales dans les jours qui 
suivent Tintervention.
Comme toute nouvelle technique, 
Tangioplastie au laser devra subir 
Tepreuve du temps avant que Ton 
puisse conclure definitivement sur
sa valeur a long terme. Quoiqu’il en 
soit, elle ouvre une nouvelle avenue 
therapeutique pour certains patients 
souffrant d’occlusion atheromateu- 
se arterielle, tant au niveau femoro- 
poplite qu’iliaque.
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HISTORY OF SURGERY
Tw o Heroes of the Class of Onety-Seven: 
Part I
Peter B. Samuels, MD, MSc, FRCSC, FACS
Frederick Banting and Norman Bethune were linked in time, place of birth, as 
classmates in medical college, veterans of World War I and heroes to different 
worlds. Both were surgeons, sharing the decisiveness that is characteristic of the 
profession. Both had their surgical ambitions frustrated. Banting, a failed 
orthopedist, was sidetracked to research: Bethune, a successful surgeon inactivated 
by tuberculosis, was directed by his interest in his disease to thoracic surgery and 
subsequently to became an advocate of socialized medicine.
Frederick Banting et Norman Bethune partageaient plusieurs points communs: nes 
au meme moment et dans la meme region, ils devinrent compagnons de classe a la 
faculte de medecine, veterans de la premiere guerre mondiale et heros de deux 
mondes differents. Les deux etaient chirurgiens, partageant l’esprit de decision qui 
characterise la profession. Les deux virent leurs ambitions de chirurgiens deques. 
Banting, un orthopediste rate, devia vers la recherche: Bethune un chirurgien qui 
avait du succes mais qui avait ete arrete par la tuberculose, se dirigea, consequence 
de son interet pour sa maladie, vers la chirurgie thoracique, et consequemment, il 
devint plaidoyer de la medecine socialisee.
S outhern Ontario is a land of farms and orchards. The peo­
ple, of English and Scottish origin, 
are conservative, devout, hard 
working and reserved. In 1890 and 
1891, in two small towns 75 km 
apart, a boy was born to each of 
two families. These boys would 
achieve world fame, their paths 
would intersect as young men and 
then they would separate, never to 
meet again. The older would be 
acclaimed at the start of his career 
and the younger would die in a 
foreign land to be enshrined there 
and later in his own country. His 
Ontario home would become a mon­
ument, and a society would be 
founded to perpetuate his ideals.
Both these men enrolled in the 
faculty of medicine at the University 
of Toronto. Their names were Fred­
erick Banting and Norman Be­
thune. Grouped alphabetically, they 
knew each other but were never 
close friends. Bethune was outgo­
ing and colourful, while Banting 
was studious, though not brilliant, 
and exceptionally persevering.
For King and Country
In 1914, a wave of patriotism
swept Canada as war was declared 
against Germany. Nine days later 
Bethune enlisted in the Canadian 
Army Medical Corps. Banting, sub­
ject to urgent pleas of the faculty 
that doctors would be needed as 
soon as possible, very reasonably 
stayed at home. Bethune served in a 
medical unit as a stretcher bearer. 
He was wounded in the leg by 
shrapnel and was returned to hospi­
tal in England in April 1915. When 
he was discharged from the army in 
November 1915, he rejoined his 
medical class. Sixty-six men of 72 
in the class of 1917 went overseas 
as medical officers after an early 
graduation of the class in December 
1916. Banting was among them. 
While serving at a front-line dress­
ing station, he was shot through 
the left forearm. At the time he was 
the only medical man left to attend 
the wounded troops. He continued 
to work until he collapsed 10 hours 
later from shock and blood loss. He 
was sent back to hospital in En­
gland and was later awarded the 
Military Cross. Invalided out, Ban­
ting returned to Canada where he 
began training at the Hospital for 
Sick Children in Toronto as an 
orthopedic surgeon.
Meanwhile, Bethune was not sent 
overseas upon graduation because 
of his previous service and wound. 
But when a young girl pinned a 
white feather, the traditional badge 
of cowardice to his coat, he re­
enlisted in the navy as a surgeon. 
Discharged from the navy in 1919, 
Bethune remained in England and
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started surgical training at the Hos­
pital for Sick Children on Great 
Ormond Street in London. In his 
spare time he joined the social 
scene. He loved women, and his 
charm made him a great favourite 
with them; he was adopted by a rich 
English widow who indulged him in 
everything. After he briefly joined 
the Royal Air Force Medical Corps 
he settled down to complete his 
surgical training at the Edinburgh 
Royal Infirmary. There, he fell in 
love with Frances Penney, a beauti­
ful Scots girl from a prominent 
family. In 1923, he completed his 
training in Edinburgh and obtained 
his fellowship. He married Frances 
and went on a prolonged honey­
moon (all expenses paid by her) and 
in 1924 returned almost penniless 
with his bride to Canada.
Banting, upon completing his or­
thopedic training and with money 
borrowed from his father, a pros­
perous farmer in Alliston, Ontario, 
set up practice in London, Ontario 
as an orthopedic surgeon. The prac­
tice did not boom. An engagement 
ring passed back and forth between 
him and his fiancee. As his practice 
bounded and his mood sank, the 
ring stayed permanently on his 
watch chain. He obtained a position 
as assistant in physiology and anat­
omy at the University of Western 
Ontario which helped defray his 
expenses and more importantly 
gave him something to do. On Oct. 
30, 1920 he was preparing a lecture 
on the physiology of the pancreas 
when he came across an article in 
the current issue of Surgery, Gyne­
cology & Obstetrics by Moses Bar­
ron entitled “Pancreatic lithiasis 
and its possible relation to diabe­
tes” .1 Banting theorized that liga­
tion of the pancreatic duct would 
lead to necrosis of the acinar en­
zyme-producing tissue of the pan­
creas, while leaving the islands of 
Langerhans undamaged, and that 
an extract of this remaining tissue
would contain the active antidiabet­
ic component.
So strong was Banting’s belief 
that he gave up his practice and 
appointment and went back to the 
University of Toronto where he 
talked Professor McLeod, chairman 
of the Department of Physiology, 
into giving him some laboratory 
space. He was assigned a senior 
biochemistry student, Charles Best, 
to help in the experimental work 
(Fig. 1).
In the summer of 1921, Banting 
and Best established that an extract 
of the duct-ligated dog pancreas 
would lower the blood sugar level 
in a depancreatized dog. More so­
phisticated help from Professor 
McLeod and James Collip, a bio­
chemist on sabbatical at the Univer­
sity of Toronto, was not long in 
coming.
In 1922, an extract of cow pan­
creas was used successfully to treat 
diabetes in patients at the Universi­
ty of Toronto. Banting had to fight 
tooth and nail to hold onto what he 
knew was his discovery. He had, 
after all, a good many old friends at 
the university and they helped him 
resist attempts to shunt him aside. 
The Discovery o f Insulin a recent 
work by Michael Bliss of the Uni­
versity of Toronto,2 covers this peri­
od in great detail and reads like a 
thriller.
A farmer’s son, somewhat bucol­
ic, unsophisticated, big, tough and 
competitive, who had failed in the 
practice of orthopedic surgery, had 
made the outstanding medical dis­
covery of the 20th century. To do 
this, he had blasted through all 
opposition, enlisted help wherever 
he could find it and within 3 years 
had brought his ideas from concep­
tion to save the lives of diabetics. In 
1923, he received the Nobel prize 
for medicine.
Bethune’s reaction to his class­
mate’s triumph is not known. He 
had his own problems. Finding no
opportunity in Canada, he started 
surgical practice in Detroit. He se­
cured an appointment at the Harper 
Hospital and at the Detroit College 
of Medicine. Charismatic and su­
premely self-confident, his practice 
was soon established. He charged 
wealthy patients what the traffic 
would bear and treated the poor for 
nothing. He lived well beyond his 
means.
His wife hated Detroit; she had 
no friends in the city and her hus­
band was too busy with his practice 
to offer her much companionship. 
Her circumstances became intolera­
ble and in 1925 she left Bethune 
and returned to Scotland. Theirs 
had seemed a fairy tale romance; 
the handsome, dashing young sur­
geon and the beautiful heiress, but 
from the start there had been con­
flict. He had used up her inheri­
tance and continually dominated 
her intellectually and emotionally.
Bethune and Koch’s Bacillus
Bethune continued to work at a
FIG. 1. Banting and Best, 1922. (Re­
produced from F.G. Banting Papers by 
permission of Thomas Fisher Rare 
Book Library, University of Toronto.)
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furious pace and for the first time 
he experienced fatigue. In his youth 
he was an athlete and had worked 
as a lumberjack, but now he could 
barely drag himself out of bed. He 
lost weight, a flush developed and, 
finally, a hemoptysis. Tuberculosis 
was diagnosed. Fortunately, with 
foresight rare in him, he had 
bought a disability policy. He sold 
his practice and in 1926 entered the 
Trudeau Sanatorium in Saranac, 
New York, with bilateral apical tu­
berculosis.
On the other hand, Banting was 
on top of the world. He was Cana­
da’s and the world’s hero. He was 
not, however, seduced by universal 
acclaim. He lived with his own 
conscience and fierce self-assess­
ment, and he was concerned as to 
his future role. Although he had 
snared the great research prize he 
was not a trained scientist and 
although insulin was saving lives, 
he was not really a skilled clinician. 
He had turned his rights to insulin 
over to the University of Toronto 
and it was produced under licence 
from the university by Eli Lilly 
Company and Connaught Laborato­
ries in Toronto.
Canada did not neglect her favou­
rite son. Banting was appointed 
professor of medical research at 
$10 000/yr in perpetuity. One mil­
lion dollars was forthcoming from 
the Rockefeller Foundation to con­
struct the Banting Institute, which 
would house laboratories of pathol­
ogy, biochemistry and physiology, 
with the upper floor set aside for 
the Banting research facility. In 
1924, he married Marion Roberts, a 
physiotherapist, whom he had met 
at the hospital. They went on a 
honeymoon trip to Central America, 
all expenses paid by the United 
Fruit Company. It was a wonderful 
trip for the young celebrity and his 
bride. Banting, conscientious to a 
fault, addressed medical meetings 
and met with leading physicians in
every capital that they visited.
Excerpts from his wife’s diary 
show a pleasant, rather superficial 
girl, dazzled by the reflected glory 
of her husband, which was in stark 
contrast to his down-to-earth atti­
tude. Banting continued to wear a 
rather ill-fitting evening suit which 
he had bought second hand in 1919 
and which he never replaced. When 
the honeymoon was over he re­
turned to Canada and his laboratory 
and settled down to a life in medical 
research.
Bethune, feeling better at the 
sanatorium, quickly became the life 
of the party. He defied all rules and 
regulations, especially bed rest and 
smoking, in obvious denial of his 
serious condition.
In 1927, his wife instituted pro­
ceedings for divorce. He left the 
sanatorium and tried desperately to 
return to teaching and practice in 
Detroit. But his disease progressed 
and he was forced to return to the 
sanatorium, accepting bed rest 
without enthusiasm. He studied the 
entire subject of tuberculosis in the 
well-stocked library and soon decid­
ed that pneumothorax was needed 
in his case. Much against the advice 
of the conservative staff he got a 
medical resident to perform a pneu­
mothorax on him. He was soon on 
the mend. The 6 months’ bed rest 
gave him time to meditate and 
re-evaluate his life’s aims. He con­
cluded that the sirens of fame and 
fortune were delusory and that he 
would go into chest surgery, a new 
unexplored field which would give 
him the opportunity to save the 
lives of tubercular patients.
He managed to gain acceptance 
for training under Dr. Edward Ar­
chibald, one of the doyens of tho­
racic surgery, at McGill University. 
Before assuming that post, he took 
preliminary training in bacteriology 
and biochemistry at the Ray Brook 
State Hospital for Tuberculosis in 
New York state. In 1928, at the age
of 38 years, he began his training in 
thoracic surgery.
Where to Go From the Top
Banting had reached his position 
of eminence by battering down ob­
stacles in his path. He would not be 
intimidated; he would not let others 
get credit for ideas and experiments 
he knew to be his and his alone. He 
was not embittered. On the con­
trary, as an administrator he be­
came the advocate of the people in 
his laboratory. It was a hard and 
fast rule that work must first be 
presented by its originators. Con­
scious of the value of training, 
perhaps through his own lack of it, 
he was constantly sending his re­
searchers all over the world to 
acquire additional experience. He 
had a good nose for talent. When 
he found promising individuals he 
allowed them, as far as possible, to 
follow their own leads. His unbiased 
approach and his refreshing can­
dour soon became known through­
out Canada.
He was appointed to a number of 
investigative commissions and soon 
left for an extensive trip through 
Canada’s Northwest Territories and 
Arctic to survey the health prob­
lems of the Inuit. Banting was 
especially adapted to going into the 
field. He loved the outdoors and 
could hike 30 km through the bush 
without fatigue. Fortunately, he 
was able to combine these field trips 
with landscape painting. Art had 
become an important part of his life 
and he had become friendly with 
leading Canadian artists in Toronto, 
frequently joining them on their 
expeditions into the countryside.
On his trip to the Northwest 
Territories he found that the Inuit 
were being grossly exploited by the 
managers of the Hudson’s Bay 
Company. The resultant malnutri­
tion and poor sanitation had led to
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a high rate of nutritional deficiency 
and infectious diseases among the 
native people. When Banting re­
turned from his trip he was, as 
usual, met by the press. He told 
them of his findings, off the record 
and in confidence; he had not yet 
made an official report to the Minis­
ter of the Interior. Banting’s fury 
when he read the reports of his trip 
in the headlines of the next edition 
of Toronto’s newspaper was unre­
strained. He told the editor in no 
uncertain terms what he though of 
him and his cohort. Banting sin­
cerely felt that legal proceedings 
would be initiated against him. He 
immediately went to Ottawa and 
explained what had happened to the 
minister. He also met with the gov­
ernor of the Hudson’s Bay Compa­
ny who accepted his explanation 
without comment. The threatened 
ejyNosion never occurred, the affair 
quietened down and the company 
took heed of his findings. Some of 
the injustices that he had reported 
were eliminated.
If Banting had a problem, it was 
meeting the world’s expectation 
that he would surpass insulin with 
a cure for cancer and a multitude of 
other human ills. His laboratory did 
investigate cancer, but a cure was 
not forthcoming. At the behest of 
the government he investigated sili­
cosis in the Ontario mines. This was 
excellent pioneering work and such 
was Banting’s prestige that he was 
able to get the support of the mine 
owners for the needed health mea­
sures.
A son was born to the Bantings 
in 1929. Although Banting was 
often away from home, his relations 
with his boy were excellent. Howev­
er, his marriage deteriorated, end­
ing in a particularly bitter divorce 
battle in 1932. The press accorded 
the proceedings the interest excited 
by his superstardom. This led to 
strained relations between Banting 
and the media thereafter.
Bethune and the Battle of 
Montreal
Bethune, now healthy, energetic 
and enthusiastic, immersed himself 
in thoracic surgery. As usual, his 
flamboyant style made him endur­
ing enemies and friends. He was 
soon surgically independent of Dr. 
Edward Archibald. Personally, they 
were the antithesis of each other. 
Archibald was courtly, quiet spo­
ken, cautious and slow. Bethune 
was exuberant, impatient, impulsive 
and quick. Bethune’s solid contri­
butions in research anchored him 
against a tide of resentment by 
some of his colleagues. Enjoying a 
moderate success, Bethune induced 
Frances to return from Scotland 
and they were remarried in 1929.
All the basic instruments of tho­
racic surgery were either revised or 
invented by Bethune. He also de­
vised the simplest and most reliable 
pneumothorax apparatus. An entire 
page in the George Pilling instru­
ment catalogue for 1932 is devoted 
to Bethune’s instruments.
In Montreal, Bethune, for the 
first time, became involved in the 
life of a city. Like Banting, he got 
to know the artists of the city. He 
took up painting, showing a re­
markable aptitude. He boasted that 
he would have a painting accepted 
for the Spring Exhibition at the 
Montreal Museum of Art — it was. 
The painting, entitled Night operat­
ing room, shows tiered seats starkly 
white and empty, contrasting with 
the night sky seen opposite 
through the panoramic windows. 
The pool of light in the centre of 
the painting bathes a huddled 
group operating. This painting now 
hangs in the medical library of the 
Royal Victoria Hospital in Montreal.
Bethune continued to stir up any 
milieu in which he settled. He 
shocked hostesses; he advanced 
views intolerable to both the social 
and medical establishments. In
some ways he anticipated the sexu­
al mores of the 1960s and later. 
The situation at the Royal Victoria 
Hospital boiled over and, in 1932, 
Bethune was dismissed. Luckily, he 
secured a job as chief of thoracic 
surgery at the Sacre-Coeur Hospi­
tal, a large French-Canadian hospi­
tal in Cartierville near Montreal, 
where he was very much at home.
All physicians have had patients 
who are so overwhelmed by poverty 
and a hostile environment that any 
treatment given is a stop-gap. Tu­
berculosis was the disease with 
which Bethune dealt most frequent­
ly. No disease is as directly linked 
to poverty, and no place in North 
America in the 1930s had so many 
tuberculous people as the Province 
of Quebec. Surgery could limit the 
tuberculous lesion in such patients, 
but often the patient returned to an 
environment in which the tubercu­
lous disease soon revived.
Bethune became increasingly 
aware of the economics of medical 
care. He realized that many people 
in Montreal could not afford private 
medical care. He attacked the prob­
lem with characteristic energy. He 
spoke to the various business and 
professional groups, pleading to ex­
tend support to those discharged 
from sanatoria, and he opened a 
free clinic in one of the poorest 
sections of the city. Bethune, the 
supreme example of an individual­
ist, did not countenance any joint 
activity of the state and medicine. 
His activity was not revolutionary 
but an extension of his characteris­
tic “noblesse oblige”.
In 1935, an international physio­
logical congress was held in Mos­
cow, of which Ivan Pavlov was the 
president. Among the seven Canadi­
an delegates were Norman Bethune, 
who was very interested in survey­
ing a system that he had publicly 
condemned, and Sir Frederick Ban­
ting, who was an invited guest and 
whose true motive in visiting Russia
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was to investigate the research fa­
cilities under socialism. Banting 
stayed on after the conference to 
survey all of Russia and its medi­
cine (Fig. 2).
After he returned to Canada, 
Banting gave a number of addresses 
portraying the Russian medical and 
research system in a very favoura­
ble light. The Russians thought 
that science was a good bet and 
subsidized research heavily. With 
this, Banting concurred; he was 
foremost a Canadian patriot and he 
saw the need for national utilization 
of all available research facilities 
and personnel. Appointed chairman 
of the new Medical Research Com­
mittee of the National Research 
Council, Banting set to work to 
increase research funds and to facil­
itate exchange of information. He 
was especially interested in prevent­
ing the talent in small institutions 
from draining into the research pool 
at Toronto and McGill. In the fall of 
1938, he set out to visit all the 
research facilities in Canada from 
Dalhousie University to the Univer­
sity of British Columbia. He had a 
fervent belief in the productive ca­
pacity of research. Another motive 
in his drive to organize research 
was his growing conviction that 
another war was inevitable. He was 
convinced that the war in the air 
would be the deciding factor in the 
conflict to come and he set up the 
cooperative study throughout the 
medical schools of Canada on prob­
lems germane to air warfare; pilot 
fatigue, decompression sickness, ac­
celeration and deceleration stresses 
and adaptation to night vision.
Bethune returned from Russia a 
changed man. He left Quebec with a 
strong feeling that things were not 
right, that society should not let 
people sink without offering aid. 
Everywhere, healthy men were job­
less, hungry and homeless; the 
sickly were helpless without any 
recourse to medical aid.
Bethune tackled the problem 
head-on. He would convince his 
profession of the necessity of social­
ized medicine. He advised the Mon­
treal Med-Chi of his feelings. The 
first time he spoke, he was the last 
speaker in a group that had visited 
Russia and he gave an allegorical 
talk entitled, “Through the looking
glass”.3 The second speech he made 
was an advocacy of socialized medi­
cine in the province. These talks did 
not go down well. He had managed 
to alienate his colleagues at every 
level — social, professional and 
political.
He set up a society, the Montreal 
Group for the Security of the Peo­
ple’s Health, whose goal was to 
plan a system of socialized medicine 
for Canada. He went to Memphis, 
Tennessee, ostensibly to lecture on 
advances in anesthesia for thoracic 
surgery to a very conservative 
group, the Mid-South Medical As­
sembly. Bethune appended, unan­
nounced, his plan for state medi­
cine. The newspapers picked up this 
addition and the newspaper picture 
(Fig. 3) of a radiant Bethune along­
side the officers of the assembly, 
their eyes averted from Bethune or 
fixed in another area, their faces 
frozen and noncommittal, is a 
comic one. Bethune’s group sug­
gested plans for both private and 
public financing of medical care. 
Variations of these plans have been 
adopted, partially or completely, in 
both Canada and the United States.
FIG. 2. Pavlov and Banting, 1936. (Reproduced from F.G. Banting Papers by 
permission of Thomas Fisher Rare Book Library, University of Toronto.)
FIG. 3. Bethune with members of the 
Mid-South Medical Assembly. (Repro­
duced by permission from Stewart R: 
The Mind o f Norman Bethune, Fitz- 
henry & Whiteside, Toronto, 1977.)
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This plan was separately submitted 
to representatives of organized 
medicine, politicians and the public. 
Organized medicine condemned 
him, politicians either ignored him 
or were apathetic and the public did 
not become involved at all.
Bethune gravitated towards the 
Communists, a group whose com­
mitment to action paralleled his 
own desire to change a system that 
he found wanting. He did not, how­
ever, become a Communist al­
though he began to study Marxism 
seriously.
BOOK REVIEWS
continued from page 11
less exposure than before to disorders 
of the spleen, but the need to be 
informed on all aspects of splenic disor­
ders is greater than ever among all 
medical specialties.
This book is an ambitious attempt to 
cover the anatomy, pathophysiology, 
pathology, imaging and management of 
splenic disorders. It comes in a hand­
some hard-cover jacket, with glossy 
pages and easily read type. The section 
headings have been thoughtfully 
planned. The text, tables and illustra­
tions are well balanced, making it a 
pleasure to read.
Any multiauthored book is suscepti­
ble to inequalities in coverage and em­
phasis on selected subjects. In this 
book, many discussions are repeated in 
different sections, a shortcoming that 
could have been avoided by tighter 
editorial control. For example, there is a 
section devoted to splenic imaging, a 
topic that is also covered in the section 
entitled “Splenomegaly — a diagnostic 
overview”.
There is a notable pediatric slant to 
many of the sections, which reflects the 
predominance of pediatricians among 
the authors. A chapter on indications 
for splenectomy in childhood is not 
balanced by a chapter on splenectomy
Bethune was a lonely man for he 
had divorced Frances for the second 
time in 1932. He set up an art 
centre for children taught by local 
artists at his expense. They en­
hanced the lives of Montreal’s chil­
dren dulled by the depression and 
stimulated some of them to become 
artists.
At this point in their lives, both 
men had gone beyond their medical 
calling and entered a political arena 
— Banting, with prescience, orga­
nizing research for a war he felt
in adults. The table on indications for 
splenectomy is based on the experience 
in a children’s hospital.
The section on anatomy is well writ­
ten. An indication of its thoroughness is 
the description of Schweigger-Seidel 
sheaths in the vessels emerging from 
the marginal zone. This structure, al­
though not as well developed in hu­
mans as in other species, is not even 
mentioned in most standard histology 
textbooks. A few more line drawings or 
photomicrographs instead of electron 
micrographs would have been prefera­
ble. A more detailed discussion of the 
immunoarchitecture would also have 
been helpful.
The chapter on hyposplenism may 
prove to be the most sought after by 
readers of this book, since it provides 
an in-depth account of a topic that is 
only briefly covered in most standard 
textbooks. It also provides a lucid de­
scription of the use of imaging and 
laboratory techniques in evaluating hy­
posplenism. The section on pathology is 
succinct and well illustrated and should 
be a good reference for general patholo­
gists. Although the potential of flow 
cytometry, immunohistochemistry and 
DNA studies is alluded to in the final 
paragraph, no instructive examples are
would come soon and Bethune re­
solving to cure a sick society.
References
1. Buss M: Banting: a Biography, McClel­
land and Stewart, Toronto, 1984
2. Idem: The Discovery of Insulin, U of 
Chicago Pr, Chicago, 1982
3. Through the Looking Glass. Bull Montre­
al Medico-Chirurgical Society 1936; 
March-April: 31-33
given. A section devoted to the surgical 
problems of diseases of the spleen 
would have made this book more ap­
pealing to surgeons.
One would expect that a book such 
as this would aim for an international 
readership. Disorders of the spleen are 
an important cause of morbidity in the 
tropics, but the meagre attention given 
to tropical diseases of the spleen is 
disappointing. Only passing mention is 
made of malaria and the tropical spleno­
megaly syndrome, far more frequent 
problems than the storage diseases 
which are covered in great detail.
In spite of the minor deficiencies, I 
found this book useful because it pro­
vided a wide range of information about 
an organ that has not received its fair 
share of attention. I would recommend 
this as a helpful reference book for 
pathologists, hematologists, radiolo­
gists and pediatricians.
B.J. Fernandes, MD, FRCPC, MRCPath, 
FRCPA
Laboratory Hematology and 
Anatomical Pathology,
Mount Sinai Hospital.
600 University Ave.,
Toronto, Ont.
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SESAP VI Critique
Item 206
Two of the anesthetic agents listed in this item have an undeserved bad reputation for producing cellular 
derangements. Administration of halothane, particularly on multiple occasions, has been associated with some 
incidence of jaundice and evidence of hepatocellular disease, and the term “halothane hepatitis” crept into the 
literature. A large multicenter study did not show a significant difference between the incidence of jaundice 
associated with halothane and jaundice associated with other anesthetic agents. The hepatocellular derangement 
produced by halothane is due to an idiosyncratic reaction, and not to direct cellular damage. Enflurane produces 
fluoride as a metabolite and thus causes renal toxicity. Although it has not been shown to produce direct hepatic 
damage, it is no longer used. Ether and isoflurane have never been shown to produce direct cellular damage.
¥
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continued from nae'e 20 TABLE 2
Renal
Function
Creatinine 
Clearance 
mL/s mL/min
Less Severe 
Infections
Life-Threatening
Infections
Mild
Impairment
0.83-1.32 50-79 500 mg 
q8h
750 mg to 1.5 g 
q8h
Moderate to severe 
impairment
0.08-0.82 5-49 250 or 500 mg 
q12h
500 mg to 1.0 g 
q12h
Hemodialysis
patients*
0-0.07 0-4 500 mg q48h or 
250 mg q24h
500 mg to 1.0g 
q48h or 500 mg 
q24h
‘ In patients undergoing hemodialysis no additional supplemental dosing is required. 
DOSING, HOWEVER, SHOULD BE SCHEDULED SO THAT THE PATIENT RECEIVES THE 
DOSE AT THE END OF THE DIALYSIS. When started 24 hours after administration of 1 g of 
CefizoxTM, hemodialysis has been shown to reduce serum levels by 50%.
When only the serum creatinine level is available, creatinine clearance may be calculated 
from the following formulae (for patients 18 years and over only). The serum creatinine level 
should represent renal function at the steady state.
Males:
Creatinine Clearance Weight (kg) x (140 -age)
(mUmin) 72 x serum creatinine (mg/100 mL)
Creatinine Clearance 
(mL/s)
Weight (kg) x (140 - age)
49 x serum creatinine ( //mol/L)
Females: 0.85 of the above values
Infants and Children: The following dosage schedule is recommended:
TABLE 3
Age Group Unit Dosage Frequency and Route
Infants (6 mo-2 yrs.), 
and 50 mg/kg IV or IM q6h orq8h, IV or IM
Children (2-12 yrs.)
The pediatric dosage should not exceed the maximum adult dosage for serious infections.
ADMINISTRATION
Intramuscular: The reconstituted solution of CefizoxTM should be injected well within the 
body of a relatively large muscle, such as the gluteus. When administering 2 g IM doses, the 
dose should be divided equally and then injected into different large muscle masses.
intravenous: Injection (bolus): The reconstituted solution of CefizoxTM should be injected 
slowly over 3 to 5 minutes, directly or through the tubing system by which the patient is 
receiving another compatible intravenous solution. During administration of the solution 
containing CefizoxTM, it is desirable to temporarily discontinue administration of the other 
solution.
Intermittent or continuous infusion: The further diluted reconstituted solution of CefizoxTM 
should be administered over a 20 to 30 minute period.
NOTE: CefizoxTM solutions should not be physically mixed with any other drug. There is a 
known incompatibility with aminoglycoside antibiotics. Therefore, they should not be 
physically mixed with CefizoxTM solutions nor administered at the same site.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFIZOXTM
Proper Name: Ceftizoxime Sodium
Chemical Name: Sodium [6R-(6<*, 7B (Z )]]-7 -[[(2 ,3 -d ihyd ro -2 -im ino-4 -th iazo ly l) 
(m ethoxyim ino)acety l]am ino]-8-oxo-5-th ia-1 -azabilcyclo[4.2.0] o c t-2 -e n e -2 -  
carboxylate
Structural Formula:
X T^ H> —AH- I —
Molecular Formula: C i3H-|2 N505S2Na 
Molecular Weight: 405.38
Description: Ceftizoxime Sodium is a white to pale yellow crystalline powder.
Composition: CefizoxTM vials contain ceftizoxime sodium (expressed in terms of free 
acid). The sodium content of each gram of CefizoxTM is approximately 60 mg (2.6 mEq 
sodium ion).
Solutions of CefizoxTM range from colourless to pale yellow, depending upon the diluent 
and volume used. The solution should be discarded if it becomes cloudy. The pH of 
freshly reconstituted solutions usually ranges from 6.0 to 8.0.
A solution of 1 g CefizoxTM in 13 mL Sterile W ater for Injection is isotonic.
RECONSTITUTION
STANDARD VIALS (1 GRAM and 2 GRAMS)
For Intramuscular Injection: Reconstitute with Sterile Water for Injection or Bacteriosta­
tic W ater for Injection.
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Reconstitution Table for Standard Vials -  I.M. Injection
Vial
Size
Diluent to be 
Added to Vial
Approximate
Available
Volume
Approximate
Average
Concentration
1 9 
2g
3.0 mL
6.0 mL
3.7 mL 
7.4 mL
270 mg/mL 
270mg/mL 4
Shake well until dissolved. i
For Intravenous Injection: Reconstitute only with Sterile Water for Injection. . .
Reconstitution Table for Standard Vials - I.V. Injection
Vial
Size
Diluent to be 
Added to Vial
Approximate
Available
Volume
Approximate
Average
Concentration
A
V
1 g 
2g
10 mL 
20 mL
10.7 mL 
21.4 mL
95 mg/mL 
95 mg/mL i,
Shake well until dissolved. i s
For Intravenous Infusion: Reconstitute as for intravenous injection. Further dilute the 
reconstituted solution to 50 to 100 mL with one of the “Solutions for Intravenous 
Infusion” (see below).
TABLE 4: Solutions for Intravenous Infusion
Sodium Chloride Injection
5%  or 10% Dextrose Injection 4
5%  Dextrose and 0.9% , 0.45% or 0.2% Sodium Chloride Injection 
Ringer’s Injection
Lactated Ringer’s Injection r ' "C
10% Invert Sugar in Sterile Water for Injection 
5% Sodium Bicarbonate in Sterile Water for Injection
5%  Dextrose in Lactated Ringer’s Injection ONLY when reconstituted with 4%  Sodium^ 
Bicarbonate Injection.
STABILITY OF SOLUTIONS
Storage: All reconstituted solutions and those further diluted should be used within 2I  
hours if stored at room temperature or within 48 hours if refrigerated. These storage I i m i t^ j  
are from the time of the initial reconstitution.
Incompatibility: CefizoxTM should not be added to blood products, protein hydrolysates] 
or amino acids. CefizoxTM should not be mixed together with an aminoglycoside.
DOSAGE FORMS
Availability: CefizoxTM js available as a sterile powder in Standard Vials of 1 gram o r l  
2 grams, containing ceftizoxime as sodium salt.
Storage: CefizoxTM powder for injection should be stored at room temperature (15°-30°C).|
FOOTNOTES
1As indicated in the manufacturer's product monograph Cefizox. Smith Kline & French Canada Ltd . 1988 
2As indicated in the manufacturer s product monograph cefoxitin, Merck Sharp & Dohme Canada, 1985 
3Lou M.A. etal.: 14th International Congr. Chemother., Kyoto. Japan. June 1985, pp 2378-2379 
4Neu H.C , Chin N X.: The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics. I 
Chemioterapia 1985;4:271-277.
5Fu K P , Neu H.C.: Antibacterial activity of ceftizoxime. a B-lactamase-stable cephalosporin. Antimicrob Agents 
Chemother. 1980;12:583-590.
6Thornsberry C.: Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotiefs- 
against clinically important bacteria. Am J. Med. 1985:79 (Suppl 2A): 15-20.
7Drulak M W.. Chow A W. Comparitive in vitro activity of ceftizoxime cefoperazone and cefoxitin against anaerobe 
bacteria. Antimicrob. Agents Chemother. 1981;20:683-685.
8Aldridge K.E. et al.: Comparision of the activities of penicillin G and new B-lactam antibiotics against clinical isolates of
Bacteroides species. Antimicrob. Agents Chemother 1984:26(3) 410-413. *
9Adapted from Parker D.D.: Abstr. Annu. Meet. Am. Soc. Microbiol .Atlanta. GA, March 1987, Abstract no. A-107, p 18
10Kitzmann R. Cost analysis of the ecomomic effect of replacement of cefoxitin with ceftizoxime. Presented at the 45th
Annual Meeting, American Society of Hospital Pharmacists. San Francisco. California
11Guastell C. Cost savings realized from interchanging ceftizoxime for cefoxitin. Am J Hosp Pharm 1988
Nov;45:2376-2377. 4
12Wikler M.A. et al.: Efficacy of ceftizoxime administered twice daily for the treatment of serious infections in hospitalized
patients. Infect. Med 1986;(Suppl.):9-12.
13Data on file. Smith Kline & French Canada Ltd.
14Sanford J.P: Guide to Antimicrobial Therapy. West Bethesda, MD:Antimicrobial Therapy Inc.. 1988:50 
15Richards DM. Heel RC. Ceftizoxime: A review of its antibacterial activity, pharmacokinetic properties and therapeutfc 
use. Drugs 1985:29:281-329.
16DiPiro J. May JR. Use of cephalosporins with enhanced antianaerobic activity for treatment and prevention of -  
anaerobic and mixed infections. Clin Pharm 1988 Apr:7:285-302. ^
17BellomoS. Antimicrobial activity of cefizoxime sodium: Comparision with cefoxitin Hosp Formul 1988:23 
(Suppl. D): 18-27. ^
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Instructions to Authors
The Canadian Journal o f Surgery will consider manuscripts of original articles, clinical research, surgical 
technique, clinical reviews, history of surgery, a limited number of case reports, editorials and letters. 
Manuscripts, in English or French, should be submitted, in triplicate, to the Coeditors, Canadian Journal o f 
Surgery, PO Box 8650, Ottawa, Ont. K1G 0G8.
A covering letter should state that the manuscript has not been published previously and is not under 
consideration by any other journal. The authors must disclose any commercial interest they may have in the 
subject of the study and the source of any financial or material support.
Manuscript Preparation
The style of the submission should be compatible with “Uniform requirements for manuscripts submitted to 
biomedical journals” (Can Med Assoc J 1988; 138: 321-328, Br Med J 1988; 296: 401-405 and Ann Intern 
Med 1988; 108: 258-265).
The authors’ names should appear on the title page and the back of each set of illustrations. All 
acknowledgements should be placed on a separate unnumbered page after the list of references.
To facilitate editing and electronic scanning, all pages — title page, abstract, text, acknowledgements, 
references, figures, legends and tables — must be double-spaced, in 10-pitch, letter-quality type, without right 
justification or proportional spacing. Manuscripts should not be printed with the draft mode of a dot-matrix 
printer.
For all manuscripts, authors should submit an original and two high-quality photocopies or additional 
printouts of the text and tables, and three camera-ready copies of the figures.
In writing a case report it is not necessary to give a detailed patient history and results of physical 
examination in the standard clinical format. Negative findings and normal results of laboratory tests need be 
included only if they are essential for ruling out a possible diagnosis. It is enough to establish the reasons for the 
diagnosis and the management. The clinical course should be described briefly and the significant observation or 
event described in sufficient detail to establish its credibility. Reference to the literature should be confined to 
supporting the principal point being made about the event or observation.
Abstracts are required for original, review and history articles and for case reports, but not for articles on 
surgical technique and editorials. Abstracts should be brief, but detailed (from 60 to 150 words long).
References should be cited in numerical order of their appearance in the text. References cited in tables should 
be numbered according to where the table is first cited in the text. The style for references should be that used 
in this issue of the Journal.
Other Considerations
Colour figures can be reproduced only at the author’s expense. Authors should submit a positive transparency 
and two colour prints of each figure.
When diskettes are sent in addition to the typed manuscript, specify the word processor and software 
programs used. We edit manuscripts with an IBM-compatible word-processing system (WordPerfect 5.0 or 4.2) 
and cannot edit from diskettes that are not IBM-compatible.
The process of initial consideration, peer review and editorial decision-making of the manuscript usually takes 
about 8 weeks. The original copy of a rejected manuscript will be returned to the authors; all other copies will be 
destroyed.
Accepted manuscripts will be edited not only to conform with CJS style and for correctness of grammar, 
syntax and punctuation but also for clarity. The corresponding author will receive a copy of the edited 
manuscript or a galley proof before publication and is responsible for obtaining coauthors’ approval of the 
changes.
Authors will be expected to sign a document transferring copyright to CJS. All accepted manuscripts become 
the permanent property of the CMA and may not be published elsewhere, in whole or in part, without written 
permission of the publisher. Reprints will be available for purchase and may be distributed as the author 
desires.*
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Directives aux auteurs
Le Journal canadien de chirurgie prendra en consideration les manuscrits d’articles originaux consacres a la 
recherche clinique, a la technique chirurgicale ou a l’histoire de la chirurgie, des revues generates, un nombre 
restreint d’observations cliniques, des editoriaux et des lettres. Les manuscrits, en franqais ou en anglais, doivent 
etre adresses, en triple exemplaire, aux redacteurs scientifiques, Journal canadien de chirurgie. CP 8650, 
Ottawa, Ont., K1G 0G8.
Dans la lettre d’accompagnement, l’auteur doit declarer que le manuscrit n’a pas ete publie auparavant et qu’il 
n'a ete soumis a la consideration d’aucun autre journal. Les auteurs doivent devoiler tout interet commercial 
qu’ils pourraient avoir en rapport avec le sujet de l’etude, ainsi que l’origine de tout appui materiel ou 
commercial.
Organisation du manuscrit
Le style doit se conformer aux “Recommandations aux auteurs pour des manuscrits devant etre soumis a des 
revues biomedicales” (Can Med Assoc J 1988; 138: 321-328, Br Med J 1988; 296: 401-405 et Ann Intern Med 
1988; 108: 258-265).
Les noms des auteurs doivent apparaitre sur la page de titre, de meme qu’a l’endos de chaque jeu 
d’illustrations. Les remerciements sont portes sur un feuillet separe, non pagine, a la suite de la bibliographie.
Pour faciliter la correction et la revision sur support electronique, toutes les pages (page de titre, resume, 
texte, remerciements, bibliographie, figures, legendes et tableaux) doivent etre dactylographies en double 
interligne, en caracteres de 10 points de qualite lettre, sans justification de la marge de droite ou espacement 
proportionnel. Les manuscrits ne doivent pas etre imprimes en mode brouillon d'une imprimante a matrice.
Pour tout manuscrit, les auteurs doivent soumettre un original et deux photocopies de bonne qualite, ou deux 
impressions supp lem enta l du texte et des tableaux, et trois copies pretes a la reproduction photographique 
des figures.
Pour les observations cliniques, il n’est pas necessaire de rapporter une anamnese detaillee avec les resultats 
de l’examen physique courant. Les resultats negatifs ou normaux ne doivent etre mentionnes que s'ils sont 
essentiels a l’exclusion d’un diagnostic possible. II suffit d’etablir les raisons qui ont contribue au diagnostic ou 
au traitement. L’evolution clinique doit etre decrite succinctement et les observations ou evenements importants 
doivent etre rapportes avec suffisamment de details pour en etablir la credibilite. La bibliographie doit se limiter 
au soutien du point que Ton veut faire ressortir quant a l’evenement ou a l’observation.
Des resumes sont exiges pour les articles de revue, ceux sur l’histoire, ainsi que pour les observations 
cliniques; ils ne sont pas requis pour les articles sur les techniques chirurgicales ou pour les editoriaux. Les 
resumes doivent etre brefs mais, neanmoins, detailles (de 60 a 150 mots).
La bibliographie doit etre etablie numeriquement, selon l’ordre d’apparition dans le texte. Les references citees 
dans les tableaux sont numerotees d’apres l’ordre de la premiere mention du tableau dans le texte. Le style 
adopte pour la bibliographie est celui qui est utilise dans ce numero du Journal.
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Les figures en couleur sont a la charge de l’auteur. II lui faudra fournir une diapositive et deux cliches couleur 
de chacune des figures.
Si le manuscrit est fourni sur disquette, en plus de la copie dactylographiee, veuillez preciser l’appareil de 
traitement de texte et le logiciel utilises. Nous revisons les textes a l’aide d'un appareil a traitement de texte 
compatible avec le systeme IBM (WordPerfect 5.0 ou 4.2) et nous ne pouvons corriger des disquettes qui ne sont 
pas compatibles.
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semaines. L’original d’un manuscrit non retenu sera retourne aux auteurs; les copies seront detruites.
Les manuscrits retenus pour publication recevront les corrections necessaires pour les rendre conformes au 
style du JCC, ainsi que pour la grammaire, la syntaxe et la ponctuation, de meme que toute correction 
qu’exigerait la comprehension du texte. L’auteur designe recevra une copie de la version revisee ou une epreuve 
d’imprimerie; il aura la responsabilite d’obtenir l’assentiment de ses co-auteurs pour les changements.
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CLASSIFIED ADVERTISING
As a further service to its readers the Canadian Journal o f  Surgery is pleased to accept suitable classified advertisements. The deadline is 1 
month before issue date. Regular classified rates (for each insertion): $50.00 for the first 40 words or less, additional words 650 each (additional 
$20.00 for frame). Special Display under 100 words, 2>/4 in. X 2 in., $120.00. $15.00 charge (first insertion only) for CJS box numbers. Display 
rates available on request.
Copy should be mailed to the Canadian Journal o f  Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
PLASTIC SURGEON: AB -  The Department 
of Surgery at the University of Alberta is 
seeking a plastic surgeon who is willing to 
commit a significant portion of time to the 
medical and surgical care of patients in the 
new Firefighter's Burn Treatment Unit in addi­
tion to surgical practice. Clinical or basic 
research experience is essential. Full universi­
ty appointment at the assistant professor 
level available for a suitable candidate. Appli­
cation deadline: Apr. 30, 1990. Apply in 
writing with accompanying curriculum vitae 
to: Dr. G.L. Lobay, Room 240, 11044 - 82 
Ave., Edmonton, AB T6G 0T2. The Univer­
sity of Alberta is committed to the princi­
ple of equity in employment but, in accor 
dance with Canadian immigration require­
ments, this advertisement is directed to 
Canadian citizens and permanent resi­
dents. -S90-04
GENERAL SURGICAL ONCOLOGY FEL­
LOWSHIP: ON -  The Division of General 
Surgery at the Toronto General Branch of the 
Toronto Hospital is offering a 1 year clinical 
fellowship available beginning July 1, 1990. 
This fellowship provides excellent exposure 
to complex general surgical oncological prob­
lems including reoperative Gl cancer surgery, 
endocrine malignancies, and head and neck 
cancers. The fellow will also have the oppor­
tunity to be involved in ongoing clinical trials 
in adjuvant therapy of breast and colorectal 
cancers and will be encouraged to initiate at 
least one new prospective or retrospective 
study with appropriate resources provided. 
Block rotations of 6-8 weeks in the Depart­
ments of Radiotherapy and Chemotherapy are 
also an integral component of this program. 
The fellow is also expected to take a minor 
part in the training of residents in general 
surgery. This fellowship is intended for indi­
viduals who have completed a general sur­
gery residency and are eligible for certifica­
tion. Send enquiries and curriculum vitae to: 
Dr. J. Ali, Director, Postgraduate Educa­
tion, Department of Surgery, Banting Insti­
tute, Room 311, 100 College St., Toronto, 
O N M 5G 1L5. -S90-03
GENERAL SURGEON: BC -  Cariboo Memo­
rial Hospital invites applications for a general 
surgeon to join a lucrative (fee-for-service) 
private practice in the central interior of British 
Columbia. The hospital has a catchment of 
40 000 and call will be shared with one other 
general surgeon. This is an excellent opportu­
nity for a specialist to develop skills, enjoy 
great recreational facilities, and join a group of 
family physicians and specialists in a harmoni­
ous working relationship. Applicants are invit­
ed to seek further information from: Dr. J. 
Grace, Chief of Staff, tel: (604) 398-8211, or 
to request a medical staff application form 
from: Executive Director, Cariboo Memori­
al Hospital, 517 N. 6th Ave., Williams 
Lake, BC V2G 2G8. Tel: (604) 392-4411.
-S90-05
CLINICAL BURN FELLOWSHIP: ON -  A
12-month clinical burn fellowship is available 
at the Toronto Regional Adult Burn Centre, at 
the Wellesley Hospital, beginning July 1, 
1990. The unit is a very well-staffed, new, 
ultra-modern, self-contained burn centre, with 
110 adult patients per year. Position totally 
funded. Clinical research available. Extensive 
research funding in place. Please contact: Dr. 
Walter Peters, Suite 224, Turner Wing, 
Wellesley Hospital, 160 Wellesley St. E., 
Toronto, ON M4Y 1J3. Tel: (416)
926-7790. -S89-37
GENERAL SURGEON: ON -  Excellent op­
portunity exists in Sarnia/Lambton County to 
develop a lucrative private practice covering 
the full scope of general surgery. The Sarnia 
hospitals provide a total of over 350 active 
care beds with above-average support ser­
vices. An interest in trauma surgery would be 
useful in connection with patients admitted to 
the Sarnia General Hospital Level II Emergency 
Trauma Program. The city of Sarnia and 
county of Lambton catchment area has a total 
population of 120 000. Superior recreation 
facilities for persons who enjoy sailing and 
other water sports, golf and curling, etc., are 
available. For further information call or write 
to: K.E. Dickie, MD, FRCSC, Chief of Sur­
gery, Sarnia General Hospital, 220 N. Mit- 
ton St., Sarnia, ON N7T 6H6. Tel: (519) 
332-0210 (office), or P.N. Mehta, MD, 
FRCSC, Chief of Surgery, St. Joseph's 
Hospital, 290 N. Russell St., Sarnia, ON 
N7T 6S3. Tel: (519) 336-7860 (office).
-S89-36
TRANSPLANT FELLOWSHIP, UNIVERSI­
TY HOSPITAL. LONDON: ON -  University 
Hospital, London, Ontario has three openings 
for fellows in multi-organ transplantation, 
starting July 1, 1990. Our 2-year fellowship 
program includes experience in clinical and 
experimental transplantation. We expect to 
perform 40-50 heart, heart-lung and lung 
transplants; 70 liver transplants; 80 kidney 
transplants and 5 bowel transplants in 1990. 
Candidates who have completed their training 
in anesthesia, internal medicine, general sur­
gery or pediatrics, and are eligible for educa­
tional or general licensure in Ontario, will be 
given priority. Submit resumes to: Dr. David 
R. Grant, Director, Transplant Unit, PO 
Box 5339, University Hospital, London, 
ON N6A 5A5. -S89-38
CLASSIFIED ADVERTISING
Unlike a tabloid or newspaper that is read today and discarded 
tomorrow, an advertisement in the Classified Advertising section 
of CJS is read today and reread tomorrow.
CJS is the only Canadian publication exclusively for surgeons.
No other Canadian surgical publication reaches over 9000 
subscribers every 2 months, giving wide coverage for your 
advertising dollar.
Average issue readership of CJS (81 %) is among the highest of 
any medical journal in Canada, and the latest readership 
studies confirm the best and most cost efficient way to reach 
Canadian surgeons is through the pages of CJS.
LET CJS CLASSIFIED ADS WORK FOR YOU - c js -1
PROFESSOR AND CHAIR OF SURGERY
Memorial University of Newfoundland invites applications for the 
position of Professor and Chair of Surgery. This is the senior 
academic appointment in the discipline. The successful 
applicant will also be Chair of the Department of Surgery in one 
of the Faculty’s affiliated institutions.
Candidates should have certification from the Royal College of 
Physicians and Surgeons of Canada and be eligible for licensure 
as a specialist in Newfoundland.
Applications and enquiries are invited, in the first instance, from 
Canadian citizens and permanent residents of Canada. They 
should be directed, on or before Mar. 1, 1990, to:
Dr. M.I. Bowraer 
Chair, Search Committee 
Memorial University of Newfoundland 
The Health Sciences Centre 
St. John’s, NF A1B 3V6
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Cardiovascular 
Research Scientist
Department of Surgery
Cardiovascular research scientists are invited to apply for the 
position of Director of laboratory-based Cardiovascular 
Surgical Research in the Department of Surgery, Faculty of 
Medicine at the University of Alberta. A stimulating 
environment and outstanding facility is available for the right 
individual, preferably with training in CVT Surgery and 
Ph.D. or M.Sc., computer skills and a proven research 
record. Minimum salary is $50,000.00 per annum and up 
with excellent benefits; salary negotiable based on 
qualifications and experience.
In accordance with Canadian immigration requirements, this 
advertisement is directed to Canadian citizens and permanent 
residents of Canada.
Applicants should send curriculum vitae and the names of 
three referees by April 30, 1990 to:
Dennis L. Modry, M.D., FRCS(C)
Director, Division of Cardiovascular and Thoracic Surgery 
2D1.02, WC Mackenzie Health Sciences Centre 
Edmonton, Alberta, Canada T6G 2B7
The University o f Alberta is committed to the principle of 
equity in employment. —S90-02
ISCOTT&WHITE TEXAS A&M UNIVERSITY 
College of M edicine
TEMPLE CAMPUS
The Department of Neurologic Surgery of the Scott 
and White Institutions and Texas A&M University 
College of Medicine is seeking applications for 
senior staff physician faculty in the Sections of 
Pain/Stereotaxic Surgery or Neurosurgical Oncology. 
Residency or post residency experience and a 
defined interest in cither subspecialty area together 
with a broad capability and interest in general 
neurosurgical disorders is desired. Basic and clinical 
research opportunities are available commensurate 
with previous experience. Medical student and 
resident teaching/daily responsibilities are required. 
The main campus is located in central Texas, north 
of Austin in the approximate center of the Dallas/ Ft. 
Worth, San Antonio, Houston triangle and benefits 
from easy access to other surrounding universities 
(Southwestern University, Georgetown; University of 
Mary Ilardin-Baylor, Belton; Baylor University, 
Waco.)
For further information, please send curriculum 
vitae and references to:
M itc h e ll S m ig ic l, M .D .
C h a i rm a n , N e u ro lo g ic  S u r g e r y  
S c o tt a n d  W h ite , T ex as  A&M U n iv e rs ity  
C o lle g e  o f  M e d ic in e  
2 4 0 1  S o u th  3 1 s t  S tr e e t  
T e m p le , TX 7 6 5 0 8
—S90-06
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An advanced systematic interplay of four 
exclusive Dornier features, now being tested, 
is designed to give physicians the ability to 
visually lock on to stones and keep
Dorm ers MPL9000
• Dual Ultra­
sound Imaging— 
designed to allow 
visualization from a trans­
ducer mounted on an 
articulated arm and
another in line 
with the shock- 
wave path.
• Computerized Patient 
Positioning—designed 
to automatically bring 
■ m ■■ f " i  w %  the stone into the correct shockwave focus.I HAN EVtK  DthUnb *- Isocen!ric Therapyhead Positioning—
^  w  ■■■■ mm w  w  process:
Multi-Purpose Lithotripter 
Targeting System Could 
Bring This Instrument More 
In Focus With Lithotripsy
designed to keep the stone isocentrically 
centered while the operator rotates the 
therapyhead to choose the optimum 
shockwave path.
• Real-Time Monitoring—designed to allow 
the operator to view the stone disintegration 
process, as it happens.
It’s all part of the Dornier MPL 9000 multi­
purpose lithotripter, now undergoing clinical 
trials. The MPL 9000 was designed to deliver 
pain-free treatment without sacrificing 
disintegration performance. It incorporates 
Dormer's proven spark-gap technology- 
unsurpassed with more successful clinical 
results than all other methods combined.
An optional x-ray upgrade designed to 
provide extended capabilities, is also 
planned.
Dornier is committed to continually 
evolving the field of lithotripsy, and to then 
make those advancements available to all our 
customers.
This keeps you and Dornier on the leading 
edge, where Dornier started it all.
Dornier Medical Systems,
208 Evans Ave., Suite 111, Toronto,
Ontario Canada M8Z1J7.
416-259-3981.
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Deutsche Aerospace
Dornier Medical Systems.
The Standard. The Leader. 
The Future.
Apolyglyconate monofilament absorbable suture
Easier 
handling 
first throw 
to last
Maxon. A softer, more supple suture that offers strength, 
superior handling characteristics and patient benefits.
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